A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

A Phase 3, Multi-Site, Randomized, Mixed-Blind, Parallel-Group Treatment Withdrawal And Re-Treatment Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01186744

Enrollment

666

Registered

2010-08-23

Start date

2010-09-30

Completion date

2013-01-31

Last updated

2018-12-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Keywords

OPT Retreatment, OPT, chronic, moderate, severe, treatment, safety, treatment withdrawal, retreatment, retreatment withdrawal, CP-690,550, Psoriasis Vulgaris, Plaque Psoriasis, tofacitinib, Xeljanz, nail psoriasis, Jak-inhibitor, oral treatment, Pruritus, Itch, DLQI, rebound, intermittent, retreat

Brief summary

The primary objectives of the study are to 1) compare the efficacy responses of CP 690,550 (5 mg BID and 10 mg BID) versus placebo following 24 weeks of CP 690,550 treatment and subsequent withdrawal of active treatment at various timepoints during the 16 week double blind active or placebo treatment period; 2) evaluate the regain of efficacy responses of CP 690,550 (5 mg BID and 10 mg BID) following 4 -16 weeks of CP 690,550 treatment withdrawal and subsequent re treatment; and 3) evaluate the safety and tolerability of CP 690,550 (5 mg BID and 10 mg BID) in subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

Interventions

DRUGCP-690,550

10 mg of CP-690,550 oral BID or placebo oral BID, as appropriate based on treatment withdrawal/retreatment design

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* 18 years or older with diagnosis of plaque-type psoriasis (psoriasis vulgaris) for at least 12 months prior to first dose of study drug; * Psoriasis Area and Severity Index (PASI) score of 12 or greater, AND Physician's Global Assessment (PGA) score of 3 (moderate) or 4 (severe); Psoriasis covering at least 10% of body surface area; * No evidence of active or latent or inadequately treated infection with Tuberculosis or other serious infections.

Exclusion criteria

* Non-plaque or drug induced forms of psoriasis; * Cannot discontinue current oral, injectable or topical therapy for psoriasis or cannot discontinue phototherapy (Psoralen Ultraviolet A; Ultraviolet B). * Any uncontrolled significant medical condition.

Design outcomes

Primary

Measure	Time frame	Description
Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B)	Weeks 4, 8 12, and 16 (Period B)	The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of body surface area (BSA) affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response defined as at least a 75 percent (%) reduction in PASI relative to baseline.
Percentage of Participants Maintaining a Physician's Global Assessment (PGA) Response During the Double-Blind Treatment Withdrawal (Period B)	Weeks 4, 8, 12, and 16 (Period B)	The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response defined as 0 (clear) or 1 (almost clear).
Percentage of Participants Achieving a PASI75 Response During CP-690,550 Re-Treatment (Period C) Among Those Who Had a Greater Than (>)50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)	Baseline and Weeks 4, 8, and 16 (Period C)	The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. PASI75 response is defined as at least 75% reduction in PASI relative to Baseline/Day 1. Baseline defined as the last observation up to first dosing date in Period C. PASI responses at each period were relative to Baseline-A, where Baseline-A was defined as the last observation up to first dosing date in Period A.
Percentage of Participants Achieving a PGA Response of Clear or Almost Clear During CP-690,550 Re-treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe During Double-Blind Treatment Withdrawal (Period B)	Baseline and Weeks 4, 8, and 16 (Period C)	The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe).

Secondary

Measure	Time frame	Description
Median Time to Loss of Adequate Response During the Double-Blind Treatment Withdrawal (Period B)	Weeks 4, 8, 12, and 16 (Period B)	Adequate response defined as \>50% reduction of the Visit A4/Week 24 (last visit in Period A) PASI response.
Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Period Between Week 24 and Week 32 (Period B)	Weeks 4 and 8 (Period B)	The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI responses at each period are relative to Baseline-A where Baseline-A was defined as the last observation up to first dosing date in Period A. Weeks 4 and 8 are relative to the Period B baseline and are the same as Weeks 28 and 32, which are relative to Period A baseline. 95% confidence interval is constructed using the normal approximation to the binomial distribution of two-sample proportion.
Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B)	Weeks 4, 8, 12, and 16 (Period B)	The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI responses at each period are relative to Baseline-A where Baseline-A was defined as the last observation up to first dosing date in Period A. 95% confidence interval is constructed using the normal approximation to the binomial distribution of two-sample proportion.
Percentage of Participants Maintaining Adequate PASI Response and Maintaining PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)	Week 24 (Period A) and Weeks 4, 8, 12, and 16 (Period B)	Adequate PASI response defined as less than or equal to 50% reduction of the Visit A4/Week 24 PASI Response.
Median Time to Loss of >50% of the Visit A4/Week 24 PASI Response and Loss of PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)	Week 24 (Period A) and Weeks 4, 8, 12, and 16 (Period B)	—
Percentage of Participants Regaining PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C	Weeks 4, 8, and 16 (Period C)	PASI75 response defined as at least a 75% reduction in PASI relative to baseline.
Median Time to Regain PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C	Weeks 4, 8, and 16 (Period C)	PASI75 response defined as at least a 75% reduction in PASI relative to baseline.
Percentage of Participants Regaining PASI75 and PGA Response (PGA of Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Who Had Lost Both PASI75 Response and PGA Response at the Beginning of Period C	Baseline and Weeks 4, 8, and 16 (Period C)	PASI75 response defined as at least a 75% reduction in PASI relative to baseline. PASI responses at each period are relative to Baseline-A, where Baseline-A is defined as the last observation up to first dosing date in Period A. 95% confidence interval constructed using the normal approximation to the binomial distribution of one-sample proportion.
Median Time to PASI75 Response During CP-690,550 Re-Treatment (Period C) For Those Who Had a >50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)	Baseline and Weeks 4, 8, and 16 (Period C)	PASI75 response defined as at least a 75% reduction in PASI relative to baseline.
Median Time to PGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe at the Beginning of Period C	Baseline and Weeks 4, 8, and 16 (Period C)	—
Percentage of Participants With a PASI75 Response During the Initial CP-690,550 Treatment (Period A)	Weeks 4, 8, 16, and 24 (Period A)	PASI75 response defined as at least a 75% reduction in PASI relative to baseline. Baseline defined as the last observation up to the first dosing date in Period A. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.
Percentage of Participants With a PASI75 Response During Double-Blind Withdrawal Treatment (Period B)	Weeks 4, 8, 12, and 16 (Period B)	PASI75 response defined as at least a 75% reduction in PASI relative to baseline. PASI responses in each period are relative to Baseline-A, where Baseline-A is defined as the last observation until first dosing date in Period A. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.
Percentage of Participants With a PASI75 Response During the CP-690,550 Re-Treatment (Period C)	Weeks 4, 8, and 16 (Period C)	PASI75 response defined as at least a 75% reduction in PASI relative to baseline. PASI responses in each period are relative to Baseline-A, where Baseline-A is defined as the last observation until first dosing date in Period A. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.
Percentage of Participants With PGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)	Weeks 4, 8, 16, and 24 (Period A)	PGA response was defined as 0 (clear) or 1 (almost clear) on a 5-point scale where 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.
Percentage of Participants With PGA Response of Clear or Almost Clear During Double-Blind Withdrawal Treatment (Period B)	Weeks 4, 8, 12, and 16 (Period B)	PGA response was defined as 0 (clear) or 1 (almost clear) on a 5-point scale where 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. 95% confidence interval is constructed using the normal approximation to the binomial distribution of two-sample proportion.
Percentage of Participants With PGA Response of Clear or Almost Clear During the CP-690,550 Re-Treatment (Period C)	Weeks 4, 8, and 16 (Period C)	PGA response was defined as 0 (clear) or 1 (almost clear) on a 5-point scale where 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.
Mean Total Percent of Psoriatic Body Surface Area (BSA) During Initial CP-690,550 Treatment (Period A)	Baseline and Weeks 4, 8, 16, and 24 (Period A)	Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.
Mean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Baseline and Weeks 4, 8, 12, and 16 (Period B)	Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.
Mean Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Baseline and Weeks 4, 8, and 16 (Period C)	Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.
Mean Change From Baseline in Total Percent of Psoriatic BSA During Initial CP-690,550 Treatment (Period A)	Weeks 4, 8, 16, and 24 (Period A)	Baseline defined as the last observation up to first dosing date in Period A.
Mean Change From Baseline in Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Weeks 4, 8, 12, and 16 (Period B)	Baseline defined as the last observation up to first dosing date in Period B.
Mean Change From Baseline in Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Weeks 4, 8, and 16 (Period C)	Baseline was defined as the last observation until first dosing date in Period C.
Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Baseline and Weeks 4, 8, 16, and 24 (Period A)	Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.
Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Baseline and Weeks 4, 8, 12, and 16 (Period B)	Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.
Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Baseline and Weeks 4, 8, and 16 (Period C)	Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.
Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Weeks 4, 8, 16, and 24 (Period A)	Baseline defined as the last observation up to first dosing date in Period A.
Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Weeks 4, 8, 12, and 16 (Period B)	Baseline defined as the last observation up to first dosing date in Period B.
Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Weeks 4, 8, and 16 (Period C)	Baseline defined as the last observation up to first dosing date in Period C.
Mean PASI Score During Initial CP-690,550 Treatment (Period A)	Baseline and Weeks 4, 8, 16, and 24 (Period A)	Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\area score\weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.
Mean PASI Score During Double-Blind Treatment Withdrawal (Period B)	Baseline and Weeks 4, 8, 12, and 16 (Period B)	Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\area score\weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.
Mean PASI Score During the CP-690,550 Re-Treatment (Period C)	Baseline and Weeks 4, 8, and 16 (Period C)	Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\area score\weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period C.
Mean Change From Baseline-A in PASI Score During Initial CP-690,550 Treatment (Period A)	Weeks 4, 8, 16, and 24 (Period A)	Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\area score\weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.
Mean Change From Baseline-B in PASI Score During Double-Blind Treatment Withdrawal (Period B)	Weeks 4, 8, 12, and 16 (Period B)	Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\area score\weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline-B defined as last observation up to first dosing date in Period B.
Mean Change From Baseline-C in PASI Score During the CP-690,550 Re-Treatment (Period C)	Weeks 4, 8, and 16 (Period C)	Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\area score\weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline-C defined as last observation up to first dosing date in Period C.
Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Baseline and Weeks 4, 8, 16, and 24 (Period A)	Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\area score\weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.
Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Baseline and Weeks 4, 8, 12, and 16 (Period B)	Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\area score\weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.
Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Baseline and Weeks 4, 8, and 16 (Period C)	Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\area score\weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period C.
Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Weeks 4, 8, 16, and 24 (Period A)	Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\area score\weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.
Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Weeks 4, 8, 12, and 16 (Period B)	Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\area score\weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.
Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Weeks 4, 8, and 16 (Period C)	Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\area score\weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period C.
Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During Period A	Weeks 4, 8, 16, and 24 (Period A)	PASI quantifies the severity of psoriasis based on both lesion severity and the percent of BSA) affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk, and lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of the body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.
Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During Period A	Weeks 4, 8, 16, and 24 (Period A)	PASI quantifies the severity of psoriasis based on both lesion severity and the percent of BSA) affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk, and lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of the body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.
Percentage of Participants Achieving at Least a 100% Reduction in PASI Relative to Baseline-A (PASI100) During Period A	Weeks 4, 8, 16, and 24 (Period A)	PASI quantifies the severity of psoriasis based on both lesion severity and the percent of BSA) affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk, and lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of the body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.
Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During the CP-690,550 Re-Treatment (Period C)	Baseline and Weeks 4, 8, and 16 (Period C)	PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head/neck, upper limbs, trunk, lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.
Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During the CP-690,550 Re-Treatment (Period C)	Baseline and Weeks 4, 8, and 16 (Period C)	PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head/neck, upper limbs, trunk, lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.
Percentage of Participants Achieving 100% Reduction in PASI Relative to Baseline-A (PASI100) During the CP-690,550 Re-Treatment (Period C)	Baseline and Weeks 4, 8, and 16 (Period C)	PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head/neck, upper limbs, trunk, lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.
Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Initial CP-690,550 Treatment (Period A)	Weeks 4, 8, 16, and 24 (Period A)	PASI quantifies the severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk, and lower limbs), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis.
Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B)	Weeks 4, 8, 12, and 16 (Period B)	PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head/neck, upper limbs, trunk, lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.
Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During the CP-690,550 Re-Treatment (Period C)	Weeks 4, 8, and 16 (Period C)	PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head/neck, upper limbs, trunk, lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.
Mean Itch Severity Item (ISI) Score During the Initial CP-690,550 Treatment (Period A)	Baseline and Weeks 4, 8, 16, and 24 (Period A)	The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate your worst itching due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms No itching (0) and Worst possible itching (10) at the ends.
Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Baseline and Weeks 4, 8, 12, and 16 (Period B)	The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate your worst itching due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms No itching (0) and Worst possible itching (10) at the ends.
Mean ISI Score During the CP-690,550 Re-Treatment (Period C)	Baseline and Weeks 4, 8, and 16 (Period C)	The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate your worst itching due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms No itching (0) and Worst possible itching (10) at the ends.
Mean Change From Baseline-A in ISI Score During the Initial CP-690,550 Treatment (Period A)	Weeks 4, 8, 16, and 24 (Period A)	The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate your worst itching due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms No itching (0) and Worst possible itching (10) at the ends. Baseline-A defined as the last observation up to first dosing date in Period A.
Mean Change From Baseline-B in ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Weeks 4, 8, 12, and 16 (Period B)	The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate your worst itching due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms No itching (0) and Worst possible itching (10) at the ends. Baseline-B defined as the last observation up to first dosing date in Period B.
Mean Change From Baseline-C in ISI Score During the CP-690,550 Re-Treatment (Period C)	Weeks 4, 8, and 16 (Period C)	The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate your worst itching due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms No itching (0) and Worst possible itching (10) at the ends. Baseline-C defined as the last observation up to first dosing date in Period C.
Percentage of Participants With ISI Score of 0 During the Initial CP-690,550 Treatment (Period A)	Weeks 4, 8, 16, and 24 (Period A)	The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate your worst itching due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms No itching (0) and Worst possible itching (10) at the ends.
Percentage of Participants With ISI Score of 0 During CP-690,550 Re-Treatment (Period C)	Baseline and Weeks 4, 8, and 16 (Period C)	The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate your worst itching due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms No itching (0) and Worst possible itching (10) at the ends.
Percentage of Participants Achieving ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A)	Weeks 4, 8, 16, and 24 (Period A)	The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate your worst itching due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms No itching (0) and Worst possible itching (10) at the ends.
Percentage of Participants Achieving an ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C)	Baseline and Weeks 4, 8, and 16 (Period C)	The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate your worst itching due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms No itching (0) and Worst possible itching (10) at the ends.
Percentage of Participants Achieving ISI ≥2-Point Reduction During the Initial CP-690,550 Treatment (Period A)	Weeks 4, 8, 16, and 24 (Period A)	The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate your worst itching due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms No itching (0) and Worst possible itching (10) at the ends.
Percentage of Participants Achieving ISI ≥2-Point Reduction During the CP-690,550 Re-Treatment (Period C)	Weeks 4, 8, and 16 (Period C)	The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate your worst itching due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms No itching (0) and Worst possible itching (10) at the ends.
ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response	Weeks 4, 8, 16, and 24 (Period A)	The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate your worst itching due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms No itching (0) and Worst possible itching (10) at the ends.
Median Time to ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A)	Weeks 4, 8, 16, and 24 (Period A)	The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate your worst itching due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms No itching (0) and Worst possible itching (10) at the ends.
ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C) - Percentage of Participants With a Response	Weeks 4, 8, and 16 (Period C)	The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate your worst itching due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms No itching (0) and Worst possible itching (10) at the ends.
Median Time to ISI Score of ≤1 During the CP-690,550 Re-Treatment (Period C)	Weeks 4, 8, and 16 (Period C)	The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate your worst itching due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms No itching (0) and Worst possible itching (10) at the ends.
ISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response	Weeks 4, 8, 16, and 24 (Period A)	The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate your worst itching due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms No itching (0) and Worst possible itching (10) at the ends.
Median Time to ISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690,550 Treatment (Period A)	Weeks 4, 8, 16, and 24 (Period A)	The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate your worst itching due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms No itching (0) and Worst possible itching (10) at the ends.
ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C) - Percentage of Participant With a Response	Weeks 4, 8, and 16 (Period C)	The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate your worst itching due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms No itching (0) and Worst possible itching (10) at the ends.
Median Time to ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C)	Weeks 4, 8, and 16 (Period C)	The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate your worst itching due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms No itching (0) and Worst possible itching (10) at the ends.
Mean Dermatology Life Quality Index (DLQI) Score During the Initial CP-690,550 Treatment (Period A)	Baseline and Weeks 4, 8, 16, and 24 (Period A)	The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.
Mean DLQI Score During the CP-690,550 Re-Treatment (Period C)	Baseline and Weeks 4, 8, and 16 (Period C)	The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.
Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Baseline and Weeks 4, 8, 12, and 16 (Period B)	The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.
Mean Change From Baseline-A in DLQI Score During the Initial CP-690,550 Treatment (Period A)	Weeks 4, 8, 16, and 24 (Period A)	The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-A defined as the last observation up to first dosing date in Period A.
Mean Change From Baseline-B in DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Weeks 4, 8, 12, and 16 (Period B)	The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-B defined as the last observation up to first dosing date in Period B.
Mean Change From Baseline-C in DLQI Score During the CP-690,550 Re-Treatment (Period C)	Weeks 4, 8, and 16 (Period C)	The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-C defined as the last observation up to first dosing date in Period C.
Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Baseline and Weeks 4, 8, 16, and 24 (Period A)	The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3).
Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Baseline and Weeks 4, 8, 12, and 16 (Period B)	The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3).
Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Baseline and Weeks 4, 8, and 16 (Period C)	The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3).
Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Weeks 4, 8, 16, and 24 (Period A)	The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-A defined as the last observation up to first dosing date in Period A.
Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Weeks 4, 8, 12, and 16 (Period B)	The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-B defined as the last observation up to first dosing date in Period B.
Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Weeks 4, 8, and 16 (Period C)	The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-C defined as the last observation up to first dosing date in Period C.
Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)	Weeks 4, 8, 16, and 24 (Period A)	The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-B Response During Double-Blind Treatment Withdrawal (Period B)	Weeks 4, 8, 12, and 16 (Period B)	The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-C Response During CP-690,550 Re-Treatment (Period C)	Weeks 4, 8, and 16 (Period C)	The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-C defined as the last observation up to first dosing date in Period C.
Percentage of Participants Achieving DLQI ≤1 Response During the Initial CP-690,550 Treatment (Period A)	Weeks 4, 8, 16, and 24 (Period A)	The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
Percentage of Participants Achieving DLQI ≤1 Response During Double-Blind Treatment Withdrawal (Period B)	Weeks 4, 8, 12, and 16 (Period B)	The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
Percentage of Participants Achieving DLQI ≤1 Response During CP-690,550 Re-Treatment (Period C)	Baseline and Weeks 4, 8, and 16 (Period C)	The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Baseline and Weeks 4, 8, 16, and 24 (Period A)	The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). Severity is measured using the following categories of scores: 0-1=no effect on patients' lives; 2-5=small effect; 6-10=moderate effect; 11-20=very large effect; 21-30=extremely large effect.
Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)	Weeks 4, 8, 16, and 24 (Period A)	The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
Median Time to DLQI ≥5-Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)	Weeks 4, 8, 16, and 24 (Period A)	The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)	Weeks 4, 8, and 16 (Period C)	The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
Median Time to DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)	Weeks 4, 8, and 16 (Period C)	The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
Mean Short-Form 36 (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores During the Initial CP-690,550 Treatment (Period A)	Baseline and Week 24 (Period A)	The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Linear transformations were performed to transform scores to a mean of 50 and standard deviations (SDs) of 10, in the general population. In norm-based scoring, each scale is scored to have same average (50)/SD (10). With this method anytime a scale score is below 50, health status is below average, and each point is one-tenth of a SD. Higher scores indicate a better health related quality of life.
Mean SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)	Baseline and Week 56 (Period C)	The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Linear transformations were performed to transform scores to a mean of 50 and SDs of 10, in the general population. In norm-based scoring, each scale is scored to have same average (50)/SD (10). With this method anytime a scale score is below 50, health status is below average, and each point is one-tenth of a SD. Higher scores indicate a better health related quality of life.
Mean Change From Baseline-A in SF-36 PCS and MCS Scores During the Initial CP-690,550 Treatment (Period A)	Week 24 (Period A)	The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Linear transformations were performed to transform scores to a mean of 50 and SDs of 10, in the general population. In norm-based scoring, each scale is scored to have same average (50)/SD (10). With this method anytime a scale score is below 50, health status is below average, and each point is one-tenth of a SD. Higher scores indicate a better health related quality of life.
Mean Change From Baseline-C in SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)	Week 56 (Period C)	The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Linear transformations were performed to transform scores to a mean of 50 and SDs of 10, in the general population. In norm-based scoring, each scale is scored to have same average (50)/SD (10). With this method anytime a scale score is below 50, health status is below average, and each point is one-tenth of a SD. Higher scores indicate a better health related quality of life.
Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Baseline and Week 24 (Period A)	The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life.
Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline and Week 56 (Period C)	The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life.
Mean Change From Baseline-A in SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Week 24 (Period A)	The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life. Baseline-A defined as the last observation up to first dosing date in Period A.
Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 (Period C)	The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life. Baseline-C defined as the last observation up to first dosing date in Period C.
Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During CP-690,550 Re-Treatment (Period C)	Weeks 4, 8, and 16 (Period C)	—
Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Baseline and Weeks 4, 8, 16 and 24 (Period A)	The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe
Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Baseline and Weeks 4, 8, 12, and 16 (Period B)	The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe.
Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Baseline and Weeks 4, 8, and 16 (Period C)	The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe.
Percentage of Participants With PtGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)	Weeks 4, 8, 16, and 24 (Period A)	The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. Response defined as score of 0 or 1.
Median Time to PASI75 Response During Initial CP-690,550 Treatment (Period A)	Weeks 4, 8, 16, and 24 (Period A)	The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. PASI75 response defined as 75% reduction in PASI relative to baseline.
Percentage of Participants Maintaining PtGA Response of Clear or Almost Clear During the Double-Blind Treatment Withdrawal (Period B) Among Participants Who Had a Response of Clear or Almost Clear at Beginning of Period B	Weeks 4, 8, 12, and 16 (Period B)	The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. Response defined as score of 0 or 1.
Mean EuroQol 5 Dimensions (EQ-5D) Health State Profile Utility Score and VAS Scores During the Initial CP-690,550 Treatment Period (Period A)	Weeks 4, 8, 16, and 24 (Period A)	EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.
Mean EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)	Baseline and Week 56 (Period C)	EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.
Mean Change From Baseline-A in EQ-5D Utility Score and VAS Scores During the Initial CP-690,550 Treatment Period (Period A)	Week 24 (Period A)	EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. Baseline-A defined as the last observation up to first dosing date in Period A.
Mean Change From Baseline-C in EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)	Week 56 (Period C)	EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. Baseline-C defined as the last observation up to first dosing date in Period C.
Mean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Baseline and Week 24 (Period A)	EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed).
Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline and Week 56 (Period C)	EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed).
Mean Change From Baseline-A in EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Week 24 (Period A)	EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Baseline-A defined as the last observation up to first dosing date in Period A.
Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 (Period C)	EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Baseline-C defined as the last observation up to first dosing date in Period C.
Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During the Initial CP-690,550 Treatment (Period A)	Weeks 4, 8, 16, and 24 (Period A)	—
Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During Double-Blind Treatment Withdrawal (Period B)	Weeks 4, 8, 12, and 16 (Period B)	—
Percentage of Participants With PtGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PtGA of Mild, Moderate or Severe During CP-690,550 Treatment Withdrawal (Period B)	Baseline and Weeks 4, 8, and 16 (Period C)	The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. Response defined as score of 0 or 1.
Median Time to PGA Response of Clear or Almost Clear During Initial CP-690,550 Treatment (Period A)	Weeks 4, 8, 16, and 24 (Period A)	The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response defined as 0 (clear) or 1 (almost clear).
Percentage of Participants Achieving Both a PASI50-75 Response and Dermatology Life Quality Index (DLQI) ≤5 Response During Initial CP-690,550 Treatment (Period A)	Weeks 4, 8, 16, and 24 (Period A)	PASI50-75 response defined as a reduction of at least 50% but less than 75%. The DLQI is a general dermatology questionnaire that consists of 10 items that assess participant health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
Percentage of Participant Maintaining an Adequate Response During the Double-Blind Treatment Withdrawal (Period B)	Weeks 4, 8, 12, and 16 (Period B)	Adequate response defined as \>50% reduction of the Visit A4/Week 24 (last visit in Period A) PASI response.

Countries

Argentina, Australia, Brazil, Bulgaria, Canada, Denmark, Finland, Greece, Netherlands, Slovakia, United Kingdom, United States

Participant flow

Participants by arm

Arm	Count
CP-690,550 5 mg BID (Period A) Participants received CP-690,550 5 milligram (mg) tablets orally twice daily (BID) for 24 continuous weeks during Period A (Initial Treatment)	218
CP-690,550 10 mg BID (Period A) Participants received CP-690,550 10 mg tablets orally BID for 24 continuous weeks during Period A (Initial Treatment)	157
CP-690,550 5 mg/CP-690,550 5 mg/CP-690,550 5 mg Participants received CP-690,550 5 mg tablets orally BID for 24 weeks in Period A (Initial Treatment) followed by CP-690,550 5 mg tablets orally BID for 4, 8, 12, or 16 weeks during Period B (Double-Blind Treatment Withdrawal) followed by CP-690,550 5 mg tablets orally BID for up to 28 weeks in Period C (Double-Blind Re-Treatment)	31
CP-690,550 5 mg/Placebo/CP-690,550 5 mg Participants received CP-690,550 5 mg tablets orally BID for 24 weeks in Period A (Initial Treatment) followed by placebo tablets orally BID for 4, 8, 12, or 16 weeks during Period B (Double-Blind Treatment Withdrawal) followed by CP-690,550 5 mg tablets orally BID for up to 28 weeks in Period C (Double-Blind Re-Treatment)	82
CP-690,550 10 mg/CP-690,550 10 mg/CP-690,550 10 mg Participants received CP-690,550 10 mg tablets orally BID for 24 weeks in Period A (Initial Treatment) followed by CP-690,550 10 mg tablets orally BID for 4, 8, 12, or 16 weeks during Period B (Double-Blind Treatment Withdrawal) followed by CP-690,550 10 mg tablets orally BID for up to 28 weeks in Period C (Double-Blind Re-Treatment)	45
CP-690,550 10 mg / Placebo / CP-690,550 10 mg Participants received CP-690,550 10 mg tablets orally BID for 24 weeks in Period A (Initial Treatment) followed by placebo tablets orally BID for 4, 8, 12, or 16 weeks during Period B (Double-Blind Treatment Withdrawal) followed by CP-690,550 10 mg tablets orally BID or up to 28 weeks in Period C (Double-Blind Re-Treatment)	133
Total	666

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003	FG004	FG005
Overall Study	Adverse Event	10	14	1	0	1	4
Overall Study	Death	1	0	0	0	0	0
Overall Study	Lack of Efficacy	156	99	0	2	2	5
Overall Study	Lost to Follow-up	15	16	2	1	1	4
Overall Study	Other	9	10	1	2	1	5
Overall Study	Protocol Violation	1	2	0	1	1	2
Overall Study	Screen failure	1	1	0	1	0	0
Overall Study	Study terminated by Sponsor	1	0	0	0	0	0
Overall Study	Withdrawal by Subject	14	10	2	5	0	6

Baseline characteristics

Characteristic	CP-690,550 5 mg BID (Period A)	CP-690,550 10 mg BID (Period A)	CP-690,550 5 mg/CP-690,550 5 mg/CP-690,550 5 mg	CP-690,550 5 mg/Placebo/CP-690,550 5 mg	CP-690,550 10 mg/CP-690,550 10 mg/CP-690,550 10 mg	CP-690,550 10 mg / Placebo / CP-690,550 10 mg	Total
Age, Continuous	42.8 years STANDARD_DEVIATION 13	45.6 years STANDARD_DEVIATION 12.6	44.3 years STANDARD_DEVIATION 13	45.2 years STANDARD_DEVIATION 13.4	48.5 years STANDARD_DEVIATION 14.8	46.1 years STANDARD_DEVIATION 13.4	44.9 years STANDARD_DEVIATION 13.2
Sex: Female, Male Female	65 Participants	50 Participants	11 Participants	27 Participants	11 Participants	44 Participants	208 Participants
Sex: Female, Male Male	153 Participants	107 Participants	20 Participants	55 Participants	34 Participants	89 Participants	458 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk
deaths Total, all-cause mortality	— / —	— / —	— / —	— / —	— / —	— / —
other Total, other adverse events	101 / 218	94 / 157	25 / 31	65 / 82	41 / 45	108 / 133
serious Total, serious adverse events	6 / 218	9 / 157	1 / 31	3 / 82	4 / 45	4 / 133

Outcome results

Primary

Percentage of Participants Achieving a PASI75 Response During CP-690,550 Re-Treatment (Period C) Among Those Who Had a Greater Than (>)50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)

The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. PASI75 response is defined as at least 75% reduction in PASI relative to Baseline/Day 1. Baseline defined as the last observation up to first dosing date in Period C. PASI responses at each period were relative to Baseline-A, where Baseline-A was defined as the last observation up to first dosing date in Period A.

Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

Population: FAS-C

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving a PASI75 Response During CP-690,550 Re-Treatment (Period C) Among Those Who Had a Greater Than (>)50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)	Baseline	50.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving a PASI75 Response During CP-690,550 Re-Treatment (Period C) Among Those Who Had a Greater Than (>)50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)	Week 4	100.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving a PASI75 Response During CP-690,550 Re-Treatment (Period C) Among Those Who Had a Greater Than (>)50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)	Week 8	100.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving a PASI75 Response During CP-690,550 Re-Treatment (Period C) Among Those Who Had a Greater Than (>)50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)	Week 16	50.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving a PASI75 Response During CP-690,550 Re-Treatment (Period C) Among Those Who Had a Greater Than (>)50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)	Week 4	13.16 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving a PASI75 Response During CP-690,550 Re-Treatment (Period C) Among Those Who Had a Greater Than (>)50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)	Week 8	31.58 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving a PASI75 Response During CP-690,550 Re-Treatment (Period C) Among Those Who Had a Greater Than (>)50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)	Week 16	31.58 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving a PASI75 Response During CP-690,550 Re-Treatment (Period C) Among Those Who Had a Greater Than (>)50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)	Baseline	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving a PASI75 Response During CP-690,550 Re-Treatment (Period C) Among Those Who Had a Greater Than (>)50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)	Week 8	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving a PASI75 Response During CP-690,550 Re-Treatment (Period C) Among Those Who Had a Greater Than (>)50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)	Week 4	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving a PASI75 Response During CP-690,550 Re-Treatment (Period C) Among Those Who Had a Greater Than (>)50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)	Week 16	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving a PASI75 Response During CP-690,550 Re-Treatment (Period C) Among Those Who Had a Greater Than (>)50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)	Baseline	0.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving a PASI75 Response During CP-690,550 Re-Treatment (Period C) Among Those Who Had a Greater Than (>)50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)	Week 16	50.85 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving a PASI75 Response During CP-690,550 Re-Treatment (Period C) Among Those Who Had a Greater Than (>)50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)	Week 4	40.68 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving a PASI75 Response During CP-690,550 Re-Treatment (Period C) Among Those Who Had a Greater Than (>)50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)	Baseline	0.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving a PASI75 Response During CP-690,550 Re-Treatment (Period C) Among Those Who Had a Greater Than (>)50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)	Week 8	49.15 percentage of participants

Primary

Percentage of Participants Achieving a PGA Response of Clear or Almost Clear During CP-690,550 Re-treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe During Double-Blind Treatment Withdrawal (Period B)

The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe).

Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

Population: The Period C-Full Analysis Set (FAS-C) included all FAS-B participants who were advanced to the re-treatment period (Period C) during the 16 weeks of Period B and had received at least one dose of investigational drug (CP-690,550 5 mg BID or 10 mg BID) during Period C.

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving a PGA Response of Clear or Almost Clear During CP-690,550 Re-treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe During Double-Blind Treatment Withdrawal (Period B)	Baseline	23.08 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving a PGA Response of Clear or Almost Clear During CP-690,550 Re-treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe During Double-Blind Treatment Withdrawal (Period B)	Week 4	23.08 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving a PGA Response of Clear or Almost Clear During CP-690,550 Re-treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe During Double-Blind Treatment Withdrawal (Period B)	Week 8	30.77 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving a PGA Response of Clear or Almost Clear During CP-690,550 Re-treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe During Double-Blind Treatment Withdrawal (Period B)	Week 16	30.77 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving a PGA Response of Clear or Almost Clear During CP-690,550 Re-treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe During Double-Blind Treatment Withdrawal (Period B)	Week 4	25.86 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving a PGA Response of Clear or Almost Clear During CP-690,550 Re-treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe During Double-Blind Treatment Withdrawal (Period B)	Week 8	39.66 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving a PGA Response of Clear or Almost Clear During CP-690,550 Re-treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe During Double-Blind Treatment Withdrawal (Period B)	Week 16	41.38 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving a PGA Response of Clear or Almost Clear During CP-690,550 Re-treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe During Double-Blind Treatment Withdrawal (Period B)	Baseline	5.17 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving a PGA Response of Clear or Almost Clear During CP-690,550 Re-treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe During Double-Blind Treatment Withdrawal (Period B)	Week 8	40.0 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving a PGA Response of Clear or Almost Clear During CP-690,550 Re-treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe During Double-Blind Treatment Withdrawal (Period B)	Week 4	33.33 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving a PGA Response of Clear or Almost Clear During CP-690,550 Re-treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe During Double-Blind Treatment Withdrawal (Period B)	Week 16	53.33 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving a PGA Response of Clear or Almost Clear During CP-690,550 Re-treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe During Double-Blind Treatment Withdrawal (Period B)	Baseline	6.67 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving a PGA Response of Clear or Almost Clear During CP-690,550 Re-treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe During Double-Blind Treatment Withdrawal (Period B)	Week 16	48.98 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving a PGA Response of Clear or Almost Clear During CP-690,550 Re-treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe During Double-Blind Treatment Withdrawal (Period B)	Week 4	51.02 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving a PGA Response of Clear or Almost Clear During CP-690,550 Re-treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe During Double-Blind Treatment Withdrawal (Period B)	Baseline	7.14 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving a PGA Response of Clear or Almost Clear During CP-690,550 Re-treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe During Double-Blind Treatment Withdrawal (Period B)	Week 8	55.10 percentage of participants

Primary

Percentage of Participants Maintaining a Physician's Global Assessment (PGA) Response During the Double-Blind Treatment Withdrawal (Period B)

Time frame: Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining a Physician's Global Assessment (PGA) Response During the Double-Blind Treatment Withdrawal (Period B)	Week 4	80.6 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining a Physician's Global Assessment (PGA) Response During the Double-Blind Treatment Withdrawal (Period B)	Week 8	67.7 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining a Physician's Global Assessment (PGA) Response During the Double-Blind Treatment Withdrawal (Period B)	Week 16	49.9 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining a Physician's Global Assessment (PGA) Response During the Double-Blind Treatment Withdrawal (Period B)	Week 12	60.6 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining a Physician's Global Assessment (PGA) Response During the Double-Blind Treatment Withdrawal (Period B)	Week 8	34.4 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining a Physician's Global Assessment (PGA) Response During the Double-Blind Treatment Withdrawal (Period B)	Week 16	22.9 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining a Physician's Global Assessment (PGA) Response During the Double-Blind Treatment Withdrawal (Period B)	Week 12	26.7 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining a Physician's Global Assessment (PGA) Response During the Double-Blind Treatment Withdrawal (Period B)	Week 4	57.3 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Maintaining a Physician's Global Assessment (PGA) Response During the Double-Blind Treatment Withdrawal (Period B)	Week 4	80.0 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Maintaining a Physician's Global Assessment (PGA) Response During the Double-Blind Treatment Withdrawal (Period B)	Week 16	63.9 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Maintaining a Physician's Global Assessment (PGA) Response During the Double-Blind Treatment Withdrawal (Period B)	Week 12	66.3 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Maintaining a Physician's Global Assessment (PGA) Response During the Double-Blind Treatment Withdrawal (Period B)	Week 8	80.0 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Maintaining a Physician's Global Assessment (PGA) Response During the Double-Blind Treatment Withdrawal (Period B)	Week 16	18.0 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Maintaining a Physician's Global Assessment (PGA) Response During the Double-Blind Treatment Withdrawal (Period B)	Week 4	52.3 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Maintaining a Physician's Global Assessment (PGA) Response During the Double-Blind Treatment Withdrawal (Period B)	Week 8	32.5 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Maintaining a Physician's Global Assessment (PGA) Response During the Double-Blind Treatment Withdrawal (Period B)	Week 12	23.8 percentage of participants

p-value: 0.0027Log Rank

p-value: <0.0001Log Rank

Primary

Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B)

The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of body surface area (BSA) affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response defined as at least a 75 percent (%) reduction in PASI relative to baseline.

Time frame: Weeks 4, 8 12, and 16 (Period B)

Population: The Period B-Full Analysis Set (FAS-B) included all participants who were re-randomized at the end of Period A and received at least 1dose of investigational drug (CP-690,550 5 mg BID or 10 mg BID) or placebo at the beginning of Period B.

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B)	Week 4	90.3 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B)	Week 8	70.3 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B)	Week 12	63.2 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B)	Week 16	56.2 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B)	Week 8	36.2 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B)	Week 12	32.4 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B)	Week 16	23.3 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B)	Week 4	63.4 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B)	Week 12	77.2 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B)	Week 8	86.6 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B)	Week 16	62.3 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B)	Week 4	91.1 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B)	Week 16	26.1 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B)	Week 8	39.6 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B)	Week 4	61.4 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B)	Week 12	33.4 percentage of participants

p-value: 0.0008Log Rank

p-value: <0.0001Log Rank

Secondary

ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C) - Percentage of Participant With a Response

The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate your worst itching due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms No itching (0) and Worst possible itching (10) at the ends.

Time frame: Weeks 4, 8, and 16 (Period C)

Population: FAS-C participants with Baseline-C ISI ≥2, where Baseline-C defined as the last observation up to first dosing date in Period C.

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C) - Percentage of Participant With a Response	Week 16	57.1 percentage of participants
CP-690,550 5 mg (Period B)	ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C) - Percentage of Participant With a Response	Week 8	35.7 percentage of participants
CP-690,550 5 mg (Period B)	ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C) - Percentage of Participant With a Response	Week 4	28.6 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C) - Percentage of Participant With a Response	Week 16	100.0 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C) - Percentage of Participant With a Response	Week 8	75.1 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C) - Percentage of Participant With a Response	Week 4	61.8 percentage of participants
CP-690,550 10 mg (Period B)	ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C) - Percentage of Participant With a Response	Week 16	36.5 percentage of participants
CP-690,550 10 mg (Period B)	ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C) - Percentage of Participant With a Response	Week 4	14.3 percentage of participants
CP-690,550 10 mg (Period B)	ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C) - Percentage of Participant With a Response	Week 8	28.6 percentage of participants
Placebo for 10 mg CP-690,550	ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C) - Percentage of Participant With a Response	Week 16	91.0 percentage of participants
Placebo for 10 mg CP-690,550	ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C) - Percentage of Participant With a Response	Week 8	86.7 percentage of participants
Placebo for 10 mg CP-690,550	ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C) - Percentage of Participant With a Response	Week 4	80.0 percentage of participants

Secondary

ISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A participants with Baseline-A ISI ≥2, where Baseline-A was defined as the last observation before the first dosing date in Period A.

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	ISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response	Week 4	82.2 percentage of participants
CP-690,550 5 mg (Period B)	ISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response	Week 8	89.5 percentage of participants
CP-690,550 5 mg (Period B)	ISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response	Week 16	93.6 percentage of participants
CP-690,550 5 mg (Period B)	ISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response	Week 24	96.2 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	ISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response	Week 24	97.8 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	ISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response	Week 4	90.3 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	ISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response	Week 16	97.8 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	ISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response	Week 8	96.5 percentage of participants

Secondary

ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C) - Percentage of Participants With a Response

Time frame: Weeks 4, 8, and 16 (Period C)

Population: FAS-C participants with a Baseline-C ISI \>1, where Baseline-C is defined as the last observation up to first dosing date in Period C.

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C) - Percentage of Participants With a Response	Week 16	40.5 percentage of participants
CP-690,550 5 mg (Period B)	ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C) - Percentage of Participants With a Response	Week 4	14.3 percentage of participants
CP-690,550 5 mg (Period B)	ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C) - Percentage of Participants With a Response	Week 8	28.6 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C) - Percentage of Participants With a Response	Week 8	37.9 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C) - Percentage of Participants With a Response	Week 4	22.8 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C) - Percentage of Participants With a Response	Week 16	79.1 percentage of participants
CP-690,550 10 mg (Period B)	ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C) - Percentage of Participants With a Response	Week 8	21.4 percentage of participants
CP-690,550 10 mg (Period B)	ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C) - Percentage of Participants With a Response	Week 4	14.3 percentage of participants
CP-690,550 10 mg (Period B)	ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C) - Percentage of Participants With a Response	Week 16	49.5 percentage of participants
Placebo for 10 mg CP-690,550	ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C) - Percentage of Participants With a Response	Week 4	41.3 percentage of participants
Placebo for 10 mg CP-690,550	ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C) - Percentage of Participants With a Response	Week 16	90.3 percentage of participants
Placebo for 10 mg CP-690,550	ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C) - Percentage of Participants With a Response	Week 8	59.8 percentage of participants

Secondary

ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A participants with Baseline-A ISI \>1, where Baseline-A was defined as the last observation before the first dosing date in Period A.

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response	Week 4	27.8 percentage of participants
CP-690,550 5 mg (Period B)	ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response	Week 16	52.4 percentage of participants
CP-690,550 5 mg (Period B)	ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response	Week 8	41.2 percentage of participants
CP-690,550 5 mg (Period B)	ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response	Week 24	72.4 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response	Week 8	67.8 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response	Week 4	47.2 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response	Week 24	83.4 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response	Week 16	78.6 percentage of participants

Secondary

Mean Change From Baseline-A in DLQI Score During the Initial CP-690,550 Treatment (Period A)

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Score During the Initial CP-690,550 Treatment (Period A)	Week 8 (n=320,317)	-7.1 scores on a scale	Standard Error 0.3
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Score During the Initial CP-690,550 Treatment (Period A)	Week 24 (n=272,275)	-7.1 scores on a scale	Standard Error 0.4
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Score During the Initial CP-690,550 Treatment (Period A)	Week 16 (n=309,301)	-7.6 scores on a scale	Standard Error 0.4
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Score During the Initial CP-690,550 Treatment (Period A)	Week 4 (n=325,328)	-5.8 scores on a scale	Standard Error 0.3
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Score During the Initial CP-690,550 Treatment (Period A)	Week 16 (n=309,301)	-9.4 scores on a scale	Standard Error 0.4
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Score During the Initial CP-690,550 Treatment (Period A)	Week 4 (n=325,328)	-7.6 scores on a scale	Standard Error 0.3
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Score During the Initial CP-690,550 Treatment (Period A)	Week 24 (n=272,275)	-9.7 scores on a scale	Standard Error 0.4
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Score During the Initial CP-690,550 Treatment (Period A)	Week 8 (n=320,317)	-9.1 scores on a scale	Standard Error 0.4

Secondary

Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-A defined as the last observation up to first dosing date in Period A.

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Personal Relationships, Week 16 (n=310,300)	-1.1 scores on a scale	Standard Error 0.09
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Daily Activities, Week 8 (n=320,318)	-1.5 scores on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Daily Activities, Week 16 (n=309,301)	-1.7 scores on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Daily Activities, Week 24 (n=272,275)	-1.6 scores on a scale	Standard Error 0.11
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Personal Relationships, Week 4 (n=326,327)	-0.8 scores on a scale	Standard Error 0.08
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Personal Relationships, Week 8 (n=321,316)	-1.0 scores on a scale	Standard Error 0.08
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Daily Activities, Week 4 (n=325,328)	-1.2 scores on a scale	Standard Error 0.09
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Personal Relationships, Week 24 (n=271,274)	-1.0 scores on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Symptoms and Feelings, Week 4 (n=326,328)	-1.9 scores on a scale	Standard Error 0.08
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Symptoms and Feelings, Week 8 (n=321,317)	-2.2 scores on a scale	Standard Error 0.09
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Symptoms and Feelings, Week 18 (n=310,301)	-2.2 scores on a scale	Standard Error 0.09
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Symptoms and Feelings, Week 24 (n=273,275)	-2.1 scores on a scale	Standard Error 0.11
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Leisure, Week 4 (n=326,328)	-1.0 scores on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Leisure, Week 16 (n=310,301)	-1.4 scores on a scale	Standard Error 0.11
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Leisure, Week 8 (n=321,318)	-1.2 scores on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Leisure, Week 24 (n=272,275)	-1.3 scores on a scale	Standard Error 0.12
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Work and School, Week 4 (n=325,328)	-0.4 scores on a scale	Standard Error 0.05
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Work and School, Week 8 (n=320,317)	-0.6 scores on a scale	Standard Error 0.05
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Work and School, Week 16 (n=308,301)	-0.6 scores on a scale	Standard Error 0.06
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Work and School, Week 24 (n=272,275)	-0.5 scores on a scale	Standard Error 0.06
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Treatment, Week 4 (n=326,327)	-0.5 scores on a scale	Standard Error 0.06
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Treatment, Week 8 (n=321,317)	-0.6 scores on a scale	Standard Error 0.06
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Treatment, Week 16 (n=310,300)	-0.6 scores on a scale	Standard Error 0.06
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Treatment, Week 24 (n=272,274)	-0.5 scores on a scale	Standard Error 0.06
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Treatment, Week 16 (n=310,300)	-0.9 scores on a scale	Standard Error 0.06
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Daily Activities, Week 4 (n=325,328)	-1.6 scores on a scale	Standard Error 0.09
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Leisure, Week 4 (n=326,328)	-1.4 scores on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Daily Activities, Week 8 (n=320,318)	-1.9 scores on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Work and School, Week 16 (n=308,301)	-0.7 scores on a scale	Standard Error 0.06
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Daily Activities, Week 16 (n=309,301)	-2.0 scores on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Leisure, Week 16 (n=310,301)	-1.7 scores on a scale	Standard Error 0.11
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Daily Activities, Week 24 (n=272,275)	-2.0 scores on a scale	Standard Error 0.11
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Treatment, Week 8 (n=321,317)	-0.8 scores on a scale	Standard Error 0.06
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Personal Relationships, Week 4 (n=326,327)	-1.0 scores on a scale	Standard Error 0.09
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Leisure, Week 8 (n=321,318)	-1.7 scores on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Personal Relationships, Week 8 (n=321,316)	-1.3 scores on a scale	Standard Error 0.09
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Work and School, Week 24 (n=272,275)	-0.7 scores on a scale	Standard Error 0.06
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Personal Relationships, Week 16 (n=310,300)	-1.3 scores on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Leisure, Week 24 (n=272,275)	-1.8 scores on a scale	Standard Error 0.12
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Personal Relationships, Week 24 (n=271,274)	-1.3 scores on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Treatment, Week 24 (n=272,274)	-1.0 scores on a scale	Standard Error 0.06
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Symptoms and Feelings, Week 4 (n=326,328)	-2.3 scores on a scale	Standard Error 0.08
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Work and School, Week 4 (n=325,328)	-0.6 scores on a scale	Standard Error 0.06
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Symptoms and Feelings, Week 8 (n=321,317)	-2.7 scores on a scale	Standard Error 0.09
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Treatment, Week 4 (n=326,327)	-0.7 scores on a scale	Standard Error 0.05
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Symptoms and Feelings, Week 18 (n=310,301)	-2.8 scores on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Work and School, Week 8 (n=320,317)	-0.7 scores on a scale	Standard Error 0.06
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Symptoms and Feelings, Week 24 (n=273,275)	-2.9 scores on a scale	Standard Error 0.1

Secondary

Mean Change From Baseline-A in EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)

Time frame: Week 24 (Period A)

Population: FAS-A; n=number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Self-Care (n=270,269)	0.0 scores on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Pain / Discomfort (n=270,271)	-0.3 scores on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Usual Activities (n=270,270)	-0.1 scores on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Anxiety / Depression (n=270,271)	-0.1 scores on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Mobility (n=269,271)	-0.1 scores on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Anxiety / Depression (n=270,271)	-0.2 scores on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Mobility (n=269,271)	-0.1 scores on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Self-Care (n=270,269)	-0.1 scores on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Usual Activities (n=270,270)	-0.2 scores on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Pain / Discomfort (n=270,271)	-0.5 scores on a scale	Standard Error 0

Secondary

Mean Change From Baseline-A in EQ-5D Utility Score and VAS Scores During the Initial CP-690,550 Treatment Period (Period A)

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. Baseline-A defined as the last observation up to first dosing date in Period A.

Time frame: Week 24 (Period A)

Population: FAS-A; n=number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in EQ-5D Utility Score and VAS Scores During the Initial CP-690,550 Treatment Period (Period A)	Week 24 Utility Score (n=269,269)	0.1 scores on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in EQ-5D Utility Score and VAS Scores During the Initial CP-690,550 Treatment Period (Period A)	Week 24 VAS (n=268, 271)	5.3 scores on a scale	Standard Error 1.5
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in EQ-5D Utility Score and VAS Scores During the Initial CP-690,550 Treatment Period (Period A)	Week 24 Utility Score (n=269,269)	0.2 scores on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in EQ-5D Utility Score and VAS Scores During the Initial CP-690,550 Treatment Period (Period A)	Week 24 VAS (n=268, 271)	9.3 scores on a scale	Standard Error 1.4

Secondary

Mean Change From Baseline-A in ISI Score During the Initial CP-690,550 Treatment (Period A)

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in ISI Score During the Initial CP-690,550 Treatment (Period A)	Week 24 (n=274,278)	-3.7 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in ISI Score During the Initial CP-690,550 Treatment (Period A)	Week 8 (n=322,321)	-3.9 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in ISI Score During the Initial CP-690,550 Treatment (Period A)	Week 16 (n=310,307)	-3.8 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in ISI Score During the Initial CP-690,550 Treatment (Period A)	Week 4 (n=326,331)	-3.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in ISI Score During the Initial CP-690,550 Treatment (Period A)	Week 16 (n=310,307)	-5.2 score on a scale	Standard Error 0.2
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in ISI Score During the Initial CP-690,550 Treatment (Period A)	Week 4 (n=326,331)	-4.6 score on a scale	Standard Error 0.2
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in ISI Score During the Initial CP-690,550 Treatment (Period A)	Week 24 (n=274,278)	-5.3 score on a scale	Standard Error 0.2
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in ISI Score During the Initial CP-690,550 Treatment (Period A)	Week 8 (n=322,321)	-5.3 score on a scale	Standard Error 0.2

Secondary

Mean Change From Baseline-A in PASI Score During Initial CP-690,550 Treatment (Period A)

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in PASI Score During Initial CP-690,550 Treatment (Period A)	Week 16 (n=311,307)	-13.1 scores on a scale	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in PASI Score During Initial CP-690,550 Treatment (Period A)	Week 4 (n=326,331)	-7.6 scores on a scale	Standard Error 0.4
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in PASI Score During Initial CP-690,550 Treatment (Period A)	Week 24 (n=277,279)	-13.4 scores on a scale	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in PASI Score During Initial CP-690,550 Treatment (Period A)	Week 8 (n=322,323)	-11.1 scores on a scale	Standard Error 0.4
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in PASI Score During Initial CP-690,550 Treatment (Period A)	Week 24 (n=277,279)	-16.0 scores on a scale	Standard Error 0.5
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in PASI Score During Initial CP-690,550 Treatment (Period A)	Week 4 (n=326,331)	-10.5 scores on a scale	Standard Error 0.4
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in PASI Score During Initial CP-690,550 Treatment (Period A)	Week 16 (n=311,307)	-15.8 scores on a scale	Standard Error 0.5
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in PASI Score During Initial CP-690,550 Treatment (Period A)	Week 8 (n=322,323)	-14.2 scores on a scale	Standard Error 0.5

Secondary

Mean Change From Baseline-A in SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)

Time frame: Week 24 (Period A)

Population: FAS-A; n=number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Role Physical (n=273,276)	2.6 scores on a scale	Standard Error 0.7
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Social Functioning (n=273,275)	3.7 scores on a scale	Standard Error 0.7
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	General Health (n=273,276)	0.7 scores on a scale	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Role Emotional (n=273,276)	3.2 scores on a scale	Standard Error 0.8
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Bodily Pain (n=273,275)	4.5 scores on a scale	Standard Error 0.7
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Mental Health (n=273,275)	3.4 scores on a scale	Standard Error 0.6
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Vitality (n=273,275)	1.3 scores on a scale	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Health Transition (n=272,275)	-0.2 scores on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Physical Functioning (n=273,276)	1.8 scores on a scale	Standard Error 0.5
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Health Transition (n=272,275)	-0.2 scores on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Physical Functioning (n=273,276)	4.6 scores on a scale	Standard Error 0.5
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Role Physical (n=273,276)	5.6 scores on a scale	Standard Error 0.6
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Bodily Pain (n=273,275)	9.0 scores on a scale	Standard Error 0.7
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	General Health (n=273,276)	1.7 scores on a scale	Standard Error 0.4
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Vitality (n=273,275)	4.8 scores on a scale	Standard Error 0.5
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Social Functioning (n=273,275)	6.6 scores on a scale	Standard Error 0.7
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Role Emotional (n=273,276)	5.6 scores on a scale	Standard Error 0.7
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Mental Health (n=273,275)	4.4 scores on a scale	Standard Error 0.6

Secondary

Mean Change From Baseline-A in SF-36 PCS and MCS Scores During the Initial CP-690,550 Treatment (Period A)

The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Linear transformations were performed to transform scores to a mean of 50 and SDs of 10, in the general population. In norm-based scoring, each scale is scored to have same average (50)/SD (10). With this method anytime a scale score is below 50, health status is below average, and each point is one-tenth of a SD. Higher scores indicate a better health related quality of life.

Time frame: Week 24 (Period A)

Population: FAS-A

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in SF-36 PCS and MCS Scores During the Initial CP-690,550 Treatment (Period A)	Physical Health Score	1.9 scores on a scale	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in SF-36 PCS and MCS Scores During the Initial CP-690,550 Treatment (Period A)	Mental Health Score	3.2 scores on a scale	Standard Error 0.6
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in SF-36 PCS and MCS Scores During the Initial CP-690,550 Treatment (Period A)	Physical Health Score	5.2 scores on a scale	Standard Error 0.5
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-A in SF-36 PCS and MCS Scores During the Initial CP-690,550 Treatment (Period A)	Mental Health Score	4.9 scores on a scale	Standard Error 0.6

Secondary

Mean Change From Baseline-B in DLQI Score During the Double-Blind Treatment Withdrawal (Period B)

Time frame: Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B; n equals the number of participants with observations

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,52,41,83)	0.9 scores on a scale	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,68,43,104)	0.5 scores on a scale	Standard Error 0.3
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,44,38,68)	1.1 scores on a scale	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,127)	0.8 scores on a scale	Standard Error 0.7
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,68,43,104)	4.1 scores on a scale	Standard Error 0.7
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,44,38,68)	3.6 scores on a scale	Standard Error 0.6
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,52,41,83)	3.4 scores on a scale	Standard Error 0.5
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,127)	3.0 scores on a scale	Standard Error 0.5
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,127)	0.1 scores on a scale	Standard Error 0.3
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,44,38,68)	0.5 scores on a scale	Standard Error 0.3
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,52,41,83)	0.6 scores on a scale	Standard Error 0.4
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,68,43,104)	0.3 scores on a scale	Standard Error 0.5
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,44,38,68)	5.4 scores on a scale	Standard Error 0.8
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,127)	4.6 scores on a scale	Standard Error 0.5
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,68,43,104)	5.4 scores on a scale	Standard Error 0.6
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,52,41,83)	4.5 scores on a scale	Standard Error 0.7

Secondary

Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-B defined as the last observation up to first dosing date in Period B.

Time frame: Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B; n equals the number of participants with observations

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 16 (n=28,44,38,68)	0.4 scores on a scale	Standard Error 0.21
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 12 (n=28,52,41,83)	0.1 scores on a scale	Standard Error 0.19
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 8 (n=30,68,43,103)	0.1 scores on a scale	Standard Error 0.15
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 4 (n=30,82,43,127)	0.0 scores on a scale	Standard Error 0.07
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 8 (n=30,68,43,104)	0.0 scores on a scale	Standard Error 0.13
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 12 (n=28,52,41,83)	0.1 scores on a scale	Standard Error 0.14
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 4 (n=30,82,43,127)	0.3 scores on a scale	Standard Error 0.22
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 4 (n=30,82,43,127)	0.2 scores on a scale	Standard Error 0.25
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 16 (n=28,44,38,68)	0.1 scores on a scale	Standard Error 0.15
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 16 (n=28,44,38,68)	0.0 scores on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 16 (n=28,44,38,68)	0.2 scores on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 12 (n=28,52,41,83)	0.1 scores on a scale	Standard Error 0.08
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 8 (n=30,68,43,104)	0.1 scores on a scale	Standard Error 0.09
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 8 (n=30,68,43,104)	0.0 scores on a scale	Standard Error 0.06
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 8 (n=30,68,43,104)	0.1 scores on a scale	Standard Error 0.06
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 4 (n=30,82,43,127)	0.0 scores on a scale	Standard Error 0.6
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 12 (n=28,52,41,83)	0.2 scores on a scale	Standard Error 0.13
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 16 (n=28,44,37,68)	0.2 scores on a scale	Standard Error 0.12
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 12 (n=28,52,41,83)	0.2 scores on a scale	Standard Error 0.12
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 16 (n=28,44,38,68)	0.2 scores on a scale	Standard Error 0.12
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 12 (n=28,52,41,83)	0.1 scores on a scale	Standard Error 0.11
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 8 (n=30,68,43,104)	0.1 scores on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 4 (n=30,82,42,127)	0.2 scores on a scale	Standard Error 0.22
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 4 (n=30,82,43,126)	0.0 scores on a scale	Standard Error 0.11
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 4 (n=30,82,43,127)	0.2 scores on a scale	Standard Error 0.06
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 4 (n=30,82,43,126)	0.4 scores on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 12 (n=28,52,41,83)	0.4 scores on a scale	Standard Error 0.11
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 4 (n=30,82,43,127)	0.5 scores on a scale	Standard Error 0.14
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 8 (n=30,68,43,104)	0.8 scores on a scale	Standard Error 0.17
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 12 (n=28,52,41,83)	0.7 scores on a scale	Standard Error 0.14
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 16 (n=28,44,38,68)	0.9 scores on a scale	Standard Error 0.19
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 8 (n=30,68,43,103)	0.6 scores on a scale	Standard Error 0.15
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 12 (n=28,52,41,83)	0.4 scores on a scale	Standard Error 0.14
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 16 (n=28,44,38,68)	0.3 scores on a scale	Standard Error 0.15
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 4 (n=30,82,43,127)	1.3 scores on a scale	Standard Error 0.17
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 8 (n=30,68,43,104)	1.5 scores on a scale	Standard Error 0.17
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 12 (n=28,52,41,83)	1.4 scores on a scale	Standard Error 0.18
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 16 (n=28,44,38,68)	1.3 scores on a scale	Standard Error 0.22
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 4 (n=30,82,42,127)	0.3 scores on a scale	Standard Error 0.11
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 8 (n=30,68,43,104)	0.5 scores on a scale	Standard Error 0.16
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 16 (n=28,44,37,68)	0.4 scores on a scale	Standard Error 0.12
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 4 (n=30,82,43,127)	0.2 scores on a scale	Standard Error 0.07
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 8 (n=30,68,43,104)	0.2 scores on a scale	Standard Error 0.09
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 12 (n=28,52,41,83)	0.1 scores on a scale	Standard Error 0.07
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 16 (n=28,44,38,68)	0.2 scores on a scale	Standard Error 0.09
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 8 (n=30,68,43,104)	0.4 scores on a scale	Standard Error 0.09
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 12 (n=28,52,41,83)	0.3 scores on a scale	Standard Error 0.7
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 16 (n=28,44,38,68)	0.5 scores on a scale	Standard Error 0.11
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 12 (n=28,52,41,83)	0.5 scores on a scale	Standard Error 0.19
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 4 (n=30,82,43,126)	-0.1 scores on a scale	Standard Error 0.08
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 16 (n=28,44,38,68)	0.5 scores on a scale	Standard Error 0.14
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 4 (n=30,82,42,127)	-0.1 scores on a scale	Standard Error 0.09
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 16 (n=28,44,38,68)	0.2 scores on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 8 (n=30,68,43,104)	0.0 scores on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 12 (n=28,52,41,83)	0.0 scores on a scale	Standard Error 0.09
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 12 (n=28,52,41,83)	0.1 scores on a scale	Standard Error 0.11
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 8 (n=30,68,43,104)	0.0 scores on a scale	Standard Error 0.06
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 16 (n=28,44,37,68)	-0.1 scores on a scale	Standard Error 0.08
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 4 (n=30,82,43,127)	0.0 scores on a scale	Standard Error 0
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 8 (n=30,68,43,104)	0.2 scores on a scale	Standard Error 0.13
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 8 (n=30,68,43,104)	0.0 scores on a scale	Standard Error 0.02
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 12 (n=28,52,41,83)	0.0 scores on a scale	Standard Error 0.09
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 12 (n=28,52,41,83)	0.1 scores on a scale	Standard Error 0.04
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 4 (n=30,82,43,127)	0.1 scores on a scale	Standard Error 0.08
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 16 (n=28,44,38,68)	0.0 scores on a scale	Standard Error 0
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 16 (n=28,44,38,68)	-0.1 scores on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 12 (n=28,52,41,83)	-0.1 scores on a scale	Standard Error 0.09
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 16 (n=28,44,38,68)	0.1 scores on a scale	Standard Error 0.05
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 4 (n=30,82,43,127)	0.1 scores on a scale	Standard Error 0.13
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 8 (n=30,68,43,103)	-0.1 scores on a scale	Standard Error 0.09
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 8 (n=30,68,43,104)	0.2 scores on a scale	Standard Error 0.17
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 4 (n=30,82,43,127)	0.1 scores on a scale	Standard Error 0.06
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 16 (n=28,44,38,68)	0.5 scores on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 16 (n=28,44,38,68)	0.8 scores on a scale	Standard Error 0.17
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 4 (n=30,82,43,127)	0.4 scores on a scale	Standard Error 0.07
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 8 (n=30,68,43,104)	0.4 scores on a scale	Standard Error 0.08
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 16 (n=28,44,38,68)	1.8 scores on a scale	Standard Error 0.21
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 16 (n=28,44,38,68)	1.1 scores on a scale	Standard Error 0.22
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 16 (n=28,44,37,68)	0.8 scores on a scale	Standard Error 0.18
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 4 (n=30,82,43,127)	0.9 scores on a scale	Standard Error 0.13
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 4 (n=30,82,42,127)	0.7 scores on a scale	Standard Error 0.12
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 12 (n=28,52,41,83)	0.3 scores on a scale	Standard Error 0.09
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 8 (n=30,68,43,103)	0.8 scores on a scale	Standard Error 0.13
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 12 (n=28,52,41,83)	1.6 scores on a scale	Standard Error 0.18
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 8 (n=30,68,43,104)	0.8 scores on a scale	Standard Error 0.15
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 12 (n=28,52,41,83)	0.9 scores on a scale	Standard Error 0.17
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 8 (n=30,68,43,104)	1.8 scores on a scale	Standard Error 0.16
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 12 (n=28,52,41,83)	0.6 scores on a scale	Standard Error 0.15
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 12 (n=28,52,41,83)	0.4 scores on a scale	Standard Error 0.09
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 4 (n=30,82,43,127)	1.7 scores on a scale	Standard Error 0.14
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 12 (n=28,52,41,83)	0.6 scores on a scale	Standard Error 0.13
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 8 (n=30,68,43,104)	1.0 scores on a scale	Standard Error 0.17
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 8 (n=30,68,43,104)	0.6 scores on a scale	Standard Error 0.08
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 16 (n=28,44,38,68)	0.4 scores on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 4 (n=30,82,43,127)	0.5 scores on a scale	Standard Error 0.08
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 4 (n=30,82,43,126)	0.5 scores on a scale	Standard Error 0.09

Secondary

Mean Change From Baseline-B in ISI Score During the Double-Blind Treatment Withdrawal (Period B)

Time frame: Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B; n equals the number of participants with observations

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,127)	0.2 score on a scale	Standard Error 0.3
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,69,43,104)	-0.0 score on a scale	Standard Error 0.3
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=29,53,41,84)	0.3 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	0.6 score on a scale	Standard Error 0.3
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,69,43,104)	2.9 score on a scale	Standard Error 0.3
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=29,53,41,84)	2.8 score on a scale	Standard Error 0.3
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	2.7 score on a scale	Standard Error 0.4
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,127)	2.4 score on a scale	Standard Error 0.3
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=29,53,41,84)	0.7 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,69,43,104)	0.6 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	0.9 score on a scale	Standard Error 0.3
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,127)	0.1 score on a scale	Standard Error 0.2
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	3.6 score on a scale	Standard Error 0.4
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,69,43,104)	3.4 score on a scale	Standard Error 0.3
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,127)	3.3 score on a scale	Standard Error 0.3
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=29,53,41,84)	3.2 score on a scale	Standard Error 0.3

Secondary

Mean Change From Baseline-B in PASI Score During Double-Blind Treatment Withdrawal (Period B)

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline-B defined as last observation up to first dosing date in Period B.

Time frame: Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B; n equals the number of participants with observations

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,53,42,84)	0.7 scores on a scale	Standard Error 0.4
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,128)	0.4 scores on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	1.0 scores on a scale	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,70,43,104)	0.9 scores on a scale	Standard Error 0.4
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,128)	3.3 scores on a scale	Standard Error 0.6
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	4.1 scores on a scale	Standard Error 0.6
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,70,43,104)	4.9 scores on a scale	Standard Error 0.7
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-B in PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,53,42,84)	4.8 scores on a scale	Standard Error 0.7
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	1.4 scores on a scale	Standard Error 0.4
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,128)	0.2 scores on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,53,42,84)	0.9 scores on a scale	Standard Error 0.4
CP-690,550 10 mg (Period B)	Mean Change From Baseline-B in PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,70,43,104)	0.3 scores on a scale	Standard Error 0.3
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	4.4 scores on a scale	Standard Error 0.5
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,128)	3.8 scores on a scale	Standard Error 0.5
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,70,43,104)	5.4 scores on a scale	Standard Error 0.6
Placebo for 10 mg CP-690,550	Mean Change From Baseline-B in PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,53,42,84)	4.5 scores on a scale	Standard Error 0.6

Secondary

Mean Change From Baseline-C in DLQI Score During the CP-690,550 Re-Treatment (Period C)

Time frame: Weeks 4, 8, and 16 (Period C)

Population: FAS-C; n equals number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,71,41,118)	0.2 scores on a scale	Standard Error 0.4
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	-0.2 scores on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=22,66,39,101)	0.5 scores on a scale	Standard Error 0.8
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,71,41,118)	-3.4 scores on a scale	Standard Error 0.5
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=22,66,39,101)	-3.3 scores on a scale	Standard Error 0.8
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	-2.9 scores on a scale	Standard Error 0.5
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in DLQI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	0.0 scores on a scale	Standard Error 0.4
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in DLQI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=22,66,39,101)	-0.0 scores on a scale	Standard Error 0.7
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in DLQI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,71,41,118)	-0.0 scores on a scale	Standard Error 0.5
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in DLQI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	-4.9 scores on a scale	Standard Error 0.6
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in DLQI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=22,66,39,101)	-6.3 scores on a scale	Standard Error 0.7
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in DLQI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,71,41,118)	-5.9 scores on a scale	Standard Error 0.6

Secondary

Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-C defined as the last observation up to first dosing date in Period C.

Time frame: Weeks 4, 8, and 16 (Period C)

Population: FAS-C; n equals the number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Week 4 (n=27,74,41,119)	-0.1 scores on a scale	Standard Error 0.08
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Week 16 (n=22,66,39,101)	0.0 scores on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Week 8 (n=26,71,41,118)	0.0 scores on a scale	Standard Error 0.14
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Week 8 (n=26,71,41,118)	0.0 scores on a scale	Standard Error 0.07
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Week 8 (n=26,71,41,118)	0.0 scores on a scale	Standard Error 0.07
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Week 4 (n=27,74,42,119)	0.0 scores on a scale	Standard Error 0.14
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Week 16 (n=22,66,39,101)	0.0 scores on a scale	Standard Error 0.11
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Week 4 (n=27,74,42,119)	0.0 scores on a scale	Standard Error 0.08
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Week 16 (n=22,66,39,101)	0.0 scores on a scale	Standard Error 0.07
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Week 8 (n=26,71,41,118)	0.2 scores on a scale	Standard Error 0.15
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Week 16 (n=22,66,39,101)	0.0 scores on a scale	Standard Error 0.08
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Week 8 (n=26,71,41,118)	0.0 scores on a scale	Standard Error 0.7
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Week 4 (n=27,74,42,119)	0.0 scores on a scale	Standard Error 0.06
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Week 16 (n=22,65,39,101)	0.4 scores on a scale	Standard Error 0.23
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Week 4 (n=27,74,42,119)	0.0 scores on a scale	Standard Error 0.06
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Week 16 (n=22,66,39,101)	0.0 scores on a scale	Standard Error 0.28
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Week 8 (n=26,71,41,118)	0.0 scores on a scale	Standard Error 0.13
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Week 4 (n=27,74,42,119)	0.0 scores on a scale	Standard Error 0.05
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Week 4 (n=27,74,42,119)	-0.4 scores on a scale	Standard Error 0.11
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Week 8 (n=26,71,41,118)	-0.3 scores on a scale	Standard Error 0.08
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Week 16 (n=22,66,39,101)	-0.3 scores on a scale	Standard Error 0.09
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Week 4 (n=27,74,42,119)	-0.7 scores on a scale	Standard Error 0.12
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Week 8 (n=26,71,41,118)	-0.7 scores on a scale	Standard Error 0.13
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Week 16 (n=22,65,39,101)	-0.7 scores on a scale	Standard Error 0.2
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Week 8 (n=26,71,41,118)	-0.6 scores on a scale	Standard Error 0.13
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Week 16 (n=22,66,39,101)	-0.6 scores on a scale	Standard Error 0.14
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Week 4 (n=27,74,42,119)	-1.0 scores on a scale	Standard Error 0.13
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Week 8 (n=26,71,41,118)	-1.1 scores on a scale	Standard Error 0.17
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Week 16 (n=22,66,39,101)	-1.0 scores on a scale	Standard Error 0.2
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Week 4 (n=27,74,41,119)	-0.3 scores on a scale	Standard Error 0.14
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Week 8 (n=26,71,41,118)	-0.4 scores on a scale	Standard Error 0.13
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Week 16 (n=22,66,39,101)	-0.4 scores on a scale	Standard Error 0.17
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Week 4 (n=27,74,42,119)	-0.2 scores on a scale	Standard Error 0.07
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Week 8 (n=26,71,41,118)	-0.3 scores on a scale	Standard Error 0.09
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Week 16 (n=22,66,39,101)	-0.3 scores on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Week 4 (n=27,74,42,119)	-0.2 scores on a scale	Standard Error 0.08
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Week 4 (n=27,74,42,119)	0.1 scores on a scale	Standard Error 0.08
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Week 16 (n=22,66,39,101)	-0.2 scores on a scale	Standard Error 0.21
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Week 4 (n=27,74,42,119)	0.0 scores on a scale	Standard Error 0.07
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Week 4 (n=27,74,41,119)	0.1 scores on a scale	Standard Error 0.06
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Week 8 (n=26,71,41,118)	0.1 scores on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Week 16 (n=22,65,39,101)	-0.1 scores on a scale	Standard Error 0.18
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Week 8 (n=26,71,41,118)	-0.2 scores on a scale	Standard Error 0.09
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Week 16 (n=22,66,39,101)	0.2 scores on a scale	Standard Error 0.12
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Week 4 (n=27,74,42,119)	0.0 scores on a scale	Standard Error 0.03
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Week 8 (n=26,71,41,118)	0.0 scores on a scale	Standard Error 0.14
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Week 8 (n=26,71,41,118)	0.0 scores on a scale	Standard Error 0.06
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Week 16 (n=22,66,39,101)	-0.1 scores on a scale	Standard Error 0.11
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Week 16 (n=22,66,39,101)	0.1 scores on a scale	Standard Error 0.09
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Week 16 (n=22,66,39,101)	0.1 scores on a scale	Standard Error 0.12
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Week 8 (n=26,71,41,118)	0.1 scores on a scale	Standard Error 0.13
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Week 4 (n=27,74,42,119)	-0.1 scores on a scale	Standard Error 0.13
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Week 4 (n=27,74,42,119)	0.1 scores on a scale	Standard Error 0.11
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Week 8 (n=26,71,41,118)	-0.1 scores on a scale	Standard Error 0.18
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Week 4 (n=27,74,42,119)	-1.5 scores on a scale	Standard Error 0.15
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Week 16 (n=22,66,39,101)	-0.7 scores on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Week 16 (n=22,66,39,101)	-0.9 scores on a scale	Standard Error 0.15
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Week 16 (n=22,66,39,101)	-1.9 scores on a scale	Standard Error 0.19
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Week 8 (n=26,71,41,118)	-0.8 scores on a scale	Standard Error 0.14
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Week 4 (n=27,74,42,119)	-0.4 scores on a scale	Standard Error 0.08
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Week 4 (n=27,74,42,119)	-0.7 scores on a scale	Standard Error 0.13
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Week 4 (n=27,74,41,119)	-0.8 scores on a scale	Standard Error 0.13
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Week 16 (n=22,65,39,101)	-1.3 scores on a scale	Standard Error 0.18
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Week 4 (n=27,74,42,119)	-0.6 scores on a scale	Standard Error 0.07
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Week 8 (n=26,71,41,118)	-0.4 scores on a scale	Standard Error 0.09
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Week 8 (n=26,71,41,118)	-1.0 scores on a scale	Standard Error 0.15
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Week 4 (n=27,74,42,119)	-1.0 scores on a scale	Standard Error 0.13
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Week 16 (n=22,66,39,101)	-0.5 scores on a scale	Standard Error 0.09
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Week 8 (n=26,71,41,118)	-1.8 scores on a scale	Standard Error 0.18
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Week 16 (n=22,66,39,101)	-1.1 scores on a scale	Standard Error 0.18
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Week 8 (n=26,71,41,118)	-1.3 scores on a scale	Standard Error 0.15
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Week 8 (n=26,71,41,118)	-0.07 scores on a scale	Standard Error 0.09

Secondary

Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)

Time frame: Week 56 (Period C)

Population: FAS-C

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Pain / Discomfort	0.0 scores on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Self-Care	0.0 scores on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Anxiety / Depression	-0.1 scores on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Usual Activities	-0.0 scores on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Mobility	0.0 scores on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Usual Activities	-0.1 scores on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Pain / Discomfort	-0.1 scores on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Anxiety / Depression	-0.1 scores on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Self-Care	-0.1 scores on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Mobility	-0.0 scores on a scale	Standard Error 0
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Usual Activities	0.0 scores on a scale	Standard Error 0
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Mobility	0.0 scores on a scale	Standard Error 0
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Self-Care	0.0 scores on a scale	Standard Error 0
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Pain / Discomfort	0.0 scores on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Anxiety / Depression	0.1 scores on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Pain / Discomfort	-0.3 scores on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Self-Care	-0.1 scores on a scale	Standard Error 0
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Mobility	-0.0 scores on a scale	Standard Error 0
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Usual Activities	-0.2 scores on a scale	Standard Error 0
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Anxiety / Depression	-0.1 scores on a scale	Standard Error 0.1

Secondary

Mean Change From Baseline-C in EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. Baseline-C defined as the last observation up to first dosing date in Period C.

Time frame: Week 56 (Period C)

Population: FAS-C

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Visual Analogue Score	-1.0 scores on a scale	Standard Error 1.6
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Utility Score	0.0 scores on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Utility Score	0.1 scores on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Visual Analogue Score	4.2 scores on a scale	Standard Error 1.7
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Utility Score	-0.0 scores on a scale	Standard Error 0
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Visual Analogue Score	6.4 scores on a scale	Standard Error 3.8
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Visual Analogue Score	6.4 scores on a scale	Standard Error 1.5
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Utility Score	0.1 scores on a scale	Standard Error 0

Secondary

Mean Change From Baseline-C in ISI Score During the CP-690,550 Re-Treatment (Period C)

Time frame: Weeks 4, 8, and 16 (Period C)

Population: FAS-C; n equals number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in ISI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	0.3 score on a scale	Standard Error 0.4
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in ISI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,100)	0.4 score on a scale	Standard Error 0.4
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in ISI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	0.1 score on a scale	Standard Error 0.4
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in ISI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	-2.3 score on a scale	Standard Error 0.3
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in ISI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,100)	-2.6 score on a scale	Standard Error 0.4
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in ISI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	-2.6 score on a scale	Standard Error 0.3
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in ISI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	-0.2 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in ISI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	0.0 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in ISI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,100)	-0.3 score on a scale	Standard Error 0.3
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in ISI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	-3.1 score on a scale	Standard Error 0.3
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in ISI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,100)	-3.6 score on a scale	Standard Error 0.3
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in ISI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	-3.4 score on a scale	Standard Error 0.3

Secondary

Mean Change From Baseline-C in PASI Score During the CP-690,550 Re-Treatment (Period C)

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline-C defined as last observation up to first dosing date in Period C.

Time frame: Weeks 4, 8, and 16 (Period C)

Population: FAS-C; n equals number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	-0.2 scores on a scale	Standard Error 0.4
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,101)	0.1 scores on a scale	Standard Error 0.6
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	0.0 scores on a scale	Standard Error 0.5
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	-2.3 scores on a scale	Standard Error 0.7
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,101)	-4.5 scores on a scale	Standard Error 0.9
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	-3.8 scores on a scale	Standard Error 0.7
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	-0.2 scores on a scale	Standard Error 0.4
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	-0.1 scores on a scale	Standard Error 0.5
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,101)	-0.0 scores on a scale	Standard Error 0.7
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	-4.8 scores on a scale	Standard Error 0.6
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,101)	-5.9 scores on a scale	Standard Error 0.6
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	-5.4 scores on a scale	Standard Error 0.6

Secondary

Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)

Time frame: Week 56 (Period C)

Population: FAS-C

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Role Emotional	-1.4 scores on a scale	Standard Error 1
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Social Functioning	-1.5 scores on a scale	Standard Error 0.7
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Health Transition Score	-0.0 scores on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	General Health	-0.7 scores on a scale	Standard Error 0.9
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Bodily Pain	-1.6 scores on a scale	Standard Error 1.6
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Role Physical	-0.7 scores on a scale	Standard Error 0.9
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Mental Health	-0.1 scores on a scale	Standard Error 1.5
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Vitality	-3.5 scores on a scale	Standard Error 1.3
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Physical Functioning	-0.4 scores on a scale	Standard Error 0.7
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Vitality	1.1 scores on a scale	Standard Error 0.9
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Role Emotional	-1.3 scores on a scale	Standard Error 1.2
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Social Functioning	2.6 scores on a scale	Standard Error 1.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Role Physical	1.2 scores on a scale	Standard Error 1.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Physical Functioning	1.2 scores on a scale	Standard Error 0.7
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Bodily Pain	3.8 scores on a scale	Standard Error 1.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Health Transition Score	-0.3 scores on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Mental Health	1.1 scores on a scale	Standard Error 0.9
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	General Health	1.9 scores on a scale	Standard Error 0.8
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Vitality	0.2 scores on a scale	Standard Error 1.6
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Physical Functioning	-0.5 scores on a scale	Standard Error 0.7
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Role Physical	0.2 scores on a scale	Standard Error 0.8
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Bodily Pain	-1.1 scores on a scale	Standard Error 1.4
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	General Health	-1.1 scores on a scale	Standard Error 0.9
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Social Functioning	-1.3 scores on a scale	Standard Error 1.9
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Role Emotional	1.9 scores on a scale	Standard Error 1.6
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Mental Health	-0.5 scores on a scale	Standard Error 1.5
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Health Transition Score	0.1 scores on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Role Emotional	4.6 scores on a scale	Standard Error 1
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	General Health	1.6 scores on a scale	Standard Error 0.8
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Bodily Pain	6.0 scores on a scale	Standard Error 1.2
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Health Transition Score	-0.2 scores on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Mental Health	4.1 scores on a scale	Standard Error 1
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Role Physical	2.7 scores on a scale	Standard Error 0.9
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Social Functioning	4.7 scores on a scale	Standard Error 1
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Vitality	3.1 scores on a scale	Standard Error 1
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Physical Functioning	0.7 scores on a scale	Standard Error 0.9

Secondary

Mean Change From Baseline-C in SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)

Time frame: Week 56 (Period C)

Population: FAS-C

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)	Physical Health Score	-0.9 scores on a scale	Standard Error 1.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)	Mental Health Score	-1.6 scores on a scale	Standard Error 1.2
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)	Mental Health Score	0.1 scores on a scale	Standard Error 1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline-C in SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)	Physical Health Score	2.7 scores on a scale	Standard Error 0.8
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)	Physical Health Score	-1.0 scores on a scale	Standard Error 0.8
CP-690,550 10 mg (Period B)	Mean Change From Baseline-C in SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)	Mental Health Score	0.5 scores on a scale	Standard Error 1.9
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)	Physical Health Score	1.8 scores on a scale	Standard Error 0.9
Placebo for 10 mg CP-690,550	Mean Change From Baseline-C in SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)	Mental Health Score	4.9 scores on a scale	Standard Error 1

Secondary

Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.

Time frame: Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B; n equals number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 12 (n=28,53,42,84)	0.3 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 16 (n=28,45,38,70)	0.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 16 (n=28,45,38,70)	0.2 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 12 (n=28,53,42,84)	0.4 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 8 (n=30,70,43,104)	0.3 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 12 (n=28,53,42,84)	0.2 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 8 (n=30,70,43,104)	0.3 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 4 (n=30,82,43,128)	0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 8 (n=30,70,43,104)	0.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 4 (n=30,82,43,128)	0.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 8 (n=30,70,43,104)	0.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 4 (n=30,82,43,128)	0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 16 (n=28,45,38,70)	0.3 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 8 (n=30,70,43,104)	0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 12 (n=28,53,42,84)	0.4 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 4 (n=30,82,43,128)	0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 4 (n=30,82,43,128)	0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 16 (n=28,45,38,70)	0.4 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 8 (n=30,70,43,104)	0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 12 (n=28,53,42,84)	0.1 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 12 (n=28,53,42,84)	0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 16 (n=28,45,38,70)	0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 12 (n=28,53,42,84)	0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 8 (n=30,70,43,104)	0.1 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 4 (n=30,82,43,128)	0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 8 (n=30,70,43,104)	0.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 16 (n=28,45,38,70)	0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 12 (n=28,53,42,84)	0.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 4 (n=30,82,43,128)	0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 16 (n=28,45,38,70)	0.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 4 (n=30,82,43,128)	0.0 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 16 (n=28,45,38,70)	0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 12 (n=28,53,42,84)	0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 8 (n=30,70,43,104)	0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 4 (n=30,82,43,128)	0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 8 (n=30,70,43,104)	0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 4 (n=30,82,43,128)	-0.0 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 12 (n=28,53,42,84)	0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 16 (n=28,45,38,70)	0.3 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 12 (n=28,53,42,84)	0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 16 (n=28,45,38,70)	0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 16 (n=28,45,38,70)	0.3 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 12 (n=28,53,42,84)	0.3 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 4 (n=30,82,43,128)	0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 8 (n=30,70,43,104)	0.2 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 4 (n=30,82,43,128)	0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 16 (n=28,45,38,70)	0.4 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 8 (n=30,70,43,104)	0.3 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 4 (n=30,82,43,128)	0.8 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 8 (n=30,70,43,104)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 12 (n=28,53,42,84)	0.8 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 16 (n=28,45,38,70)	0.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 4 (n=30,82,43,128)	0.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 8 (n=30,70,43,104)	0.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 12 (n=28,53,42,84)	0.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 16 (n=28,45,38,70)	0.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 4 (n=30,82,43,128)	0.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 8 (n=30,70,43,104)	0.8 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 16 (n=28,45,38,70)	0.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 4 (n=30,82,43,128)	0.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 8 (n=30,70,43,104)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 16 (n=28,45,38,70)	0.8 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 8 (n=30,70,43,104)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 12 (n=28,53,42,84)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 8 (n=30,70,43,104)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 16 (n=28,45,38,70)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 4 (n=30,82,43,128)	0.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 8 (n=30,70,43,104)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 12 (n=28,53,42,84)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 16 (n=28,45,38,70)	1.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 12 (n=28,53,42,84)	0.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 12 (n=28,53,42,84)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 4 (n=30,82,43,128)	0.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 16 (n=28,45,38,70)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 4 (n=30,82,43,128)	0.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 12 (n=28,53,42,84)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 8 (n=30,70,43,104)	1.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 12 (n=28,53,42,84)	1.2 score on a scale	Standard Error 0.2
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 16 (n=28,45,38,70)	1.0 score on a scale	Standard Error 0.2
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 4 (n=30,82,43,128)	0.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 8 (n=30,70,43,104)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 12 (n=28,53,42,84)	1.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 16 (n=28,45,38,70)	1.0 score on a scale	Standard Error 0.2
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 4 (n=30,82,43,128)	0.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 8 (n=30,70,43,104)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 12 (n=28,53,42,84)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 16 (n=28,45,38,70)	0.9 score on a scale	Standard Error 0.2
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 4 (n=30,82,43,128)	0.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 8 (n=30,70,43,104)	1.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 12 (n=28,53,42,84)	1.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 16 (n=28,45,38,70)	1.1 score on a scale	Standard Error 0.2
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 4 (n=30,82,43,128)	0.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 8 (n=30,70,43,104)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 12 (n=28,53,42,84)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 16 (n=28,45,38,70)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 4 (n=30,82,43,128)	0.6 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 16 (n=28,45,38,70)	0.3 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 16 (n=28,45,38,70)	0.2 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 12 (n=28,53,42,84)	0.2 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 8 (n=30,70,43,104)	0.2 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 12 (n=28,53,42,84)	0.1 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 12 (n=28,53,42,84)	0.4 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 4 (n=30,82,43,128)	0.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 16 (n=28,45,38,70)	0.3 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 12 (n=28,53,42,84)	0.3 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 16 (n=28,45,38,70)	0.3 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 8 (n=30,70,43,104)	0.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 12 (n=28,53,42,84)	0.2 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 12 (n=28,53,42,84)	0.3 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 12 (n=28,53,42,84)	0.2 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 16 (n=28,45,38,70)	0.2 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 4 (n=30,82,43,128)	0.2 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 4 (n=30,82,43,128)	0.0 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 8 (n=30,70,43,104)	0.2 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 4 (n=30,82,43,128)	0.0 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 8 (n=30,70,43,104)	0.2 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 4 (n=30,82,43,128)	0.2 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 12 (n=28,53,42,84)	0.3 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 16 (n=28,45,38,70)	0.3 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 16 (n=28,45,38,70)	0.2 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 16 (n=28,45,38,70)	0.4 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 4 (n=30,82,43,128)	-0.0 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 12 (n=28,53,42,84)	0.3 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 8 (n=30,70,43,104)	0.0 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 8 (n=30,70,43,104)	0.2 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 8 (n=30,70,43,104)	0.2 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 12 (n=28,53,42,84)	0.2 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 8 (n=30,70,43,104)	0.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 16 (n=28,45,38,70)	0.3 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 4 (n=30,82,43,128)	0.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 16 (n=28,45,38,70)	0.5 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 4 (n=30,82,43,128)	0.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 4 (n=30,82,43,128)	0.0 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 8 (n=30,70,43,104)	0.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 8 (n=30,70,43,104)	0.2 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 16 (n=28,45,38,70)	0.6 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 4 (n=30,82,43,128)	0.0 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 4 (n=30,82,43,128)	0.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 4 (n=30,82,43,128)	-0.0 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 12 (n=28,53,42,84)	0.2 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 8 (n=30,70,43,104)	-0.0 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 16 (n=28,45,38,70)	0.4 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 8 (n=30,70,43,104)	-0.0 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 12 (n=28,53,42,84)	0.0 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 12 (n=28,53,42,84)	0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 4 (n=30,82,43,128)	0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 16 (n=28,45,38,70)	0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 12 (n=28,53,42,84)	0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 8 (n=30,70,43,104)	0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 12 (n=28,53,42,84)	0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 12 (n=28,53,42,84)	0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 16 (n=28,45,38,70)	1.1 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 8 (n=30,70,43,104)	0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 12 (n=28,53,42,84)	0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 4 (n=30,82,43,128)	0.7 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 12 (n=28,53,42,84)	1.0 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 4 (n=30,82,43,128)	0.6 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 12 (n=28,53,42,84)	0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 8 (n=30,70,43,104)	1.0 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 4 (n=30,82,43,128)	0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 16 (n=28,45,38,70)	0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 12 (n=28,53,42,84)	0.6 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 4 (n=30,82,43,128)	0.7 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 8 (n=30,70,43,104)	1.0 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 12 (n=28,53,42,84)	1.0 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 16 (n=28,45,38,70)	0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 8 (n=30,70,43,104)	0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 12 (n=28,53,42,84)	0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 4 (n=30,82,43,128)	0.7 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 16 (n=28,45,38,70)	0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 8 (n=30,70,43,104)	0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 16 (n=28,45,38,70)	0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 8 (n=30,70,43,104)	1.0 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 16 (n=28,45,38,70)	0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 4 (n=30,82,43,128)	0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 4 (n=30,82,43,128)	0.5 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 16 (n=28,45,38,70)	0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 8 (n=30,70,43,104)	1.1 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 4 (n=30,82,43,128)	0.7 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 8 (n=30,70,43,104)	0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 8 (n=30,70,43,104)	0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 4 (n=30,82,43,128)	0.7 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 4 (n=30,82,43,128)	0.6 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 12 (n=28,53,42,84)	0.7 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 16 (n=28,45,38,70)	0.7 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 8 (n=30,70,43,104)	1.1 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 16 (n=28,45,38,70)	0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 16 (n=28,45,38,70)	0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 8 (n=30,70,43,104)	0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 12 (n=28,53,42,84)	1.0 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 16 (n=28,45,38,70)	1.0 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 4 (n=30,82,43,128)	0.5 score on a scale	Standard Error 0.1

Secondary

Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A; n equals number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Lower limbs, Week 24 (n=277,279)	-1.6 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Head/Neck, Week 8 (n=322,323)	-1.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Head/Neck, Week 16 (n=311,307)	-1.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Head/Neck, Week 4 (n=326,331)	-0.8 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Head/Neck, Week 8 (n=322,323)	-1.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Head/Neck, Week 16 (n=311,307)	-1.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Head/Neck, Week 24 (n=277,279)	-1.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Head/Neck, Week 4 (n=326,331)	-0.9 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Head/Neck, Week 8 (n=322,323)	-1.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Head/Neck, Week 24 (n=277,279)	-1.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Upper limbs, Week 4 (n=326,331)	-0.9 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Upper limbs, Week 8 (n=322,323)	-1.3 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Upper limbs, Week 16 (n=311,307)	-1.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Upper limbs, Week 24 (n=277,279)	-1.5 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Upper limbs, Week 4 (n=326,331)	-0.8 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Upper limbs, Week 8 (n=322,323)	-1.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Upper limbs, Week 16 (n=311,307	-1.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Upper limbs, Week 24 (n=277,279)	-1.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Upper limbs, Week 4 (n=326,331)	-0.7 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Upper limbs, Week 8 (n=322,323)	-1.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Upper limbs, Week 16 (n=311,307)	-1.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Upper limbs, Week 24 (n=277,279)	-1.3 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Trunk, Week 4 (n=326,331)	-0.9 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Trunk, Week 16 (n=311,307)	-1.5 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Trunk, Week 8 (n=322,323)	-1.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Trunk, Week 16 (n=311,307)	-1.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Trunk, Week 4 (n=326,331)	-0.8 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Trunk, Week 8 (n=322,323)	-1.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Trunk, Week 16 (n=311,307)	-1.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Trunk, Week 24 (n=277,279)	-1.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Lower limbs, Week 4 (n=326,331)	-0.9 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Lower limbs, Week 4 (n=326,331)	-0.8 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Lower limbs, Week 8 (n=322,323)	-1.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Lower limbs, Week 24 (n=277,279)	-1.6 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Lower limbs, Week 8 (n=322,323)	-1.3 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Lower limbs, Week 16 (n=311,307)	-1.6 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Head/Neck, Week 24 (n=277,279)	-1.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Head/Neck, Week 16 (n=311,307)	-1.3 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Trunk, Week 8 (n=322,323)	-1.3 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Trunk, Week 24 (n=277,279)	-1.5 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Trunk, Week 4 (n=326,331)	-0.8 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Trunk, Week 24 (n=277,279)	-1.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Lower limbs, Week 8 (n=322,323)	-1.3 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Lower limbs, Week 16 (n=311,307)	-1.6 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Lower limbs, Week 24 (n=277,279)	-1.7 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Lower limbs, Week 16 (n=311,307)	-1.5 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Lower limbs, Week 4 (n=326,331)	-0.9 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Head/Neck, Week 4 (n=326,331)	-0.8 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Lower limbs, Week 24 (n=277,279)	-2.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Head/Neck, Week 4 (n=326,331)	-1.2 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Trunk, Week 8 (n=322,323)	-1.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Head/Neck, Week 8 (n=322,323)	-1.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Trunk, Week 4 (n=326,331)	-1.1 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Head/Neck, Week 16 (n=311,307)	-1.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Head/Neck, Week 24 (n=277,279)	-1.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Trunk, Week 16 (n=311,307)	-1.8 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Head/Neck, Week 4 (n=326,331)	-1.1 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Trunk, Week 24 (n=277,279)	-1.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Head/Neck, Week 8 (n=322,323)	-1.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Head/Neck, Week 16 (n=311,307)	-1.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Lower limbs, Week 4 (n=326,331)	-1.2 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Head/Neck, Week 24 (n=277,279)	-1.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Trunk, Week 8 (n=322,323)	-1.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Head/Neck, Week 4 (n=326,331)	-1.1 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Upper limbs, Week 24 (n=277,279)	-1.8 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Head/Neck, Week 8 (n=322,323)	-1.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Head/Neck, Week 16 (n=311,307)	-1.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Trunk, Week 16 (n=311,307)	-1.8 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Head/Neck, Week 24 (n=277,279)	-1.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Upper limbs, Week 16 (n=311,307	-1.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Upper limbs, Week 4 (n=326,331)	-1.2 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Trunk, Week 24 (n=277,279)	-1.8 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Upper limbs, Week 8 (n=322,323)	-1.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Upper limbs, Week 24 (n=277,279)	-1.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Upper limbs, Week 16 (n=311,307)	-1.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Lower limbs, Week 16 (n=311,307)	-2.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Lower limbs, Week 4 (n=326,331)	-1.3 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Upper limbs, Week 4 (n=326,331)	-1.2 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Lower limbs, Week 8 (n=322,323)	-1.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Upper limbs, Week 8 (n=322,323)	-1.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Lower limbs, Week 8 (n=322,323)	-1.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Trunk, Week 24 (n=277,279)	-2.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Upper limbs, Week 24 (n=277,279)	-1.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Lower limbs, Week 24 (n=277,279)	-2.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Upper limbs, Week 4 (n=326,331)	-1.1 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Lower limbs, Week 4 (n=326,331)	-1.2 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Upper limbs, Week 8 (n=322,323)	-1.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Lower limbs, Week 24 (n=277,279)	-2.1 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Upper limbs, Week 16 (n=311,307)	-1.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Lower limbs, Week 8 (n=322,323)	-1.8 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Lower limbs, Week 16 (n=311,307)	-2.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Trunk, Week 4 (n=326,331)	-1.3 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Trunk, Week 8 (n=322,323)	-1.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Lower limbs, Week 16 (n=311,307)	-2.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Trunk, Week 16 (n=311,307)	-1.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Trunk, Week 4 (n=326,331)	-1.2 score on a scale	Standard Error 0.1

Secondary

Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period C.

Time frame: Weeks 4, 8, and 16 (Period C)

Population: FAS-C; n equals number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Week 16 (n=23,67,39,101)	-0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Week 16 (n=23,67,39,101)	0.0 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Week 4 (n=27,74,42,119)	-0.2 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Week 4 (n=27,74,42,119)	-0.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Week 8 (n=26,72,41,118)	-0.0 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Week 4 (n=27,74,42,119)	-0.0 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Week 8 (n=26,72,41,118)	0.0 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Week 4 (n=27,74,42,119)	-0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Week 16 (n=23,67,39,101)	-0.3 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Week 8 (n=26,72,41,118)	-0.1 score on a scale	Standard Error 2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Week 16 (n=23,67,39,101)	-0.2 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Week 4 (n=27,74,42,119)	-0.0 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Week 4 (n=27,74,42,119)	0.0 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Week 4 (n=27,74,42,119)	0.0 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Week 16 (n=23,67,39,101)	-0.0 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Week 4 (n=27,74,42,119)	-0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Week 8 (n=26,72,41,118)	0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Week 16 (n=23,67,39,101)	-0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Week 8 (n=26,72,41,118)	0.1 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Week 16 (n=23,67,39,101)	0.0 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Week 16 (n=23,67,39,101)	0.2 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Week 8 (n=26,72,41,118)	0.1 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Week 8 (n=26,72,41,118)	-0.0 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Week 8 (n=26,72,41,118)	0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Week 16 (n=23,67,39,101)	0.3 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Week 8 (n=26,72,41,118)	-0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Week 4 (n=27,74,42,119)	0.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Week 8 (n=26,72,41,118)	0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Week 4 (n=27,74,42,119)	0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Week 8 (n=26,72,41,118)	-0.0 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Week 4 (n=27,74,42,119)	-0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Week 8 (n=26,72,41,118)	-0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Week 16 (n=23,67,39,101)	-0.2 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Week 16 (n=23,67,39,101)	0.3 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Week 4 (n=27,74,42,119)	-0.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Week 16 (n=23,67,39,101)	-0.1 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Week 4 (n=27,74,42,119)	-0.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Week 8 (n=26,72,41,118)	-0.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Week 16 (n=23,67,39,101)	-0.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Week 16 (n=23,67,39,101)	-0.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Week 16 (n=23,67,39,101)	-0.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Week 4 (n=27,74,42,119)	-0.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Week 8 (n=26,72,41,118)	-0.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Week 8 (n=26,72,41,118)	-0.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Week 8 (n=26,72,41,118)	-0.7 score on a scale	Standard Error 1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Week 16 (n=23,67,39,101)	-0.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Week 16 (n=23,67,39,101)	-0.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Week 4 (n=27,74,42,119)	-0.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Week 16 (n=23,67,39,101)	-0.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Week 4 (n=27,74,42,119)	-0.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Week 4 (n=27,74,42,119)	-0.3 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Week 16 (n=23,67,39,101)	-0.8 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Week 8 (n=26,72,41,118)	-0.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Week 8 (n=26,72,41,118)	-0.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Week 16 (n=23,67,39,101)	-0.8 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Week 8 (n=26,72,41,118)	-0.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Week 4 (n=27,74,42,119)	-0.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Week 4 (n=27,74,42,119)	-0.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Week 8 (n=26,72,41,118)	-0.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Week 16 (n=23,67,39,101)	-0.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Week 8 (n=26,72,41,118)	-0.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Week 4 (n=27,74,42,119)	-0.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Week 16 (n=23,67,39,101)	-0.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Week 8 (n=26,72,41,118)	-0.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Week 8 (n=26,72,41,118)	-0.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Week 16 (n=23,67,39,101)	-0.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Week 16 (n=23,67,39,101)	-0.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Week 4 (n=27,74,42,119)	-0.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Week 8 (n=26,72,41,118)	-0.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Week 4 (n=27,74,42,119)	-0.3 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Week 4 (n=27,74,42,119)	-0.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Week 4 (n=27,74,42,119)	-0.5 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Week 16 (n=23,67,39,101)	-0.2 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Week 8 (n=26,72,41,118)	-0.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Week 4 (n=27,74,42,119)	-0.2 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Week 8 (n=26,72,41,118)	-0.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Week 4 (n=27,74,42,119)	-0.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Week 8 (n=26,72,41,118)	0.0 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Week 16 (n=23,67,39,101)	-0.1 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Week 4 (n=27,74,42,119)	-0.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Week 8 (n=26,72,41,118)	-0.2 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Week 16 (n=23,67,39,101)	-0.2 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Week 4 (n=27,74,42,119)	-0.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Week 16 (n=23,67,39,101)	-0.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Week 4 (n=27,74,42,119)	-0.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Week 8 (n=26,72,41,118)	-0.2 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Week 8 (n=26,72,41,118)	-0.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Week 16 (n=23,67,39,101)	-0.1 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Week 4 (n=27,74,42,119)	-0.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Week 4 (n=27,74,42,119)	0.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Week 8 (n=26,72,41,118)	-0.0 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Week 16 (n=23,67,39,101)	-0.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Week 4 (n=27,74,42,119)	0.0 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Week 8 (n=26,72,41,118)	-0.0 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Week 16 (n=23,67,39,101)	-0.2 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Week 4 (n=27,74,42,119)	0.0 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Week 8 (n=26,72,41,118)	-0.0 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Week 16 (n=23,67,39,101)	-0.2 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Week 4 (n=27,74,42,119)	-0.0 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Week 8 (n=26,72,41,118)	-0.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Week 16 (n=23,67,39,101)	-0.2 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Week 4 (n=27,74,42,119)	-0.0 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Week 16 (n=23,67,39,101)	-0.1 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Week 8 (n=26,72,41,118)	-0.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Week 16 (n=23,67,39,101)	-0.2 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Week 4 (n=27,74,42,119)	-0.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Week 8 (n=26,72,41,118)	-0.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Week 16 (n=23,67,39,101)	-0.2 score on a scale	Standard Error 0.2
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Week 16 (n=23,67,39,101)	-0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Week 4 (n=27,74,42,119)	-0.6 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Week 4 (n=27,74,42,119)	-0.7 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Week 16 (n=23,67,39,101)	-0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Week 16 (n=23,67,39,101)	-0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Week 8 (n=26,72,41,118)	-0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Week 8 (n=26,72,41,118)	-0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Week 4 (n=27,74,42,119)	-0.7 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Week 4 (n=27,74,42,119)	-0.7 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Week 16 (n=23,67,39,101)	-0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Week 16 (n=23,67,39,101)	-0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Week 4 (n=27,74,42,119)	-0.6 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Week 8 (n=26,72,41,118)	-0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Week 4 (n=27,74,42,119)	-0.6 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Week 8 (n=26,72,41,118)	-0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Week 8 (n=26,72,41,118)	-0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Week 16 (n=23,67,39,101)	-0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Week 8 (n=26,72,41,118)	-0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Week 4 (n=27,74,42,119)	-0.7 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Week 16 (n=23,67,39,101)	-1.0 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Week 4 (n=27,74,42,119)	-0.7 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Week 8 (n=26,72,41,118)	-0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Week 8 (n=26,72,41,118)	-1.0 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Week 16 (n=23,67,39,101)	-0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Week 16 (n=23,67,39,101)	-0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Week 4 (n=27,74,42,119)	-0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Week 8 (n=26,72,41,118)	-0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Week 4 (n=27,74,42,119)	-0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Week 16 (n=23,67,39,101)	-1.0 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Week 8 (n=26,72,41,118)	-0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Week 16 (n=23,67,39,101)	-0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Week 8 (n=26,72,41,118)	-0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Week 4 (n=27,74,42,119)	-0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Week 16 (n=23,67,39,101)	-1.0 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Week 4 (n=27,74,42,119)	-0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Week 8 (n=26,72,41,118)	-0.8 score on a scale	Standard Error 0.1

Secondary

Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)

Baseline defined as the last observation up to first dosing date in Period C.

Time frame: Weeks 4, 8, and 16 (Period C)

Population: FAS-C; n equals the number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Week 16 (n=23,67,39,101)	0.4 percent psoriatic BSA	Standard Error 1.41
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Week 4 (n=27,74,42,119)	-0.3 percent psoriatic BSA	Standard Error 0.36
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Week 4 (n=27,74,42,119)	-0.3 percent psoriatic BSA	Standard Error 0.92
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Week 8 (n=26,72,41,118)	0.0 percent psoriatic BSA	Standard Error 1.07
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Week 4 (n=27,74,42,119)	0.1 percent psoriatic BSA	Standard Error 0.26
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Week 8 (n=26,72,41,118)	0.8 percent psoriatic BSA	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Week 16 (n=23,67,39,101)	0.7 percent psoriatic BSA	Standard Error 0.97
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Week 4 (n=27,74,42,119)	-0.2 percent psoriatic BSA	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Week 8 (n=26,72,41,118)	0.1 percent psoriatic BSA	Standard Error 0.43
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Week 16 (n=23,67,39,101)	0.7 percent psoriatic BSA	Standard Error 0.82
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Week 8 (n=26,72,41,118)	-0.1 percent psoriatic BSA	Standard Error 0.52
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Week 16 (n=23,67,39,101)	0.2 percent psoriatic BSA	Standard Error 0.6
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Week 8 (n=26,72,41,118)	-1.3 percent psoriatic BSA	Standard Error 1.5
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Week 16 (n=23,67,39,101)	-5.0 percent psoriatic BSA	Standard Error 1.15
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Week 8 (n=26,72,41,118)	-3.0 percent psoriatic BSA	Standard Error 0.85
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Week 16 (n=23,67,39,101)	-8.1 percent psoriatic BSA	Standard Error 2.04
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Week 4 (n=27,74,42,119)	-1.6 percent psoriatic BSA	Standard Error 0.9
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Week 4 (n=27,74,42,119)	0.1 percent psoriatic BSA	Standard Error 1.12
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Week 8 (n=26,72,41,118)	-8.6 percent psoriatic BSA	Standard Error 1.68
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Week 8 (n=26,72,41,118)	-1.1 percent psoriatic BSA	Standard Error 1.04
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Week 4 (n=27,74,42,119)	-0.1 percent psoriatic BSA	Standard Error 1.44
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Week 4 (n=27,74,42,119)	-6.4 percent psoriatic BSA	Standard Error 1.4
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Week 16 (n=23,67,39,101)	-2.3 percent psoriatic BSA	Standard Error 1.15
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Week 16 (n=23,67,39,101)	-4.1 percent psoriatic BSA	Standard Error 1.44
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Week 8 (n=26,72,41,118)	-0.7 percent psoriatic BSA	Standard Error 0.78
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Week 4 (n=27,74,42,119)	0.9 percent psoriatic BSA	Standard Error 0.81
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Week 4 (n=27,74,42,119)	1.3 percent psoriatic BSA	Standard Error 1.87
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Week 4 (n=27,74,42,119)	-1.1 percent psoriatic BSA	Standard Error 0.93
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Week 8 (n=26,72,41,118)	0.1 percent psoriatic BSA	Standard Error 0.53
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Week 8 (n=26,72,41,118)	1.2 percent psoriatic BSA	Standard Error 0.91
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Week 16 (n=23,67,39,101)	2.7 percent psoriatic BSA	Standard Error 2.46
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Week 16 (n=23,67,39,101)	1.0 percent psoriatic BSA	Standard Error 0.99
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Week 16 (n=23,67,39,101)	-0.9 percent psoriatic BSA	Standard Error 1.14
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Week 4 (n=27,74,42,119)	0.5 percent psoriatic BSA	Standard Error 0.69
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Week 8 (n=26,72,41,118)	1.5 percent psoriatic BSA	Standard Error 1.92
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Week 16 (n=23,67,39,101)	-0.7 percent psoriatic BSA	Standard Error 0.77
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Week 8 (n=26,72,41,118)	-10.9 percent psoriatic BSA	Standard Error 1.51
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Week 16 (n=23,67,39,101)	-11.6 percent psoriatic BSA	Standard Error 1.84
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Week 4 (n=27,74,42,119)	-4.9 percent psoriatic BSA	Standard Error 0.94
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Week 8 (n=26,72,41,118)	-6.3 percent psoriatic BSA	Standard Error 1.11
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Week 16 (n=23,67,39,101)	-7.6 percent psoriatic BSA	Standard Error 1.2
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Week 8 (n=26,72,41,118)	-4.3 percent psoriatic BSA	Standard Error 0.85
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Week 16 (n=23,67,39,101)	-6.1 percent psoriatic BSA	Standard Error 0.93
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Week 8 (n=26,72,41,118)	-4.8 percent psoriatic BSA	Standard Error 0.88
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Week 4 (n=27,74,42,119)	-4.6 percent psoriatic BSA	Standard Error 0.88
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Week 16 (n=23,67,39,101)	-5.6 percent psoriatic BSA	Standard Error 1.02
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Week 4 (n=27,74,42,119)	-10.8 percent psoriatic BSA	Standard Error 1.53
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Week 4 (n=27,74,42,119)	-3.6 percent psoriatic BSA	Standard Error 0.97

Secondary

Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)

Baseline defined as the last observation up to first dosing date in Period B.

Time frame: Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B; n equals the number of participants with observations

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 4 (n=30,82,43,128)	-0.3 percent psoriatic BSA	Standard Error 0.98
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 16 (n=28,45,38,70)	0.4 percent psoriatic BSA	Standard Error 0.73
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 8 (n=30,70,43,104)	0.3 percent psoriatic BSA	Standard Error 0.54
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 12 (n=28,53,42,84)	0.0 percent psoriatic BSA	Standard Error 0.68
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 8 (n=30,70,43,104)	0.4 percent psoriatic BSA	Standard Error 1.41
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 4 (n=30,82,43,128)	0.4 percent psoriatic BSA	Standard Error 0.33
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 16 (n=28,45,38,70)	0.0 percent psoriatic BSA	Standard Error 0.51
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 16 (n=28,45,38,70)	-0.8 percent psoriatic BSA	Standard Error 1.42
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 12 (n=28,53,42,84)	-0.1 percent psoriatic BSA	Standard Error 0.47
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 4 (n=30,82,43,128)	0.1 percent psoriatic BSA	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 8 (n=30,70,43,104)	0.2 percent psoriatic BSA	Standard Error 0.43
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 8 (n=30,70,43,104)	0.8 percent psoriatic BSA	Standard Error 0.47
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 12 (n=28,53,42,84)	-0.9 percent psoriatic BSA	Standard Error 1.58
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 12 (n=28,53,42,84)	1.0 percent psoriatic BSA	Standard Error 0.51
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 4 (n=30,82,43,128)	-0.2 percent psoriatic BSA	Standard Error 0.42
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 16 (n=28,45,38,70)	1.1 percent psoriatic BSA	Standard Error 0.55
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 8 (n=30,70,43,104)	4.1 percent psoriatic BSA	Standard Error 0.99
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 16 (n=28,45,38,70)	3.3 percent psoriatic BSA	Standard Error 0.81
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 4 (n=30,82,43,128)	1.9 percent psoriatic BSA	Standard Error 1.17
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 4 (n=30,82,43,128)	8.0 percent psoriatic BSA	Standard Error 1.49
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 16 (n=28,45,38,70)	7.9 percent psoriatic BSA	Standard Error 1.7
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 4 (n=30,82,43,128)	2.3 percent psoriatic BSA	Standard Error 1.14
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 8 (n=30,70,43,104)	4.0 percent psoriatic BSA	Standard Error 1.34
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 12 (n=28,53,42,84)	11.8 percent psoriatic BSA	Standard Error 2.71
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 12 (n=28,53,42,84)	2.9 percent psoriatic BSA	Standard Error 0.75
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 8 (n=30,70,43,104)	2.7 percent psoriatic BSA	Standard Error 0.83
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 16 (n=28,45,38,70)	3.3 percent psoriatic BSA	Standard Error 0.94
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 4 (n=30,82,43,128)	1.1 percent psoriatic BSA	Standard Error 0.92
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 8 (n=30,70,43,104)	10.0 percent psoriatic BSA	Standard Error 1.87
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 16 (n=28,45,38,70)	2.7 percent psoriatic BSA	Standard Error 0.75
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 12 (n=28,53,42,84)	4.8 percent psoriatic BSA	Standard Error 1.14
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 12 (n=28,53,42,84)	4.6 percent psoriatic BSA	Standard Error 1.19
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 8 (n=30,70,43,104)	0.4 percent psoriatic BSA	Standard Error 0.54
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 12 (n=28,53,42,84)	1.8 percent psoriatic BSA	Standard Error 0.69
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 4 (n=30,82,43,128)	0.7 percent psoriatic BSA	Standard Error 0.44
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 8 (n=30,70,43,104)	0.6 percent psoriatic BSA	Standard Error 0.5
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 16 (n=28,45,38,70)	1.2 percent psoriatic BSA	Standard Error 0.75
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 4 (n=30,82,43,128)	-0.2 percent psoriatic BSA	Standard Error 0.29
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 12 (n=28,53,42,84)	0.4 percent psoriatic BSA	Standard Error 0.5
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 16 (n=28,45,38,70)	0.6 percent psoriatic BSA	Standard Error 0.46
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 4 (n=30,82,43,128)	0.0 percent psoriatic BSA	Standard Error 0.51
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 8 (n=30,70,43,104)	-0.2 percent psoriatic BSA	Standard Error 0.56
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 12 (n=28,53,42,84)	-0.2 percent psoriatic BSA	Standard Error 0.63
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 16 (n=28,45,38,70)	0.0 percent psoriatic BSA	Standard Error 1.09
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 4 (n=30,82,43,128)	-0.7 percent psoriatic BSA	Standard Error 0.39
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 8 (n=30,70,43,104)	-0.5 percent psoriatic BSA	Standard Error 0.66
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 12 (n=28,53,42,84)	0.3 percent psoriatic BSA	Standard Error 0.84
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 16 (n=28,45,38,70)	0.7 percent psoriatic BSA	Standard Error 0.86
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 16 (n=28,45,38,70)	3.9 percent psoriatic BSA	Standard Error 0.71
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 12 (n=28,53,42,84)	4.7 percent psoriatic BSA	Standard Error 0.86
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 8 (n=30,70,43,104)	6.2 percent psoriatic BSA	Standard Error 0.96
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 8 (n=30,70,43,104)	12.8 percent psoriatic BSA	Standard Error 1.86
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 4 (n=30,82,43,128)	3.2 percent psoriatic BSA	Standard Error 0.68
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 4 (n=30,82,43,128)	4.5 percent psoriatic BSA	Standard Error 0.76
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 4 (n=30,82,43,128)	9.3 percent psoriatic BSA	Standard Error 1.53
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 8 (n=30,70,43,104)	5.3 percent psoriatic BSA	Standard Error 0.98
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 16 (n=28,45,38,70)	8.3 percent psoriatic BSA	Standard Error 1.66
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 12 (n=28,53,42,84)	10.4 percent psoriatic BSA	Standard Error 1.95
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 8 (n=30,70,43,104)	5.6 percent psoriatic BSA	Standard Error 0.97
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 16 (n=28,45,38,70)	3.7 percent psoriatic BSA	Standard Error 0.76
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 12 (n=28,53,42,84)	3.8 percent psoriatic BSA	Standard Error 0.75
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 4 (n=30,82,43,128)	3.3 percent psoriatic BSA	Standard Error 0.74
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 16 (n=28,45,38,70)	4.9 percent psoriatic BSA	Standard Error 0.95
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 12 (n=28,53,42,84)	3.9 percent psoriatic BSA	Standard Error 0.84

Secondary

Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)

Baseline defined as the last observation up to first dosing date in Period A.

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A; n equals number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Upper limbs, Week 4 (n=326,331)	-4.9 percent change in psoriatic BSA	Standard Error 0.58
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Trunk, Week 4 (n=326,331)	-5.5 percent change in psoriatic BSA	Standard Error 0.67
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Head/Neck, Week 8 (n=322,323)	-13.8 percent change in psoriatic BSA	Standard Error 0.98
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Trunk, Week 8 (n=322,323)	-9.9 percent change in psoriatic BSA	Standard Error 0.87
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Trunk, Week 16 (n=311,306)	-12.9 percent change in psoriatic BSA	Standard Error 0.98
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Upper limbs, Week 8 (n=322,323)	-9.7 percent change in psoriatic BSA	Standard Error 0.77
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Trunk, Week 24 (n=277,279)	-13.4 percent change in psoriatic BSA	Standard Error 1.12
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Head/Neck, Week 24 (n=277,279)	-14.9 percent change in psoriatic BSA	Standard Error 1.21
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Lower limbs, Week 4 (n=326,331)	-4.8 percent change in psoriatic BSA	Standard Error 0.57
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Upper limbs, Week 16 (n=311,306)	-13.1 percent change in psoriatic BSA	Standard Error 0.89
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Lower limbs, Week 8 (n=322,323)	-10.4 percent change in psoriatic BSA	Standard Error 0.82
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Head/Neck, Week 16 (n=311,306)	-15.4 percent change in psoriatic BSA	Standard Error 1.13
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Lower limbs, Week 16 (n=311,306)	-15.9 percent change in psoriatic BSA	Standard Error 1.04
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Upper limbs, Week 24 (n=277,279)	-14.2 percent change in psoriatic BSA	Standard Error 0.98
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Lower limbs, Week 24 (n=277,279)	-17.1 percent change in psoriatic BSA	Standard Error 1.09
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Head/Neck, Week 4 (n=326,331)	-7.9 percent change in psoriatic BSA	Standard Error 0.71
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Lower limbs, Week 24 (n=277,279)	-21.2 percent change in psoriatic BSA	Standard Error 1.07
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Trunk, Week 8 (n=322,323)	-13.8 percent change in psoriatic BSA	Standard Error 1.03
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Head/Neck, Week 4 (n=326,331)	-11.7 percent change in psoriatic BSA	Standard Error 0.86
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Head/Neck, Week 8 (n=322,323)	-16.0 percent change in psoriatic BSA	Standard Error 1.04
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Head/Neck, Week 16 (n=311,306)	-17.9 percent change in psoriatic BSA	Standard Error 1.07
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Head/Neck, Week 24 (n=277,279)	-18.6 percent change in psoriatic BSA	Standard Error 1.12
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Upper limbs, Week 4 (n=326,331)	-8.8 percent change in psoriatic BSA	Standard Error 0.8
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Upper limbs, Week 8 (n=322,323)	-14.1 percent change in psoriatic BSA	Standard Error 0.92
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Upper limbs, Week 16 (n=311,306)	-17.4 percent change in psoriatic BSA	Standard Error 1.03
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Upper limbs, Week 24 (n=277,279)	-18.5 percent change in psoriatic BSA	Standard Error 1.01
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Trunk, Week 4 (n=326,331)	-8.6 percent change in psoriatic BSA	Standard Error 0.86
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Trunk, Week 16 (n=311,306)	-16.9 percent change in psoriatic BSA	Standard Error 1.17
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Trunk, Week 24 (n=277,279)	-17.8 percent change in psoriatic BSA	Standard Error 1.12
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Lower limbs, Week 4 (n=326,331)	-8.6 percent change in psoriatic BSA	Standard Error 0.85
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Lower limbs, Week 8 (n=322,323)	-14.8 percent change in psoriatic BSA	Standard Error 0.99
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Lower limbs, Week 16 (n=311,306)	-20.3 percent change in psoriatic BSA	Standard Error 1.1

Secondary

Mean Change From Baseline in Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)

Baseline was defined as the last observation until first dosing date in Period C.

Time frame: Weeks 4, 8, and 16 (Period C)

Population: FAS-C; n equals number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	0.1 percent change in psoriatic BSA	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	-0.2 percent change in psoriatic BSA	Standard Error 0.3
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,101)	0.5 percent change in psoriatic BSA	Standard Error 0.6
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	-2.3 percent change in psoriatic BSA	Standard Error 1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,101)	-4.0 percent change in psoriatic BSA	Standard Error 1.1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	-1.0 percent change in psoriatic BSA	Standard Error 1
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	0.3 percent change in psoriatic BSA	Standard Error 0.9
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,101)	0.6 percent change in psoriatic BSA	Standard Error 1.2
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	0.1 percent change in psoriatic BSA	Standard Error 0.9
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,101)	-6.8 percent change in psoriatic BSA	Standard Error 0.8
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	-4.9 percent change in psoriatic BSA	Standard Error 0.8
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	-5.5 percent change in psoriatic BSA	Standard Error 0.8

Secondary

Mean Change From Baseline in Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)

Baseline defined as the last observation up to first dosing date in Period B.

Time frame: Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B; n equals the number of participants with observations

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,128)	0.0 percent change in psoriatic BSA	Standard Error 0.4
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,70,43,104)	0.3 percent change in psoriatic BSA	Standard Error 0.4
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,53,42,84)	0.1 percent change in psoriatic BSA	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	0.3 percent change in psoriatic BSA	Standard Error 0.5
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,70,43,104)	4.1 percent change in psoriatic BSA	Standard Error 0.9
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,53,42,84)	4.8 percent change in psoriatic BSA	Standard Error 1
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	3.7 percent change in psoriatic BSA	Standard Error 0.7
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,128)	2.3 percent change in psoriatic BSA	Standard Error 0.9
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,53,42,84)	0.3 percent change in psoriatic BSA	Standard Error 0.6
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,70,43,104)	-0.1 percent change in psoriatic BSA	Standard Error 0.4
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	0.5 percent change in psoriatic BSA	Standard Error 0.7
CP-690,550 10 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,128)	-0.3 percent change in psoriatic BSA	Standard Error 0.3
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	4.5 percent change in psoriatic BSA	Standard Error 0.7
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,70,43,104)	6.3 percent change in psoriatic BSA	Standard Error 0.9
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,128)	4.1 percent change in psoriatic BSA	Standard Error 0.6
Placebo for 10 mg CP-690,550	Mean Change From Baseline in Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,53,42,84)	4.7 percent change in psoriatic BSA	Standard Error 0.7

Secondary

Mean Change From Baseline in Total Percent of Psoriatic BSA During Initial CP-690,550 Treatment (Period A)

Baseline defined as the last observation up to first dosing date in Period A.

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A; n equals number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During Initial CP-690,550 Treatment (Period A)	Week 4 (n=326,331)	-5.3 percent change in psoriatic BSA	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During Initial CP-690,550 Treatment (Period A)	Week 8 (n=322,323)	-10.4 percent change in psoriatic BSA	Standard Error 0.7
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During Initial CP-690,550 Treatment (Period A)	Week 16 (n=311,306)	-14.4 percent change in psoriatic BSA	Standard Error 0.8
CP-690,550 5 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During Initial CP-690,550 Treatment (Period A)	Week 24 (n=277,279)	-15.2 percent change in psoriatic BSA	Standard Error 0.9
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During Initial CP-690,550 Treatment (Period A)	Week 24 (n=277,279)	-19.4 percent change in psoriatic BSA	Standard Error 0.9
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During Initial CP-690,550 Treatment (Period A)	Week 4 (n=326,331)	-9.0 percent change in psoriatic BSA	Standard Error 0.7
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During Initial CP-690,550 Treatment (Period A)	Week 16 (n=311,306)	-18.5 percent change in psoriatic BSA	Standard Error 0.9
Placebo for CP-690,550 5 mg (Period B)	Mean Change From Baseline in Total Percent of Psoriatic BSA During Initial CP-690,550 Treatment (Period A)	Week 8 (n=322,323)	-14.5 percent change in psoriatic BSA	Standard Error 0.8

Secondary

Mean Dermatology Life Quality Index (DLQI) Score During the Initial CP-690,550 Treatment (Period A)

Time frame: Baseline and Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Dermatology Life Quality Index (DLQI) Score During the Initial CP-690,550 Treatment (Period A)	Baseline (n=330,333)	12.6 score on a scale	Standard Error 0.4
CP-690,550 5 mg (Period B)	Mean Dermatology Life Quality Index (DLQI) Score During the Initial CP-690,550 Treatment (Period A)	Week 16 (n=310,303)	4.7 score on a scale	Standard Error 0.3
CP-690,550 5 mg (Period B)	Mean Dermatology Life Quality Index (DLQI) Score During the Initial CP-690,550 Treatment (Period A)	Week 4 (n=326,330)	6.8 score on a scale	Standard Error 0.3
CP-690,550 5 mg (Period B)	Mean Dermatology Life Quality Index (DLQI) Score During the Initial CP-690,550 Treatment (Period A)	Week 24 (n=273,277)	5.1 score on a scale	Standard Error 0.4
CP-690,550 5 mg (Period B)	Mean Dermatology Life Quality Index (DLQI) Score During the Initial CP-690,550 Treatment (Period A)	Week 8 (n=321,319)	5.4 score on a scale	Standard Error 0.3
Placebo for CP-690,550 5 mg (Period B)	Mean Dermatology Life Quality Index (DLQI) Score During the Initial CP-690,550 Treatment (Period A)	Week 24 (n=273,277)	2.6 score on a scale	Standard Error 0.3
Placebo for CP-690,550 5 mg (Period B)	Mean Dermatology Life Quality Index (DLQI) Score During the Initial CP-690,550 Treatment (Period A)	Week 8 (n=321,319)	3.4 score on a scale	Standard Error 0.3
Placebo for CP-690,550 5 mg (Period B)	Mean Dermatology Life Quality Index (DLQI) Score During the Initial CP-690,550 Treatment (Period A)	Baseline (n=330,333)	12.6 score on a scale	Standard Error 0.4
Placebo for CP-690,550 5 mg (Period B)	Mean Dermatology Life Quality Index (DLQI) Score During the Initial CP-690,550 Treatment (Period A)	Week 4 (n=326,330)	4.8 score on a scale	Standard Error 0.3
Placebo for CP-690,550 5 mg (Period B)	Mean Dermatology Life Quality Index (DLQI) Score During the Initial CP-690,550 Treatment (Period A)	Week 16 (n=310,303)	2.9 score on a scale	Standard Error 0.3

Secondary

Mean DLQI Score During the CP-690,550 Re-Treatment (Period C)

Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

Population: FAS-C; n equals the number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean DLQI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,71,41,118)	3.9 score on a scale	Standard Error 1.3
CP-690,550 5 mg (Period B)	Mean DLQI Score During the CP-690,550 Re-Treatment (Period C)	Baseline (n=27,75,42,120)	3.6 score on a scale	Standard Error 1
CP-690,550 5 mg (Period B)	Mean DLQI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	3.4 score on a scale	Standard Error 1
CP-690,550 5 mg (Period B)	Mean DLQI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=22,66,39,101)	3.0 score on a scale	Standard Error 1
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=22,66,39,101)	3.4 score on a scale	Standard Error 0.5
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Score During the CP-690,550 Re-Treatment (Period C)	Baseline (n=27,75,42,120)	7.0 score on a scale	Standard Error 0.8
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,71,41,118)	3.1 score on a scale	Standard Error 0.4
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	4.3 score on a scale	Standard Error 0.5
CP-690,550 10 mg (Period B)	Mean DLQI Score During the CP-690,550 Re-Treatment (Period C)	Baseline (n=27,75,42,120)	2.2 score on a scale	Standard Error 0.5
CP-690,550 10 mg (Period B)	Mean DLQI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=22,66,39,101)	2.1 score on a scale	Standard Error 0.7
CP-690,550 10 mg (Period B)	Mean DLQI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	2.2 score on a scale	Standard Error 0.5
CP-690,550 10 mg (Period B)	Mean DLQI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,71,41,118)	2.2 score on a scale	Standard Error 0.5
Placebo for 10 mg CP-690,550	Mean DLQI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=22,66,39,101)	2.4 score on a scale	Standard Error 0.4
Placebo for 10 mg CP-690,550	Mean DLQI Score During the CP-690,550 Re-Treatment (Period C)	Baseline (n=27,75,42,120)	8.8 score on a scale	Standard Error 0.7
Placebo for 10 mg CP-690,550	Mean DLQI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,71,41,118)	2.7 score on a scale	Standard Error 0.4
Placebo for 10 mg CP-690,550	Mean DLQI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	3.9 score on a scale	Standard Error 0.4

Secondary

Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)

Time frame: Baseline and Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B; n equals the number of participants with observations

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,127)	3.4 score on a scale	Standard Error 0.9
CP-690,550 5 mg (Period B)	Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,52,41,83)	3.3 score on a scale	Standard Error 1.1
CP-690,550 5 mg (Period B)	Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,68,43,104)	3.1 score on a scale	Standard Error 0.9
CP-690,550 5 mg (Period B)	Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,44,38,68)	3.5 score on a scale	Standard Error 1
CP-690,550 5 mg (Period B)	Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Baseline (n=31,82,45,133)	2.6 score on a scale	Standard Error 0.7
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,52,41,83)	4.7 score on a scale	Standard Error 0.6
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,127)	4.7 score on a scale	Standard Error 0.5
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,68,43,104)	5.9 score on a scale	Standard Error 0.8
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Baseline (n=31,82,45,133)	1.8 score on a scale	Standard Error 0.3
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,44,38,68)	5.0 score on a scale	Standard Error 0.7
CP-690,550 10 mg (Period B)	Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,44,38,68)	2.0 score on a scale	Standard Error 0.4
CP-690,550 10 mg (Period B)	Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,127)	1.3 score on a scale	Standard Error 0.4
CP-690,550 10 mg (Period B)	Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,52,41,83)	1.9 score on a scale	Standard Error 0.4
CP-690,550 10 mg (Period B)	Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Baseline (n=31,82,45,133)	1.2 score on a scale	Standard Error 0.3
CP-690,550 10 mg (Period B)	Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,68,43,104)	1.6 score on a scale	Standard Error 0.5
Placebo for 10 mg CP-690,550	Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,68,43,104)	6.4 score on a scale	Standard Error 0.7
Placebo for 10 mg CP-690,550	Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Baseline (n=31,82,45,133)	1.2 score on a scale	Standard Error 0.2
Placebo for 10 mg CP-690,550	Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,44,38,68)	6.2 score on a scale	Standard Error 0.8
Placebo for 10 mg CP-690,550	Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,52,41,83)	5.3 score on a scale	Standard Error 0.7
Placebo for 10 mg CP-690,550	Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,127)	5.9 score on a scale	Standard Error 0.6

Secondary

Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)

Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

Population: FAS-C; n equals the number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Week 16 (n=22,65,39,101)	0.7 score on a scale	Standard Error 0.27
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Week 4 (n=27,74,42,119)	0.3 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Week 4 (n=27,74,41,119)	0.4 score on a scale	Standard Error 0.17
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Baseline (n=27,75,42,120)	0.4 score on a scale	Standard Error 0.23
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Baseline (n=27,75,42,120)	0.5 score on a scale	Standard Error 0.18
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Week 16 (n=22,66,39,101)	1.2 score on a scale	Standard Error 0.27
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Week 8 (n=26,71,41,118)	1.5 score on a scale	Standard Error 0.36
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Week 4 (n=27,74,42,119)	1.4 score on a scale	Standard Error 0.27
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Week 8 (n=26,71,41,118)	0.4 score on a scale	Standard Error 0.25
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Week 8 (n=26,71,41,118)	0.3 score on a scale	Standard Error 0.14
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Baseline (n=27,75,42,120)	1.4 score on a scale	Standard Error 0.32
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Week 16 (n=22,66,39,101)	0.2 score on a scale	Standard Error 0.16
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Week 4 (n=27,74,42,119)	0.4 score on a scale	Standard Error 0.24
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Week 16 (n=22,66,39,101)	0.2 score on a scale	Standard Error 0.09
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Baseline (n=27,75,42,120)	0.7 score on a scale	Standard Error 0.23
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Week 16 (n =22,66,39,101)	0.2 score on a scale	Standard Error 0.14
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Week 8 (n=26,71,41,118)	0.2 score on a scale	Standard Error 0.14
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Week 4 (n=27,74,42,119)	0.2 score on a scale	Standard Error 0.12
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Week 4 (n=27,74,42,119)	0.6 score on a scale	Standard Error 0.24
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Week 8 (n=26,71,41,118)	0.5 score on a scale	Standard Error 0.22
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Baseline (n=27,75,42,120)	0.3 score on a scale	Standard Error 0.14
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Week 16 (n=22,66,39,101)	0.4 score on a scale	Standard Error 0.24
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Week 8 (n=26,71,41,118)	0.9 score on a scale	Standard Error 0.33
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Baseline (n=27,75,42,120)	0.3 score on a scale	Standard Error 0.13
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Baseline (n=27,75,42,120)	0.5 score on a scale	Standard Error 0.09
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Week 4 (n=27,74,42,119)	0.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Baseline (n=27,75,42,120)	0.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Week 4 (n=27,74,42,119)	0.4 score on a scale	Standard Error 0.08
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Week 8 (n=26,71,41,118)	0.3 score on a scale	Standard Error 0.06
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Week 16 (n=22,66,39,101)	0.2 score on a scale	Standard Error 0.06
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Baseline (n=27,75,42,120)	1.5 score on a scale	Standard Error 0.19
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Week 4 (n=27,74,42,119)	0.9 score on a scale	Standard Error 0.14
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Week 8 (n=26,71,41,118)	0.7 score on a scale	Standard Error 0.12
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Week 16 (n=22,65,39,101)	0.8 score on a scale	Standard Error 0.14
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Baseline (n=27,75,42,120)	0.9 score on a scale	Standard Error 0.16
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Week 8 (n=26,71,41,118)	0.2 score on a scale	Standard Error 0.07
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Week 16 (n=22,66,39,101)	0.3 score on a scale	Standard Error 0.09
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Baseline (n=27,75,42,120)	2.6 score on a scale	Standard Error 0.19
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Week 4 (n=27,74,42,119)	1.6 score on a scale	Standard Error 0.15
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Week 8 (n=26,71,41,118)	1.5 score on a scale	Standard Error 0.14
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Week 16 (n=22,66,39,101)	1.5 score on a scale	Standard Error 0.15
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Baseline (n=27,75,42,120)	0.9 score on a scale	Standard Error 0.18
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Week 4 (n=27,74,41,119)	0.6 score on a scale	Standard Error 0.13
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Week 8 (n=26,71,41,118)	0.4 score on a scale	Standard Error 0.08
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Week 16 (n=22,66,39,101)	0.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Week 4 (n=27,74,42,119)	0.2 score on a scale	Standard Error 0.08
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Week 8 (n=26,71,41,118)	0.1 score on a scale	Standard Error 0.04
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Week 16 (n =22,66,39,101)	0.2 score on a scale	Standard Error 0.05
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Baseline (n=27,75,42,120)	0.1 score on a scale	Standard Error 0.04
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Week 8 (n=26,71,41,118)	1.0 score on a scale	Standard Error 0.18
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Week 4 (n=27,74,41,119)	0.2 score on a scale	Standard Error 0.09
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Baseline (n=27,75,42,120)	0.1 score on a scale	Standard Error 0.06
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Week 4 (n=27,74,42,119)	0.1 score on a scale	Standard Error 0.04
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Week 8 (n=26,71,41,118)	0.1 score on a scale	Standard Error 0.05
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Baseline (n=27,75,42,120)	0.4 score on a scale	Standard Error 0.12
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Week 16 (n=22,66,39,101)	0.2 score on a scale	Standard Error 0.08
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Week 8 (n=26,71,41,118)	0.0 score on a scale	Standard Error 0.03
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Week 8 (n=26,71,41,118)	0.3 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Week 4 (n=27,74,42,119)	0.2 score on a scale	Standard Error 0.09
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Baseline (n=27,75,42,120)	0.1 score on a scale	Standard Error 0.06
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Week 16 (n=22,66,39,101)	0.9 score on a scale	Standard Error 0.22
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Week 16 (n =22,66,39,101)	0.2 score on a scale	Standard Error 0.09
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Week 16 (n=22,66,39,101)	0.1 score on a scale	Standard Error 0.11
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Week 16 (n=22,66,39,101)	0.3 score on a scale	Standard Error 0.13
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Week 8 (n=26,71,41,118)	0.3 score on a scale	Standard Error 0.12
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Baseline (n=27,75,42,120)	0.3 score on a scale	Standard Error 0.09
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Baseline (n=27,75,42,120)	1.1 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Week 16 (n=22,65,39,101)	0.4 score on a scale	Standard Error 0.15
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Week 4 (n=27,74,42,119)	0.5 score on a scale	Standard Error 0.14
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Week 8 (n=26,71,41,118)	0.4 score on a scale	Standard Error 0.14
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Week 4 (n=27,74,42,119)	1.0 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Week 4 (n=27,74,42,119)	0.2 score on a scale	Standard Error 0.09
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Week 16 (n =22,66,39,101)	0.1 score on a scale	Standard Error 0.05
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Week 8 (n=26,71,41,118)	1.0 score on a scale	Standard Error 0.12
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Baseline (n=27,75,42,120)	1.2 score on a scale	Standard Error 0.15
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Baseline (n=27,75,42,120)	0.9 score on a scale	Standard Error 0.09
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Week 16 (n=22,66,39,101)	1.0 score on a scale	Standard Error 0.12
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Baseline (n=27,75,42,120)	1.4 score on a scale	Standard Error 0.16
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Week 4 (n=27,74,42,119)	0.4 score on a scale	Standard Error 0.05
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Week 4 (n=27,74,41,119)	0.6 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Week 8 (n=26,71,41,118)	0.4 score on a scale	Standard Error 0.09
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Week 4 (n=27,74,42,119)	0.8 score on a scale	Standard Error 0.11
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Week 8 (n=26,71,41,118)	0.3 score on a scale	Standard Error 0.05
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Leisure, Week 16 (n=22,66,39,101)	0.4 score on a scale	Standard Error 0.09
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Baseline (n=27,75,42,120)	0.6 score on a scale	Standard Error 0.09
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Baseline (n=27,75,42,120)	1.8 score on a scale	Standard Error 0.17
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Week 8 (n=26,71,41,118)	0.5 score on a scale	Standard Error 0.09
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Week 4 (n=27,74,42,119)	0.2 score on a scale	Standard Error 0.05
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Work and School, Week 8 (n=26,71,41,118)	0.2 score on a scale	Standard Error 0.05
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Week 4 (n=27,74,42,119)	1.4 score on a scale	Standard Error 0.11
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Treatment, Week 16 (n=22,66,39,101)	0.3 score on a scale	Standard Error 0.05
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Week 8 (n=26,71,41,118)	0.3 score on a scale	Standard Error 0.09
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Week 16 (n=22,66,39,101)	0.2 score on a scale	Standard Error 0.06
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Symptoms and Feelings, Baseline (n=27,75,42,120)	2.9 score on a scale	Standard Error 0.18
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Personal Relationships, Week 4 (n=27,74,42,119)	0.5 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)	Daily Activities, Week 16 (n=22,65,39,101)	0.5 score on a scale	Standard Error 0.1

Secondary

Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)

Time frame: Baseline and Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B; n equals the number of participants with observations

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 16 (n=28,44,38,68)	0.6 score on a scale	Standard Error 0.22
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 4 (n=30,82,43,126)	0.4 score on a scale	Standard Error 0.19
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 8 (n=30,68,43,103)	0.4 score on a scale	Standard Error 0.22
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 12 (n=28,52,41,83)	0.4 score on a scale	Standard Error 0.23
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Baseline (n=31,82,45,133)	0.1 score on a scale	Standard Error 0.04
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 16 (n=28,44,38,68)	0.3 score on a scale	Standard Error 0.13
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Baseline (n=31,82,45,133)	0.5 score on a scale	Standard Error 0.18
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 4 (n=30,82,43,127)	0.8 score on a scale	Standard Error 0.3
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 8 (n=30,68,43,104)	0.6 score on a scale	Standard Error 0.25
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 12 (n=28,52,41,83)	0.6 score on a scale	Standard Error 0.23
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Baseline (n=31,82,45,133)	0.3 score on a scale	Standard Error 0.13
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 16 (n=28,44,38,68)	0.4 score on a scale	Standard Error 0.23
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Baseline (n=31,82,45,133)	1.1 score on a scale	Standard Error 0.25
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 4 (n=30,82,43,127)	1.3 score on a scale	Standard Error 0.3
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 8 (n=30,68,43,104)	1.1 score on a scale	Standard Error 0.24
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 12 (n=28,52,41,83)	1.1 score on a scale	Standard Error 0.28
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 16 (n=28,44,38,68)	1.4 score on a scale	Standard Error 0.31
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Baseline (n=31,82,45,133)	0.3 score on a scale	Standard Error 0.12
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 4 (n=30,82,42,127)	0.5 score on a scale	Standard Error 0.23
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 8 (n=30,68,43,104)	0.5 score on a scale	Standard Error 0.15
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 12 (n=28,52,41,83)	0.5 score on a scale	Standard Error 0.18
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 16 (n=28,44,37,68)	0.5 score on a scale	Standard Error 0.17
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 4 (n=30,82,43,127)	0.1 score on a scale	Standard Error 0.06
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 8 (n=30,68,43,104)	0.2 score on a scale	Standard Error 0.08
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 12 (n=28,52,41,83)	0.2 score on a scale	Standard Error 0.13
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Baseline (n=31,82,45,133)	0.3 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 4 (n=30,82,43,127)	0.3 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 8 (n=30,68,43,104)	0.3 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 12 (n=28,52,41,83)	0.4 score on a scale	Standard Error 0.14
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 16 (n=28,44,38,68)	0.3 score on a scale	Standard Error 0.12
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 4 (n=30,82,43,127)	0.4 score on a scale	Standard Error 0.07
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 12 (n=28,52,41,83)	2.1 score on a scale	Standard Error 0.19
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 16 (n=28,44,38,68)	0.3 score on a scale	Standard Error 0.08
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 12 (n=28,52,41,83)	0.2 score on a scale	Standard Error 0.06
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Baseline (n=31,82,45,133)	0.3 score on a scale	Standard Error 0.07
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 16 (n=28,44,38,68)	1.9 score on a scale	Standard Error 0.19
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Baseline (n=31,82,45,133)	0.8 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 8 (n=30,68,43,104)	0.3 score on a scale	Standard Error 0.09
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 16 (n=28,44,38,68)	1.2 score on a scale	Standard Error 0.21
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Baseline (n=31,82,45,133)	0.2 score on a scale	Standard Error 0.07
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 16 (n=28,44,38,68)	0.6 score on a scale	Standard Error 0.11
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 4 (n=30,82,42,127)	0.6 score on a scale	Standard Error 0.11
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 4 (n=30,82,43,127)	0.8 score on a scale	Standard Error 0.14
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Baseline (n=31,82,45,133)	0.2 score on a scale	Standard Error 0.06
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 8 (n=30,68,43,104)	0.5 score on a scale	Standard Error 0.09
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 8 (n=30,68,43,104)	0.8 score on a scale	Standard Error 0.18
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 12 (n=28,52,41,83)	0.5 score on a scale	Standard Error 0.14
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Baseline (n=31,82,45,133)	0.1 score on a scale	Standard Error 0.04
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 8 (n=30,68,43,104)	2.2 score on a scale	Standard Error 0.19
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 4 (n=30,82,43,127)	2.0 score on a scale	Standard Error 0.19
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 16 (n=28,44,38,68)	0.5 score on a scale	Standard Error 0.16
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 8 (n=30,68,43,104)	1.1 score on a scale	Standard Error 0.19
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 16 (n=28,44,37,68)	0.5 score on a scale	Standard Error 0.15
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 12 (n=28,52,41,83)	0.4 score on a scale	Standard Error 0.09
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Baseline (n=31,82,45,133)	0.1 score on a scale	Standard Error 0.05
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 4 (n=30,82,43,126)	0.6 score on a scale	Standard Error 0.11
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 12 (n=28,52,41,83)	0.9 score on a scale	Standard Error 0.15
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 12 (n=28,52,41,83)	0.6 score on a scale	Standard Error 0.15
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 4 (n=30,82,43,127)	0.3 score on a scale	Standard Error 0.07
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 8 (n=30,68,43,103)	0.8 score on a scale	Standard Error 0.17
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 16 (n=28,44,38,68)	0.4 score on a scale	Standard Error 0.12
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 8 (n=30,68,43,104)	0.0 score on a scale	Standard Error 0.03
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Baseline (n=31,82,45,133)	0.5 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Baseline (n=31,82,45,133)	0.2 score on a scale	Standard Error 0.08
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 4 (n=30,82,43,127)	0.5 score on a scale	Standard Error 0.13
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 12 (n=28,52,41,83)	0.2 score on a scale	Standard Error 0.09
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Baseline (n=31,82,45,133)	0.2 score on a scale	Standard Error 0.07
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 4 (n=30,82,43,126)	0.1 score on a scale	Standard Error 0.05
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 12 (n=28,52,41,83)	0.1 score on a scale	Standard Error 0.05
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 4 (n=30,82,43,127)	0.3 score on a scale	Standard Error 0.09
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 16 (n=28,44,38,68)	0.0 score on a scale	Standard Error 0.03
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 8 (n=30,68,43,104)	0.4 score on a scale	Standard Error 0.13
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 8 (n=30,68,43,104)	0.7 score on a scale	Standard Error 0.16
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 12 (n=28,52,41,83)	0.3 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 12 (n=28,52,41,83)	1.0 score on a scale	Standard Error 0.19
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 8 (n=30,68,43,103)	0.1 score on a scale	Standard Error 0.07
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 4 (n=30,82,43,127)	0.2 score on a scale	Standard Error 0.06
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 16 (n=28,44,38,68)	1.0 score on a scale	Standard Error 0.16
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Baseline (n=31,82,45,133)	0.2 score on a scale	Standard Error 0.05
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 12 (n=28,52,41,83)	0.1 score on a scale	Standard Error 0.05
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 4 (n=30,82,42,127)	0.1 score on a scale	Standard Error 0.08
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 8 (n=30,68,43,104)	0.2 score on a scale	Standard Error 0.11
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 8 (n=30,68,43,104)	0.1 score on a scale	Standard Error 0.05
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 12 (n=28,52,41,83)	0.2 score on a scale	Standard Error 0.07
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 16 (n=28,44,38,68)	0.2 score on a scale	Standard Error 0.07
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 16 (n=28,44,37,68)	0.1 score on a scale	Standard Error 0.07
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Baseline (n=31,82,45,133)	0.0 score on a scale	Standard Error 0.02
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Baseline (n=31,82,45,133)	0.2 score on a scale	Standard Error 0.08
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 16 (n=28,44,38,68)	0.2 score on a scale	Standard Error 0.07
CP-690,550 10 mg (Period B)	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 4 (n=30,82,43,127)	0.0 score on a scale	Standard Error 0.02
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 12 (n=28,52,41,83)	1.1 score on a scale	Standard Error 0.17
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 16 (n=28,44,38,68)	1.3 score on a scale	Standard Error 0.21
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 12 (n=28,52,41,83)	0.5 score on a scale	Standard Error 0.08
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Baseline (n=31,82,45,133)	0.1 score on a scale	Standard Error 0.04
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 8 (n=30,68,43,103)	0.9 score on a scale	Standard Error 0.14
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 12 (n=28,52,41,83)	0.7 score on a scale	Standard Error 0.13
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 16 (n=28,44,38,68)	0.8 score on a scale	Standard Error 0.17
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Baseline (n=31,82,45,133)	0.1 score on a scale	Standard Error 0.03
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 4 (n=30,82,43,127)	2.2 score on a scale	Standard Error 0.16
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 16 (n=28,44,38,68)	0.6 score on a scale	Standard Error 0.11
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 8 (n=30,68,43,104)	2.3 score on a scale	Standard Error 0.18
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 12 (n=28,52,41,83)	2.0 score on a scale	Standard Error 0.18
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Week 16 (n=28,44,38,68)	2.2 score on a scale	Standard Error 0.21
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 4 (n=30,82,43,127)	0.5 score on a scale	Standard Error 0.08
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 4 (n=30,82,42,127)	0.9 score on a scale	Standard Error 0.13
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 8 (n=30,68,43,104)	0.9 score on a scale	Standard Error 0.15
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 12 (n=28,52,41,83)	0.7 score on a scale	Standard Error 0.14
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Treatment, Week 8 (n=30,68,43,104)	0.6 score on a scale	Standard Error 0.09
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Baseline (n=31,82,45,133)	0.1 score on a scale	Standard Error 0.02
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 4 (n=30,82,43,127)	0.5 score on a scale	Standard Error 0.09
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Personal Relationships, Week 4 (n=30,82,43,126)	0.6 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Symptoms and Feelings, Baseline (n=31,82,45,133)	0.6 score on a scale	Standard Error 0.08
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Baseline (n=31,82,45,133)	0.2 score on a scale	Standard Error 0.05
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Leisure, Week 16 (n=28,44,37,68)	0.9 score on a scale	Standard Error 0.17
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 8 (n=30,68,43,104)	0.5 score on a scale	Standard Error 0.09
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 12 (n=28,52,41,83)	0.4 score on a scale	Standard Error 0.09
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Baseline (n=31,82,45,133)	0.3 score on a scale	Standard Error 0.07
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 4 (n=30,82,43,127)	1.2 score on a scale	Standard Error 0.14
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Work and School, Week 16 (n=28,44,38,68)	0.4 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)	Daily Activities, Week 8 (n=30,68,43,104)	1.2 score on a scale	Standard Error 0.17

Secondary

Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)

Time frame: Baseline and Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Daily Activities, Baseline (n=330,333)	2.7 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Symptoms and Feelings, Baseline (n=331,333)	3.9 score on a scale	Standard Error 0.09
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Daily Activities, Week 24 (n=273,277)	1.1 score on a scale	Standard Error 0.09
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Personal Relationships, Baseline (n=331,332)	1.7 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Personal Relationships, Week 4 (n=326,330)	1.0 score on a scale	Standard Error 0.08
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Personal Relationships, Week 8 (n=321,318)	0.7 score on a scale	Standard Error 0.06
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Personal Relationships, Week 24 (n=271,276)	0.6 score on a scale	Standard Error 0.07
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Symptoms and Feelings, Week 4 (n=326,330)	2.1 score on a scale	Standard Error 0.07
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Work and School, Week 8 (n=321,319)	0.3 score on a scale	Standard Error 0.04
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Work and School, Week 16 (n=309,303)	0.3 score on a scale	Standard Error 0.04
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Work and School, Week 24 (n=273,277)	0.4 score on a scale	Standard Error 0.04
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Treatment, Baseline (n=331,332)	1.1 score on a scale	Standard Error 0.06
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Treatment, Week 4 (n=326,330)	0.6 score on a scale	Standard Error 0.04
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Treatment, Week 8 (n=321,320)	0.5 score on a scale	Standard Error 0.04
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Daily Activities, Week 4 (n=326,330)	1.5 score on a scale	Standard Error 0.09
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Daily Activities, Week 8 (n=321,320)	1.2 score on a scale	Standard Error 0.08
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Daily Activities, Week 16 (n=310,303)	1.0 score on a scale	Standard Error 0.08
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Personal Relationships, Week 16 (n=310,302)	0.6 score on a scale	Standard Error 0.06
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Symptoms and Feelings, Week 8 (n=321,319)	1.8 score on a scale	Standard Error 0.08
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Symptoms and Feelings, Week 16 (n=310,303)	1.7 score on a scale	Standard Error 0.08
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Symptoms and Feelings, Week 24 (n=273,277)	1.7 score on a scale	Standard Error 0.09
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Leisure, Baseline (n=331,333)	2.1 score on a scale	Standard Error 0.11
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Leisure, Week 4 (n=326,330)	1.1 score on a scale	Standard Error 0.09
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Leisure, Week 8 (n=321,320)	0.9 score on a scale	Standard Error 0.08
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Leisure, Week 16 (n=310,303)	0.7 score on a scale	Standard Error 0.07
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Leisure, Week 24 (n=272,277)	0.8 score on a scale	Standard Error 0.08
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Work and School, Baseline (n=330,333)	0.9 score on a scale	Standard Error 0.06
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Work and School, Week 4 (n=326,330)	0.5 score on a scale	Standard Error 0.05
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Treatment, Week 16 (n=310,303)	0.5 score on a scale	Standard Error 0.04
CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Treatment, Week 24 (n=272,277)	0.6 score on a scale	Standard Error 0.05
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Personal Relationships, Baseline (n=331,332)	1.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Personal Relationships, Week 8 (n=321,318)	0.4 score on a scale	Standard Error 0.06
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Daily Activities, Baseline (n=330,333)	2.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Leisure, Week 16 (n=310,303)	0.4 score on a scale	Standard Error 0.06
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Daily Activities, Week 24 (n=273,277)	0.6 score on a scale	Standard Error 0.07
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Symptoms and Feelings, Week 4 (n=326,330)	1.6 score on a scale	Standard Error 0.07
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Treatment, Week 4 (n=326,330)	0.5 score on a scale	Standard Error 0.04
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Personal Relationships, Week 4 (n=326,330)	0.6 score on a scale	Standard Error 0.07
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Symptoms and Feelings, Week 8 (n=321,319)	1.2 score on a scale	Standard Error 0.07
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Personal Relationships, Week 16 (n=310,302)	0.3 score on a scale	Standard Error 0.06
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Leisure, Week 24 (n=272,277)	0.4 score on a scale	Standard Error 0.05
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Personal Relationships, Week 24 (n=271,276)	0.3 score on a scale	Standard Error 0.05
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Symptoms and Feelings, Baseline (n=331,333)	3.9 score on a scale	Standard Error 0.08
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Symptoms and Feelings, Week 16 (n=310,303)	1.1 score on a scale	Standard Error 0.08
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Treatment, Week 8 (n=321,320)	0.4 score on a scale	Standard Error 0.03
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Work and School, Week 8 (n=321,319)	0.2 score on a scale	Standard Error 0.03
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Symptoms and Feelings, Week 24 (n=273,277)	1.0 score on a scale	Standard Error 0.08
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Work and School, Week 16 (n=309,303)	0.2 score on a scale	Standard Error 0.03
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Work and School, Baseline (n=330,333)	0.9 score on a scale	Standard Error 0.06
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Leisure, Baseline (n=331,333)	2.2 score on a scale	Standard Error 0.11
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Treatment, Baseline (n=331,332)	1.2 score on a scale	Standard Error 0.06
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Treatment, Week 16 (n=310,303)	0.3 score on a scale	Standard Error 0.04
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Leisure, Week 4 (n=326,330)	0.8 score on a scale	Standard Error 0.07
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Treatment, Week 24 (n=272,277)	0.2 score on a scale	Standard Error 0.03
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Work and School, Week 4 (n=326,330)	0.3 score on a scale	Standard Error 0.04
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Daily Activities, Week 4 (n=326,330)	1.1 score on a scale	Standard Error 0.07
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Leisure, Week 8 (n=321,320)	0.5 score on a scale	Standard Error 0.06
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Daily Activities, Week 8 (n=321,320)	0.8 score on a scale	Standard Error 0.07
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Work and School, Week 24 (n=273,277)	0.1 score on a scale	Standard Error 0.03
Placebo for CP-690,550 5 mg (Period B)	Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)	Daily Activities, Week 16 (n=310,303)	0.6 score on a scale	Standard Error 0.07

Secondary

Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)

Time frame: Baseline and Week 56 (Period C)

Population: FAS-C; n equals the number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Mobility (n=22,65,34,96)	1.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Pain/Discomfort (n=22,65,34,96)	1.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Self-Care (n=22,65,34,96)	1.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Anxiety/Depression (n=22,65,34,96)	1.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Mobility (n=27,75,42,120)	1.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Anxiety/Depression (n=27,75,42,120)	1.3 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Usual Activities (n=27,75,42,120)	1.3 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Self-Care (n=27,75,42,120)	1.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Pain/Discomfort (n=27,75,42,120)	1.5 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Usual Activities (n=22,65,34,96)	1.1 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Pain/Discomfort (n=22,65,34,96)	1.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Usual Activities (n=22,65,34,96)	1.1 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Pain/Discomfort (n=27,75,42,120)	1.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Mobility (n=22,65,34,96)	1.1 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Self-Care (n=27,75,42,120)	1.1 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Mobility (n=27,75,42,120)	1.2 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Anxiety/Depression (n=27,75,42,120)	1.3 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Self-Care (n=22,65,34,96)	1.0 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Usual Activities (n=27,75,42,120)	1.2 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Anxiety/Depression (n=22,65,34,96)	1.3 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Mobility (n=22,65,34,96)	1.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Mobility (n=27,75,42,120)	1.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Self-Care (n=27,75,42,120)	1.0 score on a scale	Standard Error 0
CP-690,550 10 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Self-Care (n=22,65,34,96)	1.0 score on a scale	Standard Error 0
CP-690,550 10 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Usual Activities (n=27,75,42,120)	1.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Usual Activities (n=22,65,34,96)	1.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Pain/Discomfort (n=27,75,42,120)	1.3 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Pain/Discomfort (n=22,65,34,96)	1.3 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Anxiety/Depression (n=27,75,42,120)	1.2 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Anxiety/Depression (n=22,65,34,96)	1.2 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Mobility (n=27,75,42,120)	1.2 score on a scale	Standard Error 0
Placebo for 10 mg CP-690,550	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Pain/Discomfort (n=22,65,34,96)	1.4 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Self-Care (n=22,65,34,96)	1.0 score on a scale	Standard Error 0
Placebo for 10 mg CP-690,550	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Self-Care (n=27,75,42,120)	1.1 score on a scale	Standard Error 0
Placebo for 10 mg CP-690,550	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Anxiety/Depression (n=22,65,34,96)	1.2 score on a scale	Standard Error 0
Placebo for 10 mg CP-690,550	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Anxiety/Depression (n=27,75,42,120)	1.3 score on a scale	Standard Error 0
Placebo for 10 mg CP-690,550	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Mobility (n=22,65,34,96)	1.2 score on a scale	Standard Error 0
Placebo for 10 mg CP-690,550	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Pain/Discomfort (n=27,75,42,120)	1.7 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Usual Activities (n=22,65,34,96)	1.1 score on a scale	Standard Error 0
Placebo for 10 mg CP-690,550	Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Usual Activities (n=27,75,42,120)	1.3 score on a scale	Standard Error 0

Secondary

Mean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)

Time frame: Baseline and Week 24 (Period A)

Population: FAS-A; n=number of participants with an observation.

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Mobility, Baseline (n=329,332)	1.3 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Mobility, Week 24 (n=270,274)	1.2 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Self-Care, Baseline (n=330,332)	1.1 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Self-Care, Week 24 (n=270,272)	1.1 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Usual Activities Baseline (n=330,332)	1.4 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Usual Activities Week 24 (n=270,273)	1.2 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Pain/Discomfort Baseline (n=330,332)	1.8 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Pain/Discomfort Week 24 (n=270,274)	1.5 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Anxiety/Depression Baseline (n=330,332)	1.4 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Anxiety/Depression Week 24 (n=270,274)	1.3 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Pain/Discomfort Week 24 (n=270,274)	1.4 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Mobility, Baseline (n=329,332)	1.3 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Usual Activities Week 24 (n=270,273)	1.1 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Mobility, Week 24 (n=270,274)	1.2 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Anxiety/Depression Week 24 (n=270,274)	1.3 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Self-Care, Baseline (n=330,332)	1.1 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Pain/Discomfort Baseline (n=330,332)	1.9 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Self-Care, Week 24 (n=270,272)	1.0 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Anxiety/Depression Baseline (n=330,332)	1.4 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)	Usual Activities Baseline (n=330,332)	1.4 score on a scale	Standard Error 0

Secondary

Mean EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)

Time frame: Baseline and Week 56 (Period C)

Population: FAS-C; n equals the number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)	Baseline Utility Score (n=27,75,42,120)	0.8 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Utility Score (n=22,65,34,96)	0.9 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)	Baseline VAS (n=27,75,42,120)	79.6 score on a scale	Standard Error 3.4
CP-690,550 5 mg (Period B)	Mean EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)	Week 56 VAS (n=22,65,34,96)	82.0 score on a scale	Standard Error 2.5
Placebo for CP-690,550 5 mg (Period B)	Mean EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Utility Score (n=22,65,34,96)	0.9 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)	Baseline VAS (n=27,75,42,120)	76.5 score on a scale	Standard Error 2.2
Placebo for CP-690,550 5 mg (Period B)	Mean EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)	Week 56 VAS (n=22,65,34,96)	82.3 score on a scale	Standard Error 1.7
Placebo for CP-690,550 5 mg (Period B)	Mean EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)	Baseline Utility Score (n=27,75,42,120)	0.8 score on a scale	Standard Error 0
CP-690,550 10 mg (Period B)	Mean EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)	Baseline VAS (n=27,75,42,120)	76.8 score on a scale	Standard Error 3.5
CP-690,550 10 mg (Period B)	Mean EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Utility Score (n=22,65,34,96)	0.9 score on a scale	Standard Error 0
CP-690,550 10 mg (Period B)	Mean EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)	Week 56 VAS (n=22,65,34,96)	82.7 score on a scale	Standard Error 2.7
CP-690,550 10 mg (Period B)	Mean EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)	Baseline Utility Score (n=27,75,42,120)	0.9 score on a scale	Standard Error 0
Placebo for 10 mg CP-690,550	Mean EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)	Week 56 VAS (n=22,65,34,96)	83.8 score on a scale	Standard Error 1.2
Placebo for 10 mg CP-690,550	Mean EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Utility Score (n=22,65,34,96)	0.9 score on a scale	Standard Error 0
Placebo for 10 mg CP-690,550	Mean EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)	Baseline Utility Score (n=27,75,42,120)	0.8 score on a scale	Standard Error 0
Placebo for 10 mg CP-690,550	Mean EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)	Baseline VAS (n=27,75,42,120)	75.3 score on a scale	Standard Error 1.8

Secondary

Mean EuroQol 5 Dimensions (EQ-5D) Health State Profile Utility Score and VAS Scores During the Initial CP-690,550 Treatment Period (Period A)

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A; n=number of participants with an observation.

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean EuroQol 5 Dimensions (EQ-5D) Health State Profile Utility Score and VAS Scores During the Initial CP-690,550 Treatment Period (Period A)	Utility Score, Baseline (n=329,332)	0.7 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean EuroQol 5 Dimensions (EQ-5D) Health State Profile Utility Score and VAS Scores During the Initial CP-690,550 Treatment Period (Period A)	Utility Score, Week 24 (n=270,272)	0.8 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean EuroQol 5 Dimensions (EQ-5D) Health State Profile Utility Score and VAS Scores During the Initial CP-690,550 Treatment Period (Period A)	VAS, Baseline (n=329,332)	69.9 score on a scale	Standard Error 1.3
CP-690,550 5 mg (Period B)	Mean EuroQol 5 Dimensions (EQ-5D) Health State Profile Utility Score and VAS Scores During the Initial CP-690,550 Treatment Period (Period A)	VAS, Week 24 (n=269,274)	75.6 score on a scale	Standard Error 1.2
Placebo for CP-690,550 5 mg (Period B)	Mean EuroQol 5 Dimensions (EQ-5D) Health State Profile Utility Score and VAS Scores During the Initial CP-690,550 Treatment Period (Period A)	VAS, Week 24 (n=269,274)	80.3 score on a scale	Standard Error 1
Placebo for CP-690,550 5 mg (Period B)	Mean EuroQol 5 Dimensions (EQ-5D) Health State Profile Utility Score and VAS Scores During the Initial CP-690,550 Treatment Period (Period A)	Utility Score, Baseline (n=329,332)	0.7 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean EuroQol 5 Dimensions (EQ-5D) Health State Profile Utility Score and VAS Scores During the Initial CP-690,550 Treatment Period (Period A)	VAS, Baseline (n=329,332)	70.6 score on a scale	Standard Error 1.3
Placebo for CP-690,550 5 mg (Period B)	Mean EuroQol 5 Dimensions (EQ-5D) Health State Profile Utility Score and VAS Scores During the Initial CP-690,550 Treatment Period (Period A)	Utility Score, Week 24 (n=270,272)	0.9 score on a scale	Standard Error 0

Secondary

Mean ISI Score During the CP-690,550 Re-Treatment (Period C)

Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

Population: FAS-C; n equals the number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean ISI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,100)	2.3 score on a scale	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean ISI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	2.6 score on a scale	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean ISI Score During the CP-690,550 Re-Treatment (Period C)	Baseline (n=27,75,42,120)	2.3 score on a scale	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean ISI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	2.4 score on a scale	Standard Error 0.5
Placebo for CP-690,550 5 mg (Period B)	Mean ISI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,100)	2.2 score on a scale	Standard Error 0.3
Placebo for CP-690,550 5 mg (Period B)	Mean ISI Score During the CP-690,550 Re-Treatment (Period C)	Baseline (n=27,75,42,120)	4.9 score on a scale	Standard Error 0.3
Placebo for CP-690,550 5 mg (Period B)	Mean ISI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	2.6 score on a scale	Standard Error 0.2
Placebo for CP-690,550 5 mg (Period B)	Mean ISI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	2.3 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean ISI Score During the CP-690,550 Re-Treatment (Period C)	Baseline (n=27,75,42,120)	1.7 score on a scale	Standard Error 0.4
CP-690,550 10 mg (Period B)	Mean ISI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	1.7 score on a scale	Standard Error 0.4
CP-690,550 10 mg (Period B)	Mean ISI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	1.5 score on a scale	Standard Error 0.3
CP-690,550 10 mg (Period B)	Mean ISI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,100)	1.4 score on a scale	Standard Error 0.4
Placebo for 10 mg CP-690,550	Mean ISI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	1.8 score on a scale	Standard Error 0.2
Placebo for 10 mg CP-690,550	Mean ISI Score During the CP-690,550 Re-Treatment (Period C)	Baseline (n=27,75,42,120)	5.2 score on a scale	Standard Error 0.3
Placebo for 10 mg CP-690,550	Mean ISI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	2.1 score on a scale	Standard Error 0.2
Placebo for 10 mg CP-690,550	Mean ISI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,100)	1.6 score on a scale	Standard Error 0.2

Secondary

Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B)

Time frame: Baseline and Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B; n equals the number of participants with observations

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Baseline (n=31,82,45,133)	1.5 score on a scale	Standard Error 0.4
CP-690,550 5 mg (Period B)	Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=29,53,41,84)	1.9 score on a scale	Standard Error 0.4
CP-690,550 5 mg (Period B)	Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	2.2 score on a scale	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,127)	1.7 score on a scale	Standard Error 0.4
CP-690,550 5 mg (Period B)	Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,69,43,104)	1.5 score on a scale	Standard Error 0.4
Placebo for CP-690,550 5 mg (Period B)	Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,127)	3.6 score on a scale	Standard Error 0.3
Placebo for CP-690,550 5 mg (Period B)	Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=29,53,41,84)	4.0 score on a scale	Standard Error 0.4
Placebo for CP-690,550 5 mg (Period B)	Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,69,43,104)	4.0 score on a scale	Standard Error 0.4
Placebo for CP-690,550 5 mg (Period B)	Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Baseline (n=31,82,45,133)	1.2 score on a scale	Standard Error 0.2
Placebo for CP-690,550 5 mg (Period B)	Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	3.7 score on a scale	Standard Error 0.4
CP-690,550 10 mg (Period B)	Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,127)	0.7 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Baseline (n=31,82,45,133)	0.6 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,69,43,104)	1.2 score on a scale	Standard Error 0.3
CP-690,550 10 mg (Period B)	Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=29,53,41,84)	1.3 score on a scale	Standard Error 0.3
CP-690,550 10 mg (Period B)	Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	1.6 score on a scale	Standard Error 0.4
Placebo for 10 mg CP-690,550	Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=29,53,41,84)	3.8 score on a scale	Standard Error 0.3
Placebo for 10 mg CP-690,550	Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Baseline (n=31,82,45,133)	0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,127)	4.1 score on a scale	Standard Error 0.3
Placebo for 10 mg CP-690,550	Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,69,43,104)	4.1 score on a scale	Standard Error 0.3
Placebo for 10 mg CP-690,550	Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	4.0 score on a scale	Standard Error 0.4

Secondary

Mean Itch Severity Item (ISI) Score During the Initial CP-690,550 Treatment (Period A)

Time frame: Baseline and Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Itch Severity Item (ISI) Score During the Initial CP-690,550 Treatment (Period A)	Week 4 (n=326,331)	3.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Itch Severity Item (ISI) Score During the Initial CP-690,550 Treatment (Period A)	Week 16 (n=310,307)	2.9 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Itch Severity Item (ISI) Score During the Initial CP-690,550 Treatment (Period A)	Week 8 (n=322,321)	2.8 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean Itch Severity Item (ISI) Score During the Initial CP-690,550 Treatment (Period A)	Week 24 (n=274,278)	2.9 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean Itch Severity Item (ISI) Score During the Initial CP-690,550 Treatment (Period A)	Baseline (n=331,335)	6.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Itch Severity Item (ISI) Score During the Initial CP-690,550 Treatment (Period A)	Week 24 (n=274,278)	1.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Itch Severity Item (ISI) Score During the Initial CP-690,550 Treatment (Period A)	Baseline (n=331,335)	6.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Itch Severity Item (ISI) Score During the Initial CP-690,550 Treatment (Period A)	Week 4 (n=326,331)	2.2 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Itch Severity Item (ISI) Score During the Initial CP-690,550 Treatment (Period A)	Week 8 (n=322,321)	1.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean Itch Severity Item (ISI) Score During the Initial CP-690,550 Treatment (Period A)	Week 16 (n=310,307)	1.7 score on a scale	Standard Error 0.1

Secondary

Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.

Time frame: Baseline and Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B; n equals number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 8 (n=30,70,43,104)	0.5 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 12 (n=28,53,42,84)	0.6 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Baseline (n=31,82,45,133)	0.5 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Baseline (n=31,82,45,133)	0.5 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 12 (n=28,53,42,84)	0.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 4 (n=30,82,43,128)	0.7 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 4 (n=30,82,43,128)	0.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 8 (n=30,70,43,104)	0.9 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 12 (n=28,53,42,84)	0.7 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 16 (n=28,45,38,70)	0.5 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 16 (n=28,45,38,70)	0.9 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 8 (n=30,70,43,104)	0.5 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Baseline (n=31,82,45,133)	0.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 8 (n=30,70,43,104)	0.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 4 (n=30,82,43,128)	0.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 4 (n=30,82,43,128)	0.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 16 (n=28,45,38,70)	1.1 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 16 (n=28,45,38,70)	0.6 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 12 (n=28,53,42,84)	0.5 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 16 (n=28,45,38,70)	0.6 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Baseline (n=31,82,45,133)	0.3 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 16 (n=28,45,38,70)	0.6 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 12 (n=28,53,42,84)	0.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Baseline (n=31,82,45,133)	0.5 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 12 (n=28,53,42,84)	0.6 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Baseline (n=31,82,45,133)	0.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 4 (n=30,82,43,128)	0.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 8 (n=30,70,43,104)	0.6 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 8 (n=30,70,43,104)	0.5 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 4 (n=30,82,43,128)	0.6 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 12 (n=28,53,42,84)	0.6 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 4 (n=30,82,43,128)	0.6 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 16 (n=28,45,38,70)	0.6 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Baseline (n=31,82,45,133)	0.6 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 8 (n=30,70,43,104)	0.7 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Baseline (n=31,82,45,133)	0.5 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 4 (n=30,82,43,128)	0.8 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 8 (n=30,70,43,104)	0.7 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 8 (n=30,70,43,104)	0.9 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 16 (n=28,45,38,70)	0.8 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 12 (n=28,53,42,84)	1.0 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 8 (n=30,70,43,104)	0.8 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 16 (n=28,45,38,70)	1.0 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 12 (n=28,53,42,84)	0.7 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Baseline (n=31,82,45,133)	0.7 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 12 (n=28,53,42,84)	0.8 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 4 (n=30,82,43,128)	0.8 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 16 (n=28,45,38,70)	0.6 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 4 (n=30,82,43,128)	0.5 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 8 (n=30,70,43,104)	0.8 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 12 (n=28,53,42,84)	1.0 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 16 (n=28,45,38,70)	0.7 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 16 (n=28,45,38,70)	1.1 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 4 (n=30,82,43,128)	0.6 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Baseline (n=31,82,45,133)	0.8 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 4 (n=30,82,43,128)	0.8 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Baseline (n=31,82,45,133)	0.5 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 8 (n=30,70,43,104)	0.9 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Baseline (n=31,82,45,133)	0.3 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 12 (n=28,53,42,84)	1.0 score on a scale	Standard Error 0.2
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 4 (n=30,82,43,128)	1.1 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 16 (n=28,45,38,70)	1.3 score on a scale	Standard Error 0.2
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 4 (n=30,82,43,128)	1.3 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 8 (n=30,70,43,104)	1.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Baseline (n=31,82,45,133)	0.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Baseline (n=31,82,45,133)	0.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 16 (n=28,45,38,70)	0.8 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 16 (n=28,45,38,70)	1.4 score on a scale	Standard Error 0.2
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Baseline (n=31,82,45,133)	0.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 4 (n=30,82,43,128)	1.1 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 8 (n=30,70,43,104)	1.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 8 (n=30,70,43,104)	1.2 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Baseline (n=31,82,45,133)	0.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 8 (n=30,70,43,104)	1.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 4 (n=30,82,43,128)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 12 (n=28,53,42,84)	1.2 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 12 (n=28,53,42,84)	1.5 score on a scale	Standard Error 0.2
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 4 (n=30,82,43,128)	1.3 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Baseline (n=31,82,45,133)	0.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 16 (n=28,45,38,70)	1.3 score on a scale	Standard Error 0.2
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 16 (n=28,45,38,70)	1.4 score on a scale	Standard Error 0.2
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 4 (n=30,82,43,128)	1.3 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 12 (n=28,53,42,84)	1.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Baseline (n=31,82,45,133)	0.3 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 16 (n=28,45,38,70)	1.6 score on a scale	Standard Error 0.2
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 4 (n=30,82,43,128)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 12 (n=28,53,42,84)	1.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 4 (n=30,82,43,128)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 8 (n=30,70,43,104)	1.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 8 (n=30,70,43,104)	1.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 8 (n=30,70,43,104)	1.2 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 8 (n=30,70,43,104)	1.2 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 4 (n=30,82,43,128)	1.3 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Baseline (n=31,82,45,133)	0.3 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Baseline (n=31,82,45,133)	0.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 12 (n=28,53,42,84)	1.2 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 16 (n=28,45,38,70)	1.3 score on a scale	Standard Error 0.2
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 12 (n=28,53,42,84)	1.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 4 (n=30,82,43,128)	1.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 16 (n=28,45,38,70)	1.2 score on a scale	Standard Error 0.2
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 12 (n=28,53,42,84)	1.6 score on a scale	Standard Error 0.2
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 12 (n=28,53,42,84)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 16 (n=28,45,38,70)	0.8 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 12 (n=28,53,42,84)	1.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 16 (n=28,45,38,70)	0.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Baseline (n=31,82,45,133)	0.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 16 (n=28,45,38,70)	1.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 8 (n=30,70,43,104)	1.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Baseline (n=31,82,45,133)	0.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 12 (n=28,53,42,84)	1.1 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 8 (n=30,70,43,104)	1.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 16 (n=28,45,38,70)	1.1 score on a scale	Standard Error 0.2
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 4 (n=30,82,43,128)	1.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 8 (n=30,70,43,104)	1.3 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Baseline (n=31,82,45,133)	0.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 12 (n=28,53,42,84)	1.1 score on a scale	Standard Error 0.2
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 8 (n=30,70,43,104)	1.1 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Baseline (n=31,82,45,133)	0.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 4 (n=30,82,43,128)	1.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 12 (n=28,53,42,84)	1.4 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 16 (n=28,45,38,70)	0.6 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 8 (n=30,70,43,104)	0.4 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Baseline (n=31,82,45,133)	0.3 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 4 (n=30,82,43,128)	0.4 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 12 (n=28,53,42,84)	0.5 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 16 (n=28,45,38,70)	0.5 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Baseline (n=31,82,45,133)	0.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 4 (n=30,82,43,128)	0.3 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 8 (n=30,70,43,104)	0.3 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 12 (n=28,53,42,84)	0.4 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 16 (n=28,45,38,70)	0.3 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Baseline (n=31,82,45,133)	0.2 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 4 (n=30,82,43,128)	0.3 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 8 (n=30,70,43,104)	0.4 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 12 (n=28,53,42,84)	0.5 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 16 (n=28,45,38,70)	0.5 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Baseline (n=31,82,45,133)	0.8 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 4 (n=30,82,43,128)	0.8 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 8 (n=30,70,43,104)	0.9 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 12 (n=28,53,42,84)	0.9 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 16 (n=28,45,38,70)	1.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Baseline (n=31,82,45,133)	0.6 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 4 (n=30,82,43,128)	0.7 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 8 (n=30,70,43,104)	0.8 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 12 (n=28,53,42,84)	1.0 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 16 (n=28,45,38,70)	1.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Baseline (n=31,82,45,133)	0.7 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 4 (n=30,82,43,128)	0.7 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 8 (n=30,70,43,104)	0.8 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 12 (n=28,53,42,84)	1.0 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 16 (n=28,45,38,70)	1.3 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Baseline (n=31,82,45,133)	0.4 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 4 (n=30,82,43,128)	0.4 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 8 (n=30,70,43,104)	0.5 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 12 (n=28,53,42,84)	0.5 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 16 (n=28,45,38,70)	0.5 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Baseline (n=31,82,45,133)	0.3 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 4 (n=30,82,43,128)	0.3 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 8 (n=30,70,43,104)	0.4 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 12 (n=28,53,42,84)	0.5 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 16 (n=28,45,38,70)	0.6 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Baseline (n=31,82,45,133)	0.3 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 4 (n=30,82,43,128)	0.3 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 12 (n=28,53,42,84)	0.5 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 8 (n=30,70,43,104)	0.3 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Baseline (n=31,82,45,133)	0.8 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 4 (n=30,82,43,128)	0.8 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 8 (n=30,70,43,104)	0.8 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 12 (n=28,53,42,84)	0.9 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 16 (n=28,45,38,70)	1.0 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Baseline (n=31,82,45,133)	0.6 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 4 (n=30,82,43,128)	0.6 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 8 (n=30,70,43,104)	0.6 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 12 (n=28,53,42,84)	0.8 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 16 (n=28,45,38,70)	0.9 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Baseline (n=31,82,45,133)	0.6 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 4 (n=30,82,43,128)	0.6 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 8 (n=30,70,43,104)	0.6 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 12 (n=28,53,42,84)	0.7 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 16 (n=28,45,38,70)	0.9 score on a scale	Standard Error 0.2
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 16 (n=28,45,38,70)	1.0 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 4 (n=30,82,43,128)	1.2 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Baseline (n=31,82,45,133)	0.5 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 8 (n=30,70,43,104)	1.3 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Baseline (n=31,82,45,133)	0.5 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 16 (n=28,45,38,70)	1.4 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 12 (n=28,53,42,84)	1.3 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 4 (n=30,82,43,128)	1.1 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 4 (n=30,82,43,128)	1.3 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Week 8 (n=30,70,43,104)	1.4 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 4 (n=30,82,43,128)	1.0 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 8 (n=30,70,43,104)	1.5 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Upper limbs, Baseline (n=31,82,45,133)	0.5 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 12 (n=28,53,42,84)	1.3 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 4 (n=30,82,43,128)	1.1 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 12 (n=28,53,42,84)	1.4 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 8 (n=30,70,43,104)	1.4 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 4 (n=30,82,43,128)	1.3 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Baseline (n=31,82,45,133)	0.3 score on a scale	Standard Error 0
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Lower limbs, Week 16 (n=28,45,38,70)	1.3 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Baseline (n=31,82,45,133)	0.5 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 16 (n=28,45,38,70)	0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Upper limbs, Week 16 (n=28,45,38,70)	1.3 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Baseline (n=31,82,45,133)	0.3 score on a scale	Standard Error 0
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 12 (n=28,53,42,84)	1.1 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 8 (n=30,70,43,104)	1.3 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 8 (n=30,70,43,104)	1.3 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 4 (n=30,82,43,128)	1.0 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Week 4 (n=30,82,43,128)	1.1 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Head/Neck, Baseline (n=31,82,45,133)	0.3 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 8 (n=30,70,43,104)	1.4 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 8 (n=30,70,43,104)	1.3 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 16 (n=28,45,38,70)	0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 12 (n=28,53,42,84)	0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 8 (n=30,70,43,104)	1.4 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 12 (n=28,53,42,84)	1.2 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 8 (n=30,70,43,104)	1.1 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Week 4 (n=30,82,43,128)	0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 16 (n=28,45,38,70)	1.3 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Lower limbs, Week 16 (n=28,45,38,70)	1.2 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Head/Neck, Baseline (n=31,82,45,133)	0.2 score on a scale	Standard Error 0
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 16 (n=28,45,38,70)	1.1 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 12 (n=28,53,42,84)	0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 8 (n=30,70,43,104)	1.1 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 16 (n=28,45,38,70)	1.0 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Baseline (n=31,82,45,133)	0.3 score on a scale	Standard Error 0
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Week 4 (n=30,82,43,128)	0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Induration Trunk, Baseline (n=31,82,45,133)	0.3 score on a scale	Standard Error 0
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Week 12 (n=28,53,42,84)	1.3 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 4 (n=30,82,43,128)	0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 16 (n=28,45,38,70)	1.1 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 4 (n=30,82,43,128)	1.1 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 8 (n=30,70,43,104)	1.1 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Baseline (n=31,82,45,133)	0.4 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 16 (n=28,45,38,70)	1.4 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Trunk, Week 12 (n=28,53,42,84)	1.1 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Lower limbs, Baseline (n=31,82,45,133)	0.4 score on a scale	Standard Error 0
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Trunk, Week 12 (n=28,53,42,84)	0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Scaling Upper limbs, Week 12 (n=28,53,42,84)	1.4 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)	Erythema Head/Neck, Week 12 (n=28,53,42,84)	1.1 score on a scale	Standard Error 0.1

Secondary

Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.

Time frame: Baseline and Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A; n equals number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Head/Neck, Week 16 (n=311,307)	0.8 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Head/Neck, Baseline (n=331,335)	2.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Upper limbs, Week 16 (n=311,307)	1.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Upper limbs, Baseline (n=331,335)	2.6 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Upper limbs, Week 24 (n=277,279)	1.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Trunk, Week 24 (n=277,279)	1.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Trunk, Week 8 (n=322,323)	1.3 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Lower limbs, Week 4 (n=326,331)	2.1 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Head/Neck, Baseline (n=331,335)	2.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Head/Neck, Week 4 (n=326,331)	1.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Head/Neck, Week 8 (n=322,323)	1.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Head/Neck, Week 16 (n=311,307)	1.0 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Head/Neck, Week 24 (n=277,279)	1.0 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Head/Neck, Baseline (n=331,335)	2.0 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Head/Neck, Week 4 (n=326,331)	1.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Head/Neck, Week 8 (n=322,323)	0.9 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Head/Neck, Week 24 (n=277,279)	0.8 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Head/Neck, Week 4 (n=326,331)	1.3 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Head/Neck, Week 8 (n=322,323)	1.0 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Head/Neck, Week 16 (n=311,307)	0.9 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Head/Neck, Week 24 (n=277,279)	0.9 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Upper limbs, Baseline (n=331,335)	2.8 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Upper limbs, Week 4 (n=326,331)	1.9 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Upper limbs, Week 8 (n=322,323)	1.6 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Upper limbs, Week 24 (n=277,279)	1.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Upper limbs, Week 4 (n=326,331)	1.9 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Upper limbs, Week 8 (n=322,323)	1.5 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Upper limbs, Week 16 (n=311,307	1.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Upper limbs, Week 24 (n=277,279)	1.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Upper limbs, Baseline (n=331,335)	2.7 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Upper limbs, Week 4 (n=326,331)	1.9 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Upper limbs, Week 8 (n=322,323)	1.5 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Upper limbs, Week 16 (n=311,307)	1.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Trunk, Baseline (n=331,335)	2.9 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Trunk, Week 4 (n=326,331)	1.9 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Trunk, Week 8 (n=322,323)	1.6 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Trunk, Week 16 (n=311,307)	1.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Trunk, Baseline (n=331,335)	2.6 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Trunk, Week 4 (n=326,331)	1.8 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Trunk, Week 8 (n=322,323)	1.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Trunk, Week 16 (n=311,307)	1.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Trunk, Week 24 (n=277,279)	1.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Trunk, Baseline (n=331,335)	2.6 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Trunk, Week 4 (n=326,331)	1.7 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Trunk, Week 16 (n=311,307)	1.2 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Trunk, Week 24 (n=277,279)	1.1 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Lower limbs, Baseline (n=331,335)	3.1 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Lower limbs, Week 4 (n=326,331)	2.2 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Lower limbs, Week 8 (n=322,323)	1.9 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Lower limbs, Week 16 (n=311,307)	1.5 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Lower limbs, Week 24 (n=277,279)	1.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Lower limbs, Baseline (n=331,335)	2.9 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Lwer limbs, Week 8 (n=322,323)	1.6 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Lower limbs, Week 16 (n=311,307)	1.3 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Lower limbs, Week 24 (n=277,279)	1.3 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Lower limbs, Baseline (n=331,335)	2.9 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Lower limbs, Week 4 (n=326,331)	2.0 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Lower limbs, Week 8 (n=322,323)	1.6 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Lower limbs, Week 16 (n=311,307)	1.3 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Lower limbs, Week 24 (n=277,279)	1.3 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Lower limbs, Baseline (n=331,335)	2.9 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Upper limbs, Week 8 (n=322,323)	1.1 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Trunk, Week 24 (n=277,279)	0.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Upper limbs, Week 16 (n=311,307)	1.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Upper limbs, Week 24 (n=277,279)	1.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Lwer limbs, Week 8 (n=322,323)	1.2 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Trunk, Baseline (n=331,335)	2.8 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Lower limbs, Week 16 (n=311,307)	1.1 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Lower limbs, Baseline (n=331,335)	3.1 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Lower limbs, Week 4 (n=326,331)	1.8 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Trunk, Week 4 (n=326,331)	1.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Head/Neck, Baseline (n=331,335)	2.2 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Lower limbs, Week 24 (n=277,279)	1.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Head/Neck, Week 4 (n=326,331)	1.1 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Trunk, Week 8 (n=322,323)	1.1 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Head/Neck, Week 8 (n=322,323)	0.7 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Lower limbs, Week 4 (n=326,331)	1.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Head/Neck, Week 16 (n=311,307)	0.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Trunk, Week 16 (n=311,307)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Head/Neck, Week 24 (n=277,279)	0.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Trunk, Week 24 (n=277,279)	0.8 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Head/Neck, Baseline (n=331,335)	1.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Lower limbs, Week 16 (n=311,307)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Head/Neck, Week 4 (n=326,331)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Trunk, Baseline (n=331,335)	2.6 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Head/Neck, Week 8 (n=322,323)	0.6 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Head/Neck, Week 16 (n=311,307)	0.5 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Lower limbs, Week 8 (n=322,323)	1.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Head/Neck, Week 24 (n=277,279)	0.5 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Head/Neck, Baseline (n=331,335)	2.1 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Trunk, Week 4 (n=326,331)	1.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Head/Neck, Week 4 (n=326,331)	1.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Lower limbs, Week 16 (n=311,307)	1.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Head/Neck, Week 8 (n=322,323)	0.6 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Trunk, Week 8 (n=322,323)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Head/Neck, Week 16 (n=311,307)	0.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Lower limbs, Week 24 (n=277,279)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Head/Neck, Week 24 (n=277,279)	0.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Trunk, Week 16 (n=311,307)	0.8 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Upper limbs, Baseline (n=331,335)	2.8 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Lower limbs, Week 24 (n=277,279)	1.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Upper limbs, Week 4 (n=326,331)	1.6 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Trunk, Week 24 (n=277,279)	0.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Upper limbs, Week 8 (n=322,323)	1.2 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Upper limbs, Week 16 (n=311,307)	1.1 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Lower limbs, Week 8 (n=322,323)	1.2 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Erythema Upper limbs, Week 24 (n=277,279)	1.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Upper limbs, Baseline (n=331,335)	2.6 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Trunk, Baseline (n=331,335)	2.5 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Upper limbs, Week 4 (n=326,331)	1.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Lower limbs, Baseline (n=331,335)	2.9 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Upper limbs, Week 8 (n=322,323)	1.1 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Trunk, Week 4 (n=326,331)	1.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Upper limbs, Week 16 (n=311,307	1.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Trunk, Week 8 (n=322,323)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Upper limbs, Week 24 (n=277,279)	1.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Induration Lower limbs, Week 4 (n=326,331)	1.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Upper limbs, Baseline (n=331,335)	2.6 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Trunk, Week 16 (n=311,307)	0.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)	Scaling Upper limbs, Week 4 (n=326,331)	1.5 score on a scale	Standard Error 0.1

Secondary

Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period C.

Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

Population: FAS-C; n equals number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Week 4 (n=27,74,42,119)	0.3 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Week 8 (n=26,72,41,118)	0.5 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Week 4 (n=27,74,42,119)	0.7 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Week 16 (n=23,67,39,101)	1.0 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Week 4 (n=27,74,42,119)	0.8 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Week 16 (n=23,67,39,101)	0.5 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Baseline (n=27,75,42,120)	0.7 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Baseline (n=27,75,42,120)	1.1 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Week 8 (n=26,72,41,118)	0.8 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Baseline (n=27,75,42,120)	0.7 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Week 16 (n=23,67,39,101)	0.9 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Week 4 (n=27,74,42,119)	1.0 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Week 8 (n=26,72,41,118)	0.7 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Week 4 (n=27,74,42,119)	0.5 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Week 8 (n=26,72,41,118)	1.0 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Week 16 (n=23,67,39,101)	0.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Baseline (n=27,75,42,120)	1.1 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Week 8 (n=26,72,41,118)	0.5 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Week 8 (n=26,72,41,118)	0.7 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Week 4 (n=27,74,42,119)	1.1 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Week 16 (n=23,67,39,101)	0.7 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Week 16 (n=23,67,39,101)	0.4 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Week 8 (n=26,72,41,118)	0.8 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Baseline (n=27,75,42,120)	0.9 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Week 16 (n=23,67,39,101)	1.0 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Baseline (n=27,75,42,120)	0.7 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Week 8 (n=26,72,41,118)	0.8 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Baseline (n=27,75,42,120)	0.6 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Week 8 (n=26,72,41,118)	0.9 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Baseline (n=27,75,42,120)	0.6 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Week 16 (n=23,67,39,101)	0.7 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Week 4 (n=27,74,42,119)	0.7 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Week 16 (n=23,67,39,101)	0.5 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Baseline (n=27,75,42,120)	0.7 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Week 8 (n=26,72,41,118)	0.8 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Week 8 (n=26,72,41,118)	0.7 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Baseline (n=27,75,42,120)	0.5 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Week 8 (n=26,72,41,118)	0.4 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Week 4 (n=27,74,42,119)	0.9 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Week 16 (n=23,67,39,101)	1.0 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Week 16 (n=23,67,39,101)	1.1 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Week 4 (n=27,74,42,119)	0.6 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Week 4 (n=27,74,42,119)	0.6 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Baseline (n=27,75,42,120)	0.6 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Baseline (n=27,75,42,120)	1.0 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Week 4 (n=27,74,42,119)	0.7 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Week 4 (n=27,74,42,119)	0.5 score on a scale	Standard Error 0.2
CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Week 16 (n=23,67,39,101)	1.2 score on a scale	Standard Error 0.2
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Baseline (n=27,75,42,120)	1.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Week 8 (n=26,72,41,118)	1.3 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Week 16 (n=23,67,39,101)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Week 16 (n=23,67,39,101)	1.1 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Baseline (n=27,75,42,120)	1.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Week 4 (n=27,74,42,119)	1.1 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Baseline (n=27,75,42,120)	1.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Week 8 (n=26,72,41,118)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Week 8 (n=26,72,41,118)	0.8 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Week 16 (n=23,67,39,101)	1.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Week 4 (n=27,74,42,119)	1.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Baseline (n=27,75,42,120)	1.3 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Baseline (n=27,75,42,120)	2.1 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Week 4 (n=27,74,42,119)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Baseline (n=27,75,42,120)	1.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Week 8 (n=26,72,41,118)	0.8 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Week 4 (n=27,74,42,119)	1.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Week 16 (n=23,67,39,101)	0.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Week 8 (n=26,72,41,118)	1.2 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Week 16 (n=23,67,39,101)	1.1 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Week 8 (n=26,72,41,118)	1.2 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Week 16 (n=23,67,39,101)	1.3 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Baseline (n=27,75,42,120)	1.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Week 16 (n=23,67,39,101)	1.3 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Week 4 (n=27,74,42,119)	1.2 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Week 4 (n=27,74,42,119)	1.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Week 4 (n=27,74,42,119)	1.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Week 8 (n=26,72,41,118)	1.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Baseline (n=27,75,42,120)	1.8 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Week 16 (n=23,67,39,101)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Week 16 (n=23,67,39,101)	1.2 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Baseline (n=27,75,42,120)	1.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Week 4 (n=27,74,42,119)	1.3 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Week 8 (n=26,72,41,118)	1.3 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Week 8 (n=26,72,41,118)	1.0 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Week 16 (n=23,67,39,101)	1.3 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Week 16 (n=23,67,39,101)	0.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Week 4 (n=27,74,42,119)	1.4 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Week 8 (n=26,72,41,118)	1.2 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Baseline (n=27,75,42,120)	1.8 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Week 4 (n=27,74,42,119)	1.5 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Week 8 (n=26,72,41,118)	1.2 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Week 8 (n=26,72,41,118)	1.2 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Week 16 (n=23,67,39,101)	1.1 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Week 4 (n=27,74,42,119)	1.6 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Baseline (n=27,75,42,120)	1.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Baseline (n=27,75,42,120)	1.9 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Week 4 (n=27,74,42,119)	1.5 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Baseline (n=27,75,42,120)	0.4 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Week 4 (n=27,74,42,119)	1.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Week 8 (n=26,72,41,118)	1.0 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Week 16 (n=23,67,39,101)	1.1 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Baseline (n=27,75,42,120)	1.3 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Week 4 (n=27,74,42,119)	1.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Week 8 (n=26,72,41,118)	1.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Week 16 (n=23,67,39,101)	1.1 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Baseline (n=27,75,42,120)	0.7 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Week 4 (n=27,74,42,119)	0.6 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Week 8 (n=26,72,41,118)	0.7 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Week 16 (n=23,67,39,101)	0.6 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Baseline (n=27,75,42,120)	0.7 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Week 4 (n=27,74,42,119)	0.6 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Week 8 (n=26,72,41,118)	0.6 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Week 16 (n=23,67,39,101)	0.6 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Baseline (n=27,75,42,120)	0.7 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Week 4 (n=27,74,42,119)	0.6 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Week 8 (n=26,72,41,118)	0.6 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Week 16 (n=23,67,39,101)	0.6 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Baseline (n=27,75,42,120)	1.0 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Baseline (n=27,75,42,120)	1.0 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Week 4 (n=27,74,42,119)	0.9 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Week 8 (n=26,72,41,118)	0.8 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Week 16 (n=23,67,39,101)	0.8 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Week 4 (n=27,74,42,119)	0.9 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Week 8 (n=26,72,41,118)	0.9 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Week 16 (n=23,67,39,101)	0.9 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Baseline (n=27,75,42,120)	0.5 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Week 4 (n=27,74,42,119)	0.6 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Week 8 (n=26,72,41,118)	0.5 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Week 16 (n=23,67,39,101)	0.4 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Week 4 (n=27,74,42,119)	0.4 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Week 8 (n=26,72,41,118)	0.3 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Week 16 (n=23,67,39,101)	0.2 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Baseline (n=27,75,42,120)	0.5 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Week 4 (n=27,74,42,119)	0.6 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Week 8 (n=26,72,41,118)	0.5 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Week 16 (n=23,67,39,101)	0.4 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Baseline (n=27,75,42,120)	1.2 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Week 4 (n=27,74,42,119)	1.1 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Week 8 (n=26,72,41,118)	1.0 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Week 16 (n=23,67,39,101)	1.1 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Baseline (n=27,75,42,120)	1.1 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Baseline (n=27,75,42,120)	1.1 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Week 4 (n=27,74,42,119)	1.0 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Week 8 (n=26,72,41,118)	0.9 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Week 16 (n=23,67,39,101)	0.9 score on a scale	Standard Error 0.2
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Baseline (n=27,75,42,120)	1.6 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Week 8 (n=26,72,41,118)	0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Week 4 (n=27,74,42,119)	1.3 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Week 16 (n=23,67,39,101)	0.5 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Baseline (n=27,75,42,120)	1.7 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Week 16 (n=23,67,39,101)	0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Week 4 (n=27,74,42,119)	1.1 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Baseline (n=27,75,42,120)	1.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Week 8 (n=26,72,41,118)	1.0 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Baseline (n=27,75,42,120)	1.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Week 4 (n=27,74,42,119)	1.1 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Week 4 (n=27,74,42,119)	1.1 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Week 4 (n=27,74,42,119)	1.0 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Week 16 (n=23,67,39,101)	0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Week 8 (n=26,72,41,118)	1.0 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Week 16 (n=23,67,39,101)	0.7 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Week 8 (n=26,72,41,118)	0.7 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Week 8 (n=26,72,41,118)	1.0 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Upper limbs, Week 16 (n=23,67,39,101)	0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Week 4 (n=27,74,42,119)	0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Trunk, Baseline (n=27,75,42,120)	1.5 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Week 16 (n=23,67,39,101)	0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Baseline (n=27,75,42,120)	1.7 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Week 16 (n=23,67,39,101)	0.7 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Week 8 (n=26,72,41,118)	0.7 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Lower limbs, Week 16 (n=23,67,39,101)	0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Week 4 (n=27,74,42,119)	0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Lower limbs, Baseline (n=27,75,42,120)	1.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Trunk, Baseline (n=27,75,42,120)	1.5 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Week 8 (n=26,72,41,118)	0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Week 4 (n=27,74,42,119)	1.0 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Week 16 (n=23,67,39,101)	0.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Trunk, Baseline (n=27,75,42,120)	1.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Week 8 (n=26,72,41,118)	1.0 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Week 8 (n=26,72,41,118)	0.5 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Lower limbs, Baseline (n=27,75,42,120)	1.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Week 16 (n=23,67,39,101)	0.5 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Week 4 (n=27,74,42,119)	0.6 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Week 16 (n=23,67,39,101)	0.9 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Baseline (n=27,75,42,120)	1.6 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Head/Neck, Baseline (n=27,75,42,120)	1.4 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Week 16 (n=23,67,39,101)	0.6 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Upper limbs, Week 8 (n=26,72,41,118)	1.0 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Week 4 (n=27,74,42,119)	0.7 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Week 8 (n=26,72,41,118)	0.7 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Erythema Head/Neck, Week 4 (n=27,74,42,119)	0.7 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Induration Upper limbs, Week 4 (n=27,74,42,119)	1.1 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)	Scaling Head/Neck, Week 8 (n=26,72,41,118)	0.6 score on a scale	Standard Error 0.1

Secondary

Mean PASI Score During Double-Blind Treatment Withdrawal (Period B)

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.

Time frame: Baseline and Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B; n equals the number of participants with observations

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,53,42,84)	2.3 score on a scale	Standard Error 0.4
CP-690,550 5 mg (Period B)	Mean PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,128)	2.0 score on a scale	Standard Error 0.3
CP-690,550 5 mg (Period B)	Mean PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	2.7 score on a scale	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,70,43,104)	2.4 score on a scale	Standard Error 0.4
CP-690,550 5 mg (Period B)	Mean PASI Score During Double-Blind Treatment Withdrawal (Period B)	Baseline (n=31,82,45,133)	1.6 score on a scale	Standard Error 0.2
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,70,43,104)	6.5 score on a scale	Standard Error 0.7
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,53,42,84)	6.4 score on a scale	Standard Error 0.7
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	5.5 score on a scale	Standard Error 0.7
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,128)	5.0 score on a scale	Standard Error 0.6
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Score During Double-Blind Treatment Withdrawal (Period B)	Baseline (n=31,82,45,133)	1.8 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,70,43,104)	2.0 score on a scale	Standard Error 0.4
CP-690,550 10 mg (Period B)	Mean PASI Score During Double-Blind Treatment Withdrawal (Period B)	Baseline (n=31,82,45,133)	1.7 score on a scale	Standard Error 0.2
CP-690,550 10 mg (Period B)	Mean PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,128)	1.8 score on a scale	Standard Error 0.3
CP-690,550 10 mg (Period B)	Mean PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,53,42,84)	2.5 score on a scale	Standard Error 0.4
CP-690,550 10 mg (Period B)	Mean PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	2.9 score on a scale	Standard Error 0.5
Placebo for 10 mg CP-690,550	Mean PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,53,42,84)	5.6 score on a scale	Standard Error 0.6
Placebo for 10 mg CP-690,550	Mean PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,128)	5.3 score on a scale	Standard Error 0.6
Placebo for 10 mg CP-690,550	Mean PASI Score During Double-Blind Treatment Withdrawal (Period B)	Baseline (n=31,82,45,133)	1.5 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,70,43,104)	6.8 score on a scale	Standard Error 0.7
Placebo for 10 mg CP-690,550	Mean PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	5.5 score on a scale	Standard Error 0.6

Secondary

Mean PASI Score During Initial CP-690,550 Treatment (Period A)

Time frame: Baseline and Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean PASI Score During Initial CP-690,550 Treatment (Period A)	Week 4 (n=326,331)	13.5 score on a scale	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean PASI Score During Initial CP-690,550 Treatment (Period A)	Week 16 (n=311,307)	8.1 score on a scale	Standard Error 0.4
CP-690,550 5 mg (Period B)	Mean PASI Score During Initial CP-690,550 Treatment (Period A)	Week 8 (n=322,323)	10.1 score on a scale	Standard Error 0.4
CP-690,550 5 mg (Period B)	Mean PASI Score During Initial CP-690,550 Treatment (Period A)	Week 24 (n=277,279)	7.6 score on a scale	Standard Error 0.4
CP-690,550 5 mg (Period B)	Mean PASI Score During Initial CP-690,550 Treatment (Period A)	Baseline (n=331,335)	21.1 score on a scale	Standard Error 0.5
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Score During Initial CP-690,550 Treatment (Period A)	Week 24 (n=277,279)	4.4 score on a scale	Standard Error 0.4
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Score During Initial CP-690,550 Treatment (Period A)	Baseline (n=331,335)	20.9 score on a scale	Standard Error 0.4
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Score During Initial CP-690,550 Treatment (Period A)	Week 4 (n=326,331)	10.4 score on a scale	Standard Error 0.4
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Score During Initial CP-690,550 Treatment (Period A)	Week 8 (n=322,323)	6.5 score on a scale	Standard Error 0.4
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Score During Initial CP-690,550 Treatment (Period A)	Week 16 (n=311,307)	5.0 score on a scale	Standard Error 0.4

Secondary

Mean PASI Score During the CP-690,550 Re-Treatment (Period C)

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period C.

Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

Population: FAS-C; n equals the number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	2.6 score on a scale	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,101)	2.9 score on a scale	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	2.5 score on a scale	Standard Error 0.4
CP-690,550 5 mg (Period B)	Mean PASI Score During the CP-690,550 Re-Treatment (Period C)	Baseline (n=27,75,42,120)	2.7 score on a scale	Standard Error 0.5
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	7.8 score on a scale	Standard Error 1
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	6.0 score on a scale	Standard Error 0.9
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Score During the CP-690,550 Re-Treatment (Period C)	Baseline (n=27,75,42,120)	9.9 score on a scale	Standard Error 0.9
Placebo for CP-690,550 5 mg (Period B)	Mean PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,101)	5.2 score on a scale	Standard Error 0.8
CP-690,550 10 mg (Period B)	Mean PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,101)	3.5 score on a scale	Standard Error 0.7
CP-690,550 10 mg (Period B)	Mean PASI Score During the CP-690,550 Re-Treatment (Period C)	Baseline (n=27,75,42,120)	3.4 score on a scale	Standard Error 0.6
CP-690,550 10 mg (Period B)	Mean PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	3.3 score on a scale	Standard Error 0.6
CP-690,550 10 mg (Period B)	Mean PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	3.2 score on a scale	Standard Error 0.6
Placebo for 10 mg CP-690,550	Mean PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	4.1 score on a scale	Standard Error 0.5
Placebo for 10 mg CP-690,550	Mean PASI Score During the CP-690,550 Re-Treatment (Period C)	Baseline (n=27,75,42,120)	9.8 score on a scale	Standard Error 0.8
Placebo for 10 mg CP-690,550	Mean PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,101)	3.5 score on a scale	Standard Error 0.5
Placebo for 10 mg CP-690,550	Mean PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	5.0 score on a scale	Standard Error 0.5

Secondary

Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)

Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.

Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

Population: FAS-C; n equals the number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Baseline (n=27,75,42,120)	2.2 percent psoriatic BSA	Standard Error 0.77
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Week 8 (n=26,72,41,118)	2.4 percent psoriatic BSA	Standard Error 0.73
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Baseline (n=27,75,42,120)	3.2 percent psoriatic BSA	Standard Error 0.72
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Baseline (n=27,75,42,120)	4.0 percent psoriatic BSA	Standard Error 1.23
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Week 16 (n=23,67,39,101)	4.0 percent psoriatic BSA	Standard Error 1.02
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Week 4 (n=27,74,42,119)	3.6 percent psoriatic BSA	Standard Error 1.33
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Week 4 (n=27,74,42,119)	3.4 percent psoriatic BSA	Standard Error 0.82
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Week 8 (n=26,72,41,118)	4.1 percent psoriatic BSA	Standard Error 0.99
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Week 8 (n=26,72,41,118)	1.4 percent psoriatic BSA	Standard Error 0.38
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Week 16 (n=23,67,39,101)	3.0 percent psoriatic BSA	Standard Error 0.96
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Week 8 (n=26,72,41,118)	3.9 percent psoriatic BSA	Standard Error 1.25
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Week 16 (n=23,67,39,101)	4.6 percent psoriatic BSA	Standard Error 1.5
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Week 16 (n=23,67,39,101)	1.8 percent psoriatic BSA	Standard Error 0.45
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Week 4 (n=27,74,42,119)	1.1 percent psoriatic BSA	Standard Error 0.27
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Week 4 (n=27,74,42,119)	2.0 percent psoriatic BSA	Standard Error 0.68
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Baseline (n=27,75,42,120)	1.4 percent psoriatic BSA	Standard Error 0.44
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Week 8 (n=26,72,41,118)	9.5 percent psoriatic BSA	Standard Error 2.01
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Baseline (n=27,75,42,120)	9.4 percent psoriatic BSA	Standard Error 1.21
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Week 4 (n=27,74,42,119)	9.5 percent psoriatic BSA	Standard Error 1.81
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Week 8 (n=26,72,41,118)	8.0 percent psoriatic BSA	Standard Error 1.73
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Week 16 (n=23,67,39,101)	6.5 percent psoriatic BSA	Standard Error 1.26
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Week 16 (n=23,67,39,101)	9.8 percent psoriatic BSA	Standard Error 1.97
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Baseline (n=27,75,42,120)	18.6 percent psoriatic BSA	Standard Error 2.62
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Baseline (n=27,75,42,120)	12.5 percent psoriatic BSA	Standard Error 1.73
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Week 4 (n=27,74,42,119)	11.1 percent psoriatic BSA	Standard Error 1.92
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Week 8 (n=26,72,41,118)	8.9 percent psoriatic BSA	Standard Error 1.83
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Week 16 (n=23,67,39,101)	7.0 percent psoriatic BSA	Standard Error 1.33
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Week 4 (n=27,74,42,119)	12.5 percent psoriatic BSA	Standard Error 2.09
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Baseline (n=27,75,42,120)	10.9 percent psoriatic BSA	Standard Error 1.73
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Week 4 (n=27,74,42,119)	11.1 percent psoriatic BSA	Standard Error 2.33
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Week 8 (n=26,72,41,118)	10.2 percent psoriatic BSA	Standard Error 2.16
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Week 16 (n=23,67,39,101)	7.1 percent psoriatic BSA	Standard Error 1.54
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Week 8 (n=26,72,41,118)	3.5 percent psoriatic BSA	Standard Error 1.76
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Week 16 (n=23,67,39,101)	1.4 percent psoriatic BSA	Standard Error 0.46
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Week 8 (n=26,72,41,118)	3.3 percent psoriatic BSA	Standard Error 1.08
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Baseline (n=27,75,42,120)	2.0 percent psoriatic BSA	Standard Error 0.85
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Week 4 (n=27,74,42,119)	2.9 percent psoriatic BSA	Standard Error 0.76
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Week 16 (n=23,67,39,101)	3.0 percent psoriatic BSA	Standard Error 1.33
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Baseline (n=27,75,42,120)	3.7 percent psoriatic BSA	Standard Error 1.15
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Week 4 (n=27,74,42,119)	3.2 percent psoriatic BSA	Standard Error 1.72
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Week 8 (n=26,72,41,118)	3.0 percent psoriatic BSA	Standard Error 1.1
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Week 4 (n=27,74,42,119)	4.1 percent psoriatic BSA	Standard Error 0.9
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Week 4 (n=27,74,42,119)	2.6 percent psoriatic BSA	Standard Error 0.95
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Week 8 (n=26,72,41,118)	3.7 percent psoriatic BSA	Standard Error 0.92
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Baseline (n=27,75,42,120)	2.0 percent psoriatic BSA	Standard Error 0.61
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Baseline (n=27,75,42,120)	3.6 percent psoriatic BSA	Standard Error 0.63
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Week 16 (n=23,67,39,101)	4.7 percent psoriatic BSA	Standard Error 2.34
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Week 16 (n=23,67,39,101)	4.6 percent psoriatic BSA	Standard Error 1.24
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Week 16 (n=23,67,39,101)	3.5 percent psoriatic BSA	Standard Error 0.64
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Week 8 (n=26,72,41,118)	5.9 percent psoriatic BSA	Standard Error 1.15
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Baseline (n=27,75,42,120)	18.3 percent psoriatic BSA	Standard Error 1.95
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Week 8 (n=26,72,41,118)	6.3 percent psoriatic BSA	Standard Error 1.02
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Week 16 (n=23,67,39,101)	6.1 percent psoriatic BSA	Standard Error 1.31
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Baseline (n=27,75,42,120)	13.2 percent psoriatic BSA	Standard Error 1.4
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Week 4 (n=27,74,42,119)	8.4 percent psoriatic BSA	Standard Error 1.23
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Week 8 (n=26,72,41,118)	6.7 percent psoriatic BSA	Standard Error 0.97
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Upper limbs, Week 16 (n=23,67,39,101)	5.3 percent psoriatic BSA	Standard Error 1.02
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Baseline (n=27,75,42,120)	11.1 percent psoriatic BSA	Standard Error 1.35
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Week 4 (n=27,74,42,119)	6.7 percent psoriatic BSA	Standard Error 1.1
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Trunk, Week 16 (n=23,67,39,101)	4.8 percent psoriatic BSA	Standard Error 1.16
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Baseline (n=27,75,42,120)	10.4 percent psoriatic BSA	Standard Error 1.27
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Week 4 (n=27,74,42,119)	6.9 percent psoriatic BSA	Standard Error 1.06
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Lower limbs, Week 8 (n=26,72,41,118)	5.8 percent psoriatic BSA	Standard Error 0.92
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)	Head/Neck, Week 4 (n=27,74,42,119)	7.5 percent psoriatic BSA	Standard Error 1.12

Secondary

Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)

Time frame: Baseline and Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B; n equals the number of participants with observations

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 12 (n=28,53,42,84)	3.1 percent psoriatic BSA	Standard Error 0.59
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 16 (n=28,45,38,70)	3.8 percent psoriatic BSA	Standard Error 1.19
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Baseline (n=31,82,45,133)	1.3 percent psoriatic BSA	Standard Error 0.37
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 8 (n=30,70,43,104)	2.8 percent psoriatic BSA	Standard Error 0.58
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 4 (n=30,82,43,128)	2.4 percent psoriatic BSA	Standard Error 0.48
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Baseline (n=31,82,45,133)	2.1 percent psoriatic BSA	Standard Error 0.42
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Baseline (n=31,82,45,133)	4.2 percent psoriatic BSA	Standard Error 1.53
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 16 (n=28,45,38,70)	1.4 percent psoriatic BSA	Standard Error 0.42
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 16 (n=28,45,38,70)	2.1 percent psoriatic BSA	Standard Error 0.74
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 12 (n=28,53,42,84)	1.7 percent psoriatic BSA	Standard Error 0.61
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 4 (n=30,82,43,128)	4.1 percent psoriatic BSA	Standard Error 1.44
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 12 (n=28,53,42,84)	1.2 percent psoriatic BSA	Standard Error 0.35
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 8 (n=30,70,43,104)	1.9 percent psoriatic BSA	Standard Error 0.56
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 4 (n=30,82,43,128)	1.8 percent psoriatic BSA	Standard Error 0.53
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 8 (n=30,70,43,104)	4.8 percent psoriatic BSA	Standard Error 1.8
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 8 (n=30,70,43,104)	1.5 percent psoriatic BSA	Standard Error 0.36
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Baseline (n=31,82,45,133)	1.6 percent psoriatic BSA	Standard Error 0.52
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 16 (n=28,45,38,70)	3.2 percent psoriatic BSA	Standard Error 0.7
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 12 (n=28,53,42,84)	3.8 percent psoriatic BSA	Standard Error 1
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 4 (n=30,82,43,128)	1.2 percent psoriatic BSA	Standard Error 0.33
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 4 (n=30,82,43,128)	7.5 percent psoriatic BSA	Standard Error 1.19
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Baseline (n=31,82,45,133)	3.3 percent psoriatic BSA	Standard Error 0.79
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 4 (n=30,82,43,128)	11.3 percent psoriatic BSA	Standard Error 1.99
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 8 (n=30,70,43,104)	13.0 percent psoriatic BSA	Standard Error 2.34
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 12 (n=28,53,42,84)	13.5 percent psoriatic BSA	Standard Error 2.96
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 16 (n=28,45,38,70)	9.2 percent psoriatic BSA	Standard Error 2.11
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Baseline (n=31,82,45,133)	5.1 percent psoriatic BSA	Standard Error 1
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 8 (n=30,70,43,104)	8.9 percent psoriatic BSA	Standard Error 1.41
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 12 (n=28,53,42,84)	8.8 percent psoriatic BSA	Standard Error 1.38
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 16 (n=28,45,38,70)	6.5 percent psoriatic BSA	Standard Error 1.13
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Baseline (n=31,82,45,133)	3.2 percent psoriatic BSA	Standard Error 0.88
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 4 (n=30,82,43,128)	5.1 percent psoriatic BSA	Standard Error 1
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 8 (n=30,70,43,104)	7.4 percent psoriatic BSA	Standard Error 1.73
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 12 (n=28,53,42,84)	4.4 percent psoriatic BSA	Standard Error 0.67
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 16 (n=28,45,38,70)	4.8 percent psoriatic BSA	Standard Error 0.9
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Baseline (n=31,82,45,133)	3.8 percent psoriatic BSA	Standard Error 1.02
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 4 (n=30,82,43,128)	4.9 percent psoriatic BSA	Standard Error 0.75
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 8 (n=30,70,43,104)	6.1 percent psoriatic BSA	Standard Error 1.07
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 12 (n=28,53,42,84)	7.0 percent psoriatic BSA	Standard Error 1.24
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 16 (n=28,45,38,70)	6.0 percent psoriatic BSA	Standard Error 1.3
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 12 (n=28,53,42,84)	2.4 percent psoriatic BSA	Standard Error 0.8
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 16 (n=28,45,38,70)	1.8 percent psoriatic BSA	Standard Error 0.91
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 8 (n=30,70,43,104)	1.5 percent psoriatic BSA	Standard Error 0.46
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 8 (n=30,70,43,104)	1.7 percent psoriatic BSA	Standard Error 0.53
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 4 (n=30,82,43,128)	1.5 percent psoriatic BSA	Standard Error 0.44
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Baseline (n=31,82,45,133)	2.1 percent psoriatic BSA	Standard Error 0.44
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 8 (n=30,70,43,104)	3.6 percent psoriatic BSA	Standard Error 0.68
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Baseline (n=31,82,45,133)	3.1 percent psoriatic BSA	Standard Error 0.55
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 8 (n=30,70,43,104)	1.5 percent psoriatic BSA	Standard Error 0.37
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 16 (n=28,45,38,70)	3.5 percent psoriatic BSA	Standard Error 0.66
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Baseline (n=31,82,45,133)	1.5 percent psoriatic BSA	Standard Error 0.53
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 4 (n=30,82,43,128)	3.0 percent psoriatic BSA	Standard Error 0.55
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 16 (n=28,45,38,70)	2.3 percent psoriatic BSA	Standard Error 0.8
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 4 (n=30,82,43,128)	1.4 percent psoriatic BSA	Standard Error 0.38
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 16 (n=28,45,38,70)	3.0 percent psoriatic BSA	Standard Error 1.03
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 12 (n=28,53,42,84)	2.8 percent psoriatic BSA	Standard Error 0.72
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 12 (n=28,53,42,84)	1.4 percent psoriatic BSA	Standard Error 0.39
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 12 (n=28,53,42,84)	3.3 percent psoriatic BSA	Standard Error 0.62
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 4 (n=30,82,43,128)	1.6 percent psoriatic BSA	Standard Error 0.53
CP-690,550 10 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Baseline (n=31,82,45,133)	0.9 percent psoriatic BSA	Standard Error 0.34
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 8 (n=30,70,43,104)	15.1 percent psoriatic BSA	Standard Error 1.97
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 16 (n=28,45,38,70)	6.9 percent psoriatic BSA	Standard Error 1.28
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 16 (n=28,45,38,70)	5.1 percent psoriatic BSA	Standard Error 0.78
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Baseline (n=31,82,45,133)	2.6 percent psoriatic BSA	Standard Error 0.59
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 4 (n=30,82,43,128)	12.2 percent psoriatic BSA	Standard Error 1.59
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 8 (n=30,70,43,104)	7.5 percent psoriatic BSA	Standard Error 1.3
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 4 (n=30,82,43,128)	6.0 percent psoriatic BSA	Standard Error 1.05
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 8 (n=30,70,43,104)	7.9 percent psoriatic BSA	Standard Error 1.29
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Baseline (n=31,82,45,133)	2.8 percent psoriatic BSA	Standard Error 0.7
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 12 (n=28,53,42,84)	5.3 percent psoriatic BSA	Standard Error 1.04
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Trunk, Week 16 (n=28,45,38,70)	5.5 percent psoriatic BSA	Standard Error 1.05
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 12 (n=28,53,42,84)	5.4 percent psoriatic BSA	Standard Error 0.95
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 4 (n=30,82,43,128)	7.6 percent psoriatic BSA	Standard Error 0.97
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Baseline (n=31,82,45,133)	3.1 percent psoriatic BSA	Standard Error 0.5
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 16 (n=28,45,38,70)	9.6 percent psoriatic BSA	Standard Error 1.76
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Head/Neck, Week 12 (n=28,53,42,84)	11.5 percent psoriatic BSA	Standard Error 2.03
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 8 (n=30,70,43,104)	8.9 percent psoriatic BSA	Standard Error 1.25
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Week 4 (n=30,82,43,128)	5.7 percent psoriatic BSA	Standard Error 0.9
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Upper limbs, Week 12 (n=28,53,42,84)	6.6 percent psoriatic BSA	Standard Error 1
Placebo for 10 mg CP-690,550	Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)	Lower limbs, Baseline (n=31,82,45,133)	2.4 percent psoriatic BSA	Standard Error 0.49

Secondary

Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)

Time frame: Baseline and Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A; n equals number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Head/Neck, Baseline (n=331,335)	28.7 percent psoriatic BSA	Standard Error 1.25
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Head/Neck, Week 4 (n=326,331)	20.5 percent psoriatic BSA	Standard Error 1.2
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Head/Neck, Week 8 (n=322,323)	14.8 percent psoriatic BSA	Standard Error 1.06
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Head/Neck, Week 16 (n=311,306)	12.6 percent psoriatic BSA	Standard Error 1.05
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Head/Neck, Week 24 (n=277,279)	12.8 percent psoriatic BSA	Standard Error 1.17
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Upper limbs, Baseline (n=331,335)	26.5 percent psoriatic BSA	Standard Error 1.04
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Upper limbs, Week 4 (n=326,331)	21.8 percent psoriatic BSA	Standard Error 1.02
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Upper limbs, Week 8 (n=322,323)	17.0 percent psoriatic BSA	Standard Error 0.95
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Upper Limbs, Week 16 (n=311,306)	13.6 percent psoriatic BSA	Standard Error 0.92
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Upper limbs, Week 24 (n=277,279)	12.2 percent psoriatic BSA	Standard Error 0.98
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Trunk, Baseline (n=331,335)	26.0 percent psoriatic BSA	Standard Error 1.23
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Trunk, Week 4 (n=326,331)	20.8 percent psoriatic BSA	Standard Error 1.16
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Trunk, Week 8 (n=322,323)	16.5 percent psoriatic BSA	Standard Error 1.11
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Trunk, Week 16 (n=311,306)	13.5 percent psoriatic BSA	Standard Error 1.05
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Trunk, Week 24 (n=277,279)	12.5 percent psoriatic BSA	Standard Error 1.05
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Lower limbs, Baseline (n=331,335)	28.7 percent psoriatic BSA	Standard Error 1.14
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Lower limbs, Week 4 (n=326,331)	24.1 percent psoriatic BSA	Standard Error 1.13
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Lower limbs, Week 8 (n=322,323)	18.5 percent psoriatic BSA	Standard Error 1.05
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Lower limbs, Week 16 (n=311,306)	13.1 percent psoriatic BSA	Standard Error 0.95
CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Lower limbs, Week 24 (n=277,279)	11.3 percent psoriatic BSA	Standard Error 0.9
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Lower limbs, Week 8 (n=322,323)	13.4 percent psoriatic BSA	Standard Error 0.93
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Head/Neck, Baseline (n=331,335)	25.9 percent psoriatic BSA	Standard Error 1.17
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Trunk, Baseline (n=331,335)	25.9 percent psoriatic BSA	Standard Error 1.18
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Head/Neck, Week 4 (n=326,331)	14.3 percent psoriatic BSA	Standard Error 1.04
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Lower limbs, Baseline (n=331,335)	28.9 percent psoriatic BSA	Standard Error 1.12
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Head/Neck, Week 8 (n=322,323)	9.7 percent psoriatic BSA	Standard Error 0.96
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Trunk, Week 4 (n=326,331)	17.2 percent psoriatic BSA	Standard Error 1.02
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Head/Neck, Week 16 (n=311,306)	7.5 percent psoriatic BSA	Standard Error 0.88
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Lower limbs, Week 24 (n=277,279)	6.1 percent psoriatic BSA	Standard Error 0.71
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Head/Neck, Week 24 (n=277,279)	6.3 percent psoriatic BSA	Standard Error 0.89
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Trunk, Week 8 (n=322,323)	11.4 percent psoriatic BSA	Standard Error 0.94
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Upper limbs, Baseline (n=331,335)	26.2 percent psoriatic BSA	Standard Error 1.06
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Lower limbs, Week 4 (n=326,331)	20.2 percent psoriatic BSA	Standard Error 0.99
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Upper limbs, Week 4 (n=326,331)	17.3 percent psoriatic BSA	Standard Error 0.91
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Trunk, Week 16 (n=311,306)	8.5 percent psoriatic BSA	Standard Error 0.95
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Upper limbs, Week 8 (n=322,323)	11.7 percent psoriatic BSA	Standard Error 0.83
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Lower limbs, Week 16 (n=311,306)	7.9 percent psoriatic BSA	Standard Error 0.79
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Upper Limbs, Week 16 (n=311,306)	8.0 percent psoriatic BSA	Standard Error 0.7
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Trunk, Week 24 (n=277,279)	6.9 percent psoriatic BSA	Standard Error 0.85
Placebo for CP-690,550 5 mg (Period B)	Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)	Upper limbs, Week 24 (n=277,279)	6.5 percent psoriatic BSA	Standard Error 0.65

Secondary

Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)

Time frame: Baseline and Week 56 (Period C)

Population: FAS-C; n equals the number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Role Emotional (n=27,75,42,120)	51.1 score on a scale	Standard Error 1.8
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline General Health (n=27,75,42,120)	52.0 score on a scale	Standard Error 1.7
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Role Emotional (n=22,65,34,98)	50.5 score on a scale	Standard Error 1.8
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 General Health (n=22,65,34,98)	51.5 score on a scale	Standard Error 1.8
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Vitality (n=27,75,42,120)	53.8 score on a scale	Standard Error 2.2
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Health Transition (n=27,75,42,120)	2.9 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Social Functioning (n=27,75,42,120)	51.2 score on a scale	Standard Error 1.8
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Physical Functioning (n=27,75,42,120)	50.7 score on a scale	Standard Error 1.8
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Health Transition (n=22,65,34,98)	3.0 score on a scale	Standard Error 0.1
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Physical Functioning (n=22,65,34,98)	51.7 score on a scale	Standard Error 1.9
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Social Functioning (n=22,65,34,98)	52.2 score on a scale	Standard Error 1.6
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Role Physical (n=27,75,42,120)	51.2 score on a scale	Standard Error 1.6
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Mental Health (n=22,65,34,98)	51.1 score on a scale	Standard Error 1.8
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Role Physical (n=22,65,34,98)	52.5 score on a scale	Standard Error 1.6
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Vitality (n=22,65,34,98)	52.2 score on a scale	Standard Error 2.2
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Bodily Pain (n=27,75,42,120)	52.8 score on a scale	Standard Error 1.9
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Mental Health (n=27,75,42,120)	51.2 score on a scale	Standard Error 2
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Bodily Pain (n=22,65,34,98)	53.9 score on a scale	Standard Error 2.1
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Role Physical (n=22,65,34,98)	51.4 score on a scale	Standard Error 1.2
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Physical Functioning (n=22,65,34,98)	52.4 score on a scale	Standard Error 1.1
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline General Health (n=27,75,42,120)	49.6 score on a scale	Standard Error 1.1
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Role Emotional (n=27,75,42,120)	51.6 score on a scale	Standard Error 0.8
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Health Transition (n=27,75,42,120)	3.1 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Mental Health (n=22,65,34,98)	51.1 score on a scale	Standard Error 1.2
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 General Health (n=22,65,34,98)	51.8 score on a scale	Standard Error 1
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Mental Health (n=27,75,42,120)	50.2 score on a scale	Standard Error 1.1
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Vitality (n=27,75,42,120)	52.2 score on a scale	Standard Error 1.1
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Health Transition (n=22,65,34,98)	2.7 score on a scale	Standard Error 0.1
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Social Functioning (n=27,75,42,120)	49.7 score on a scale	Standard Error 1
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Vitality (n=22,65,34,98)	53.2 score on a scale	Standard Error 1.1
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Role Physical (n=27,75,42,120)	50.5 score on a scale	Standard Error 1
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Social Functioning (n=22,65,34,98)	52.4 score on a scale	Standard Error 1
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Role Emotional (n=22,65,34,98)	50.0 score on a scale	Standard Error 1.3
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Physical Functioning (n=27,75,42,120)	51.3 score on a scale	Standard Error 1
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Bodily Pain (n=27,75,42,120)	48.8 score on a scale	Standard Error 1.2
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Bodily Pain (n=22,65,34,98)	52.7 score on a scale	Standard Error 1
CP-690,550 10 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Mental Health (n=22,65,34,98)	52.2 score on a scale	Standard Error 1.5
CP-690,550 10 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 General Health (n=22,65,34,98)	51.1 score on a scale	Standard Error 1.4
CP-690,550 10 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Social Functioning (n=27,75,42,120)	51.5 score on a scale	Standard Error 1.4
CP-690,550 10 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Social Functioning (n=22,65,34,98)	51.3 score on a scale	Standard Error 1.7
CP-690,550 10 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Role Emotional (n=27,75,42,120)	50.3 score on a scale	Standard Error 1.7
CP-690,550 10 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Physical Functioning (n=27,75,42,120)	52.7 score on a scale	Standard Error 1.3
CP-690,550 10 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Physical Functioning (n=22,65,34,98)	52.3 score on a scale	Standard Error 1.6
CP-690,550 10 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Role Physical (n=27,75,42,120)	53.3 score on a scale	Standard Error 1.1
CP-690,550 10 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Role Physical (n=22,65,34,98)	54.2 score on a scale	Standard Error 1.1
CP-690,550 10 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Bodily Pain (n=27,75,42,120)	54.1 score on a scale	Standard Error 1.5
CP-690,550 10 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Bodily Pain (n=22,65,34,98)	53.5 score on a scale	Standard Error 1.8
CP-690,550 10 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline General Health (n=27,75,42,120)	51.9 score on a scale	Standard Error 1.4
CP-690,550 10 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Vitality (n=27,75,42,120)	54.1 score on a scale	Standard Error 1.5
CP-690,550 10 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Vitality (n=22,65,34,98)	54.8 score on a scale	Standard Error 1.7
CP-690,550 10 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Role Emotional (n=22,65,34,98)	52.9 score on a scale	Standard Error 1.1
CP-690,550 10 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Mental Health (n=27,75,42,120)	51.6 score on a scale	Standard Error 1.8
CP-690,550 10 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Health Transition (n=27,75,42,120)	2.8 score on a scale	Standard Error 0.1
CP-690,550 10 mg (Period B)	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Health Transition (n=22,65,34,98)	2.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Social Functioning (n=27,75,42,120)	48.1 score on a scale	Standard Error 1
Placebo for 10 mg CP-690,550	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Role Emotional (n=22,65,34,98)	53.0 score on a scale	Standard Error 0.6
Placebo for 10 mg CP-690,550	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Bodily Pain (n=27,75,42,120)	47.1 score on a scale	Standard Error 1.1
Placebo for 10 mg CP-690,550	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Role Physical (n=22,65,34,98)	51.9 score on a scale	Standard Error 0.8
Placebo for 10 mg CP-690,550	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 General Health (n=22,65,34,98)	50.7 score on a scale	Standard Error 0.8
Placebo for 10 mg CP-690,550	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Mental Health (n=27,75,42,120)	48.4 score on a scale	Standard Error 1
Placebo for 10 mg CP-690,550	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Role Physical (n=27,75,42,120)	49.1 score on a scale	Standard Error 0.9
Placebo for 10 mg CP-690,550	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Physical Functioning (n=22,65,34,98)	51.3 score on a scale	Standard Error 0.9
Placebo for 10 mg CP-690,550	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Physical Functioning (n=27,75,42,120)	51.1 score on a scale	Standard Error 0.8
Placebo for 10 mg CP-690,550	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Mental Health (n=22,65,34,98)	52.7 score on a scale	Standard Error 0.8
Placebo for 10 mg CP-690,550	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Role Emotional (n=27,75,42,120)	48.0 score on a scale	Standard Error 1
Placebo for 10 mg CP-690,550	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Social Functioning (n=22,65,34,98)	53.2 score on a scale	Standard Error 0.6
Placebo for 10 mg CP-690,550	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Health Transition (n=22,65,34,98)	2.8 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Health Transition (n=27,75,42,120)	3.0 score on a scale	Standard Error 0.1
Placebo for 10 mg CP-690,550	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Vitality (n=22,65,34,98)	54.3 score on a scale	Standard Error 0.9
Placebo for 10 mg CP-690,550	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline Vitality (n=27,75,42,120)	51.3 score on a scale	Standard Error 0.9
Placebo for 10 mg CP-690,550	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Baseline General Health (n=27,75,42,120)	48.7 score on a scale	Standard Error 0.9
Placebo for 10 mg CP-690,550	Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Bodily Pain (n=22,65,34,98)	52.7 score on a scale	Standard Error 0.9

Secondary

Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)

Time frame: Baseline and Week 24 (Period A)

Population: FAS-A; n=number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Baseline Vitality (n=331,334)	49.2 score on a scale	Standard Error 0.6
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Baseline Physical Functioning (n=331,335)	48.3 score on a scale	Standard Error 0.6
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Week 24 Vitality (n=273,276)	51.0 score on a scale	Standard Error 0.6
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Baseline Social Functioning (n=331,334)	44.6 score on a scale	Standard Error 0.7
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Baseline Bodily Pain (n=331,334)	44.7 score on a scale	Standard Error 0.6
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Week 24 Social Functioning (n=273,276)	48.9 score on a scale	Standard Error 0.6
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Baseline Role Physical (n=331,335)	47.2 score on a scale	Standard Error 0.6
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Baseline Role Emotional (n=331,335)	45.5 score on a scale	Standard Error 0.7
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Week 24 Bodily Pain (n=273,276)	50.0 score on a scale	Standard Error 0.6
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Week 24 Role Emotional (n=273,276)	49.2 score on a scale	Standard Error 0.6
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Baseline Mental Health (n=331,334)	45.0 score on a scale	Standard Error 0.6
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Week 24 Physical Functioning (n=273,276)	50.7 score on a scale	Standard Error 0.6
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Week 24 Mental Health (n=273,276)	48.8 score on a scale	Standard Error 0.6
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Baseline General Health (n=330,335)	48.1 score on a scale	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Baseline Health Transition Score (n=331,334)	3.0 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Week 24 Role Physical (n=273,276)	50.2 score on a scale	Standard Error 0.6
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Week 24 Health Transition Score (n=272, 276)	2.8 score on a scale	Standard Error 0
CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Week 24 General Health (n=273,276)	49.0 score on a scale	Standard Error 0.6
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Week 24 Health Transition Score (n=272, 276)	2.8 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Week 24 Vitality (n=273,276)	54.2 score on a scale	Standard Error 0.5
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Week 24 Role Emotional (n=273,276)	51.2 score on a scale	Standard Error 0.5
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Baseline Physical Functioning (n=331,335)	48.0 score on a scale	Standard Error 0.6
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Week 24 Physical Functioning (n=273,276)	52.7 score on a scale	Standard Error 0.5
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Baseline Role Physical (n=331,335)	47.6 score on a scale	Standard Error 0.6
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Week 24 Role Physical (n=273,276)	53.1 score on a scale	Standard Error 0.5
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Baseline Bodily Pain (n=331,334)	44.2 score on a scale	Standard Error 0.7
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Week 24 Bodily Pain (n=273,276)	53.2 score on a scale	Standard Error 0.5
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Baseline General Health (n=330,335)	48.9 score on a scale	Standard Error 0.5
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Baseline Vitality (n=331,334)	49.3 score on a scale	Standard Error 0.5
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Baseline Social Functioning (n=331,334)	44.6 score on a scale	Standard Error 0.7
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Week 24 Social Functioning (n=273,276)	51.7 score on a scale	Standard Error 0.5
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Baseline Role Emotional (n=331,335)	45.8 score on a scale	Standard Error 0.7
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Baseline Mental Health (n=331,334)	46.4 score on a scale	Standard Error 0.6
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Week 24 Mental Health (n=273,276)	51.0 score on a scale	Standard Error 0.6
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Baseline Health Transition Score (n=331,334)	3.1 score on a scale	Standard Error 0
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)	Week 24 General Health (n=273,276)	50.3 score on a scale	Standard Error 0.5

Secondary

Mean SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)

Time frame: Baseline and Week 56 (Period C)

Population: FAS-C; n equals the number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)	Baseline Physical Health Score (n=27,75,42,120)	51.8 score on a scale	Standard Error 1.8
CP-690,550 5 mg (Period B)	Mean SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Physical Health Score (n=22,65,34,98)	52.9 score on a scale	Standard Error 1.8
CP-690,550 5 mg (Period B)	Mean SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)	Baseline Mental Health Score (n=27,75,42,120)	51.7 score on a scale	Standard Error 1.9
CP-690,550 5 mg (Period B)	Mean SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Mental Health Score (n=22,65,34,98)	50.8 score on a scale	Standard Error 1.8
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Physical Health Score (n=22,65,34,98)	52.7 score on a scale	Standard Error 1
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)	Baseline Mental Health Score (n=27,75,42,120)	51.0 score on a scale	Standard Error 1.1
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Mental Health Score (n=22,65,34,98)	50.9 score on a scale	Standard Error 1.2
Placebo for CP-690,550 5 mg (Period B)	Mean SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)	Baseline Physical Health Score (n=27,75,42,120)	49.9 score on a scale	Standard Error 1.1
CP-690,550 10 mg (Period B)	Mean SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)	Baseline Mental Health Score (n=27,75,42,120)	50.8 score on a scale	Standard Error 1.9
CP-690,550 10 mg (Period B)	Mean SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Physical Health Score (n=22,65,34,98)	52.9 score on a scale	Standard Error 1.4
CP-690,550 10 mg (Period B)	Mean SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Mental Health Score (n=22,65,34,98)	52.4 score on a scale	Standard Error 1.5
CP-690,550 10 mg (Period B)	Mean SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)	Baseline Physical Health Score (n=27,75,42,120)	53.8 score on a scale	Standard Error 1.1
Placebo for 10 mg CP-690,550	Mean SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Mental Health Score (n=22,65,34,98)	53.7 score on a scale	Standard Error 0.8
Placebo for 10 mg CP-690,550	Mean SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)	Week 56 Physical Health Score (n=22,65,34,98)	51.2 score on a scale	Standard Error 0.9
Placebo for 10 mg CP-690,550	Mean SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)	Baseline Physical Health Score (n=27,75,42,120)	49.7 score on a scale	Standard Error 0.8
Placebo for 10 mg CP-690,550	Mean SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)	Baseline Mental Health Score (n=27,75,42,120)	48.3 score on a scale	Standard Error 1

Secondary

Mean Short-Form 36 (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores During the Initial CP-690,550 Treatment (Period A)

The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Linear transformations were performed to transform scores to a mean of 50 and standard deviations (SDs) of 10, in the general population. In norm-based scoring, each scale is scored to have same average (50)/SD (10). With this method anytime a scale score is below 50, health status is below average, and each point is one-tenth of a SD. Higher scores indicate a better health related quality of life.

Time frame: Baseline and Week 24 (Period A)

Population: FAS-A; n=number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Short-Form 36 (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores During the Initial CP-690,550 Treatment (Period A)	Baseline Physical Health Score (n=330,334)	48.1 score on a scale	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean Short-Form 36 (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores During the Initial CP-690,550 Treatment (Period A)	Week 24 Physical Health Score (n=273,276)	50.5 score on a scale	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean Short-Form 36 (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores During the Initial CP-690,550 Treatment (Period A)	Baseline Mental Health Score (n=330,334)	45.2 score on a scale	Standard Error 0.7
CP-690,550 5 mg (Period B)	Mean Short-Form 36 (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores During the Initial CP-690,550 Treatment (Period A)	Week 24 Mental Health Score (n=273,276)	48.9 score on a scale	Standard Error 0.6
Placebo for CP-690,550 5 mg (Period B)	Mean Short-Form 36 (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores During the Initial CP-690,550 Treatment (Period A)	Week 24 Mental Health Score (n=273,276)	51.2 score on a scale	Standard Error 0.6
Placebo for CP-690,550 5 mg (Period B)	Mean Short-Form 36 (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores During the Initial CP-690,550 Treatment (Period A)	Baseline Physical Health Score (n=330,334)	47.8 score on a scale	Standard Error 0.5
Placebo for CP-690,550 5 mg (Period B)	Mean Short-Form 36 (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores During the Initial CP-690,550 Treatment (Period A)	Baseline Mental Health Score (n=330,334)	46.1 score on a scale	Standard Error 0.6
Placebo for CP-690,550 5 mg (Period B)	Mean Short-Form 36 (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores During the Initial CP-690,550 Treatment (Period A)	Week 24 Physical Health Score (n=273,276)	52.9 score on a scale	Standard Error 0.5

Secondary

Mean Total Percent of Psoriatic Body Surface Area (BSA) During Initial CP-690,550 Treatment (Period A)

Time frame: Baseline and Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A; n equals the number of participants with an observation.

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic Body Surface Area (BSA) During Initial CP-690,550 Treatment (Period A)	Week 4 (n=326,331)	22.3 percent psoriatic BSA	Standard Error 0.9
CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic Body Surface Area (BSA) During Initial CP-690,550 Treatment (Period A)	Week 16 (n=311,306)	13.3 percent psoriatic BSA	Standard Error 0.8
CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic Body Surface Area (BSA) During Initial CP-690,550 Treatment (Period A)	Week 8 (n=322,323)	17.2 percent psoriatic BSA	Standard Error 0.9
CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic Body Surface Area (BSA) During Initial CP-690,550 Treatment (Period A)	Week 24 (n=277,279)	12.0 percent psoriatic BSA	Standard Error 0.8
CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic Body Surface Area (BSA) During Initial CP-690,550 Treatment (Period A)	Baseline (n=331,335)	27.5 percent psoriatic BSA	Standard Error 0.9
Placebo for CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic Body Surface Area (BSA) During Initial CP-690,550 Treatment (Period A)	Week 24 (n=277,279)	6.4 percent psoriatic BSA	Standard Error 0.7
Placebo for CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic Body Surface Area (BSA) During Initial CP-690,550 Treatment (Period A)	Baseline (n=331,335)	27.2 percent psoriatic BSA	Standard Error 0.9
Placebo for CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic Body Surface Area (BSA) During Initial CP-690,550 Treatment (Period A)	Week 4 (n=326,331)	18.1 percent psoriatic BSA	Standard Error 0.8
Placebo for CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic Body Surface Area (BSA) During Initial CP-690,550 Treatment (Period A)	Week 8 (n=322,323)	12.1 percent psoriatic BSA	Standard Error 0.8
Placebo for CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic Body Surface Area (BSA) During Initial CP-690,550 Treatment (Period A)	Week 16 (n=311,306)	8.1 percent psoriatic BSA	Standard Error 0.7

Secondary

Mean Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)

Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

Population: FAS-C; n equals the number of participants with an observation

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Baseline (n=27,75,42,120)	2.3 percent psoriatic BSA	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	2.1 percent psoriatic BSA	Standard Error 0.4
CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	2.5 percent psoriatic BSA	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,101)	2.9 percent psoriatic BSA	Standard Error 0.5
Placebo for CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Baseline (n=27,75,42,120)	11.4 percent psoriatic BSA	Standard Error 1.3
Placebo for CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	10.6 percent psoriatic BSA	Standard Error 1.7
Placebo for CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	9.0 percent psoriatic BSA	Standard Error 1.6
Placebo for CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,101)	7.1 percent psoriatic BSA	Standard Error 1.2
CP-690,550 10 mg (Period B)	Mean Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,101)	3.7 percent psoriatic BSA	Standard Error 1.3
CP-690,550 10 mg (Period B)	Mean Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Baseline (n=27,75,42,120)	3.0 percent psoriatic BSA	Standard Error 0.8
CP-690,550 10 mg (Period B)	Mean Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	3.1 percent psoriatic BSA	Standard Error 0.9
CP-690,550 10 mg (Period B)	Mean Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	3.3 percent psoriatic BSA	Standard Error 1
Placebo for 10 mg CP-690,550	Mean Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	7.2 percent psoriatic BSA	Standard Error 0.9
Placebo for 10 mg CP-690,550	Mean Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Baseline (n=27,75,42,120)	12.0 percent psoriatic BSA	Standard Error 1.2
Placebo for 10 mg CP-690,550	Mean Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	6.1 percent psoriatic BSA	Standard Error 0.8
Placebo for 10 mg CP-690,550	Mean Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,101)	4.5 percent psoriatic BSA	Standard Error 0.8

Secondary

Mean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)

Time frame: Baseline and Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B; n equals the number of participants with observations

Arm	Measure	Group	Value (MEAN)	Dispersion
CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,53,42,84)	2.0 percent psoriatic BSA	Standard Error 0.4
CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,128)	1.9 percent psoriatic BSA	Standard Error 0.4
CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	2.2 percent psoriatic BSA	Standard Error 0.5
CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,70,43,104)	2.2 percent psoriatic BSA	Standard Error 0.4
CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Baseline (n=31,82,45,133)	1.9 percent psoriatic BSA	Standard Error 0.4
Placebo for CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,70,43,104)	7.7 percent psoriatic BSA	Standard Error 1.2
Placebo for CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,53,42,84)	7.2 percent psoriatic BSA	Standard Error 1
Placebo for CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	6.0 percent psoriatic BSA	Standard Error 0.9
Placebo for CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,128)	6.1 percent psoriatic BSA	Standard Error 0.8
Placebo for CP-690,550 5 mg (Period B)	Mean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Baseline (n=31,82,45,133)	3.8 percent psoriatic BSA	Standard Error 0.8
CP-690,550 10 mg (Period B)	Mean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,70,43,104)	2.0 percent psoriatic BSA	Standard Error 0.4
CP-690,550 10 mg (Period B)	Mean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Baseline (n=31,82,45,133)	2.0 percent psoriatic BSA	Standard Error 0.3
CP-690,550 10 mg (Period B)	Mean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,128)	1.8 percent psoriatic BSA	Standard Error 0.4
CP-690,550 10 mg (Period B)	Mean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,53,42,84)	2.3 percent psoriatic BSA	Standard Error 0.5
CP-690,550 10 mg (Period B)	Mean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	2.6 percent psoriatic BSA	Standard Error 0.7
Placebo for 10 mg CP-690,550	Mean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,53,42,84)	6.2 percent psoriatic BSA	Standard Error 0.9
Placebo for 10 mg CP-690,550	Mean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,128)	6.8 percent psoriatic BSA	Standard Error 0.9
Placebo for 10 mg CP-690,550	Mean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Baseline (n=31,82,45,133)	2.7 percent psoriatic BSA	Standard Error 0.4
Placebo for 10 mg CP-690,550	Mean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,70,43,104)	8.7 percent psoriatic BSA	Standard Error 1.2
Placebo for 10 mg CP-690,550	Mean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	6.0 percent psoriatic BSA	Standard Error 0.8

Secondary

Median Time to DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

Time frame: Weeks 4, 8, and 16 (Period C)

Population: FAS-C participants with Baseline-C DLQI ≥5, where Baseline-C defined as the last observation up to first dosing date in Period C.

Arm	Measure	Value (MEDIAN)
CP-690,550 5 mg (Period B)	Median Time to DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)	NA weeks
Placebo for CP-690,550 5 mg (Period B)	Median Time to DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)	8.1 weeks
CP-690,550 10 mg (Period B)	Median Time to DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)	NA weeks
Placebo for 10 mg CP-690,550	Median Time to DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)	4.4 weeks

Secondary

Median Time to DLQI ≥5-Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A participants with Baseline-A DLQI ≥5, where Baseline-A was defined as the last observation before the first dosing date in Period A.

Arm	Measure	Value (MEDIAN)
CP-690,550 5 mg (Period B)	Median Time to DLQI ≥5-Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)	4.4 weeks
Placebo for CP-690,550 5 mg (Period B)	Median Time to DLQI ≥5-Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)	4.1 weeks

Secondary

Median Time to ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C)

Time frame: Weeks 4, 8, and 16 (Period C)

Population: FAS-C participants with Baseline-C ISI \>1, where Baseline-C defined as the last observation up to first dosing date in Period C.

Arm	Measure	Value (MEDIAN)
CP-690,550 5 mg (Period B)	Median Time to ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C)	16.6 weeks
Placebo for CP-690,550 5 mg (Period B)	Median Time to ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C)	4.9 weeks
CP-690,550 10 mg (Period B)	Median Time to ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C)	NA weeks
Placebo for 10 mg CP-690,550	Median Time to ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C)	4.3 weeks

Secondary

Median Time to ISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690,550 Treatment (Period A)

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A participants with Baseline-A ISI ≥2, where Baseline-A was defined as the last observation before the first dosing date in Period A.

Arm	Measure	Value (MEDIAN)
CP-690,550 5 mg (Period B)	Median Time to ISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690,550 Treatment (Period A)	4.1 weeks
Placebo for CP-690,550 5 mg (Period B)	Median Time to ISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690,550 Treatment (Period A)	4.1 weeks

Secondary

Median Time to ISI Score of ≤1 During the CP-690,550 Re-Treatment (Period C)

Time frame: Weeks 4, 8, and 16 (Period C)

Population: FAS-C participants with Baseline-C ISI \>1, where Baseline-C defined as the last observation up to first dosing date in Period C.

Arm	Measure	Value (MEDIAN)
CP-690,550 5 mg (Period B)	Median Time to ISI Score of ≤1 During the CP-690,550 Re-Treatment (Period C)	NA weeks
Placebo for CP-690,550 5 mg (Period B)	Median Time to ISI Score of ≤1 During the CP-690,550 Re-Treatment (Period C)	16.1 weeks
CP-690,550 10 mg (Period B)	Median Time to ISI Score of ≤1 During the CP-690,550 Re-Treatment (Period C)	NA weeks
Placebo for 10 mg CP-690,550	Median Time to ISI Score of ≤1 During the CP-690,550 Re-Treatment (Period C)	8.3 weeks

Secondary

Median Time to ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A)

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A participants with Baseline-A ISI \>1, where Baseline-A was defined as the last observation before the first dosing date in Period A.

Arm	Measure	Value (MEDIAN)
CP-690,550 5 mg (Period B)	Median Time to ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A)	16.4 weeks
Placebo for CP-690,550 5 mg (Period B)	Median Time to ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A)	8.0 weeks

Secondary

Median Time to Loss of >50% of the Visit A4/Week 24 PASI Response and Loss of PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)

Time frame: Week 24 (Period A) and Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B

Arm	Measure	Value (MEDIAN)
CP-690,550 5 mg (Period B)	Median Time to Loss of >50% of the Visit A4/Week 24 PASI Response and Loss of PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)	NA weeks
Placebo for CP-690,550 5 mg (Period B)	Median Time to Loss of >50% of the Visit A4/Week 24 PASI Response and Loss of PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)	16.4 weeks
CP-690,550 10 mg (Period B)	Median Time to Loss of >50% of the Visit A4/Week 24 PASI Response and Loss of PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)	NA weeks
Placebo for 10 mg CP-690,550	Median Time to Loss of >50% of the Visit A4/Week 24 PASI Response and Loss of PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)	16.1 weeks

Secondary

Median Time to Loss of Adequate Response During the Double-Blind Treatment Withdrawal (Period B)

Adequate response defined as \>50% reduction of the Visit A4/Week 24 (last visit in Period A) PASI response.

Time frame: Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B

Arm	Measure	Value (MEDIAN)
CP-690,550 5 mg (Period B)	Median Time to Loss of Adequate Response During the Double-Blind Treatment Withdrawal (Period B)	NA weeks
Placebo for CP-690,550 5 mg (Period B)	Median Time to Loss of Adequate Response During the Double-Blind Treatment Withdrawal (Period B)	16.4 weeks
CP-690,550 10 mg (Period B)	Median Time to Loss of Adequate Response During the Double-Blind Treatment Withdrawal (Period B)	NA weeks
Placebo for 10 mg CP-690,550	Median Time to Loss of Adequate Response During the Double-Blind Treatment Withdrawal (Period B)	16.1 weeks

Secondary

Median Time to PASI75 Response During CP-690,550 Re-Treatment (Period C) For Those Who Had a >50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)

PASI75 response defined as at least a 75% reduction in PASI relative to baseline.

Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

Population: FAS-C

Arm	Measure	Value (MEDIAN)
CP-690,550 5 mg (Period B)	Median Time to PASI75 Response During CP-690,550 Re-Treatment (Period C) For Those Who Had a >50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)	4.5 weeks
Placebo for CP-690,550 5 mg (Period B)	Median Time to PASI75 Response During CP-690,550 Re-Treatment (Period C) For Those Who Had a >50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)	16.4 weeks
CP-690,550 10 mg (Period B)	Median Time to PASI75 Response During CP-690,550 Re-Treatment (Period C) For Those Who Had a >50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)	NA weeks
Placebo for 10 mg CP-690,550	Median Time to PASI75 Response During CP-690,550 Re-Treatment (Period C) For Those Who Had a >50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)	8.1 weeks

Secondary

Median Time to PASI75 Response During Initial CP-690,550 Treatment (Period A)

The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. PASI75 response defined as 75% reduction in PASI relative to baseline.

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: The Period A-Full Analysis Set (FAS-A) included all participants who were randomized at baseline and received at least 1 dose of the randomized investigational drug (CP-690,550 5mg BID or 10 mg BID) during Period A.

Arm	Measure	Value (MEDIAN)
CP-690,550 5 mg (Period B)	Median Time to PASI75 Response During Initial CP-690,550 Treatment (Period A)	24.3 weeks
Placebo for CP-690,550 5 mg (Period B)	Median Time to PASI75 Response During Initial CP-690,550 Treatment (Period A)	8.7 weeks

Secondary

Median Time to PGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe at the Beginning of Period C

Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

Population: FAS-C

Arm	Measure	Value (MEDIAN)
CP-690,550 5 mg (Period B)	Median Time to PGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe at the Beginning of Period C	16.3 weeks
Placebo for CP-690,550 5 mg (Period B)	Median Time to PGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe at the Beginning of Period C	16.1 weeks
CP-690,550 10 mg (Period B)	Median Time to PGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe at the Beginning of Period C	13.1 weeks
Placebo for 10 mg CP-690,550	Median Time to PGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe at the Beginning of Period C	8.1 weeks

Secondary

Median Time to PGA Response of Clear or Almost Clear During Initial CP-690,550 Treatment (Period A)

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A

Arm	Measure	Value (MEDIAN)
CP-690,550 5 mg (Period B)	Median Time to PGA Response of Clear or Almost Clear During Initial CP-690,550 Treatment (Period A)	24.1 weeks
Placebo for CP-690,550 5 mg (Period B)	Median Time to PGA Response of Clear or Almost Clear During Initial CP-690,550 Treatment (Period A)	8.1 weeks

Secondary

Median Time to Regain PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C

PASI75 response defined as at least a 75% reduction in PASI relative to baseline.

Time frame: Weeks 4, 8, and 16 (Period C)

Population: FAS-C

Arm	Measure	Value (MEDIAN)
CP-690,550 5 mg (Period B)	Median Time to Regain PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C	16.4 weeks
Placebo for CP-690,550 5 mg (Period B)	Median Time to Regain PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C	16.4 weeks
CP-690,550 10 mg (Period B)	Median Time to Regain PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C	NA weeks
Placebo for 10 mg CP-690,550	Median Time to Regain PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C	12.4 weeks

Secondary

Percentage of Participant Maintaining an Adequate Response During the Double-Blind Treatment Withdrawal (Period B)

Adequate response defined as \>50% reduction of the Visit A4/Week 24 (last visit in Period A) PASI response.

Time frame: Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participant Maintaining an Adequate Response During the Double-Blind Treatment Withdrawal (Period B)	Week 4	100.0 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participant Maintaining an Adequate Response During the Double-Blind Treatment Withdrawal (Period B)	Week 12	96.7 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participant Maintaining an Adequate Response During the Double-Blind Treatment Withdrawal (Period B)	Week 8	96.7 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participant Maintaining an Adequate Response During the Double-Blind Treatment Withdrawal (Period B)	Week 16	92.3 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participant Maintaining an Adequate Response During the Double-Blind Treatment Withdrawal (Period B)	Week 8	72.0 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participant Maintaining an Adequate Response During the Double-Blind Treatment Withdrawal (Period B)	Week 4	90.0 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participant Maintaining an Adequate Response During the Double-Blind Treatment Withdrawal (Period B)	Week 16	32.8 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participant Maintaining an Adequate Response During the Double-Blind Treatment Withdrawal (Period B)	Week 12	58.8 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participant Maintaining an Adequate Response During the Double-Blind Treatment Withdrawal (Period B)	Week 8	97.7 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participant Maintaining an Adequate Response During the Double-Blind Treatment Withdrawal (Period B)	Week 4	100.0 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participant Maintaining an Adequate Response During the Double-Blind Treatment Withdrawal (Period B)	Week 12	93.0 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participant Maintaining an Adequate Response During the Double-Blind Treatment Withdrawal (Period B)	Week 16	93.0 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participant Maintaining an Adequate Response During the Double-Blind Treatment Withdrawal (Period B)	Week 16	42.9 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participant Maintaining an Adequate Response During the Double-Blind Treatment Withdrawal (Period B)	Week 12	58.5 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participant Maintaining an Adequate Response During the Double-Blind Treatment Withdrawal (Period B)	Week 8	68.4 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participant Maintaining an Adequate Response During the Double-Blind Treatment Withdrawal (Period B)	Week 4	85.9 percentage of participants

Secondary

Percentage of Participants Achieving 100% Reduction in PASI Relative to Baseline-A (PASI100) During the CP-690,550 Re-Treatment (Period C)

PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head/neck, upper limbs, trunk, lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.

Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

Population: FAS-C; n equals the number of participants with an observation

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving 100% Reduction in PASI Relative to Baseline-A (PASI100) During the CP-690,550 Re-Treatment (Period C)	Baseline	18.52 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving 100% Reduction in PASI Relative to Baseline-A (PASI100) During the CP-690,550 Re-Treatment (Period C)	Week 4	18.52 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving 100% Reduction in PASI Relative to Baseline-A (PASI100) During the CP-690,550 Re-Treatment (Period C)	Week 8	18.52 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving 100% Reduction in PASI Relative to Baseline-A (PASI100) During the CP-690,550 Re-Treatment (Period C)	Week 16	14.81 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving 100% Reduction in PASI Relative to Baseline-A (PASI100) During the CP-690,550 Re-Treatment (Period C)	Week 4	9.33 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving 100% Reduction in PASI Relative to Baseline-A (PASI100) During the CP-690,550 Re-Treatment (Period C)	Week 8	13.33 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving 100% Reduction in PASI Relative to Baseline-A (PASI100) During the CP-690,550 Re-Treatment (Period C)	Week 16	10.67 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving 100% Reduction in PASI Relative to Baseline-A (PASI100) During the CP-690,550 Re-Treatment (Period C)	Baseline	5.33 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving 100% Reduction in PASI Relative to Baseline-A (PASI100) During the CP-690,550 Re-Treatment (Period C)	Week 8	21.43 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving 100% Reduction in PASI Relative to Baseline-A (PASI100) During the CP-690,550 Re-Treatment (Period C)	Week 4	21.43 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving 100% Reduction in PASI Relative to Baseline-A (PASI100) During the CP-690,550 Re-Treatment (Period C)	Week 16	26.19 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving 100% Reduction in PASI Relative to Baseline-A (PASI100) During the CP-690,550 Re-Treatment (Period C)	Baseline	23.81 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving 100% Reduction in PASI Relative to Baseline-A (PASI100) During the CP-690,550 Re-Treatment (Period C)	Week 16	20.83 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving 100% Reduction in PASI Relative to Baseline-A (PASI100) During the CP-690,550 Re-Treatment (Period C)	Week 4	15.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving 100% Reduction in PASI Relative to Baseline-A (PASI100) During the CP-690,550 Re-Treatment (Period C)	Baseline	5.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving 100% Reduction in PASI Relative to Baseline-A (PASI100) During the CP-690,550 Re-Treatment (Period C)	Week 8	19.17 percentage of participants

Secondary

Percentage of Participants Achieving an ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C)

Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

Population: FAS-C participants with a Baseline-C ISI \>1, where Baseline-C is defined as the last observation up to first dosing date in Period C.

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving an ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C)	Week 4	14.29 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving an ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C)	Week 8	21.43 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving an ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C)	Baseline	0.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving an ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C)	Week 16	21.43 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving an ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C)	Baseline	0.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving an ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C)	Week 16	41.94 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving an ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C)	Week 8	33.87 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving an ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C)	Week 4	22.58 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving an ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C)	Baseline	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving an ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C)	Week 4	14.29 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving an ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C)	Week 16	35.71 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving an ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C)	Week 8	21.43 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving an ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C)	Week 16	50.53 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving an ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C)	Week 4	41.05 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving an ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C)	Week 8	55.79 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving an ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C)	Baseline	0.00 percentage of participants

Secondary

Percentage of Participants Achieving at Least a 100% Reduction in PASI Relative to Baseline-A (PASI100) During Period A

PASI quantifies the severity of psoriasis based on both lesion severity and the percent of BSA) affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk, and lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of the body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 100% Reduction in PASI Relative to Baseline-A (PASI100) During Period A	Week 4	0.91 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 100% Reduction in PASI Relative to Baseline-A (PASI100) During Period A	Week 8	2.72 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 100% Reduction in PASI Relative to Baseline-A (PASI100) During Period A	Week 16	7.25 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 100% Reduction in PASI Relative to Baseline-A (PASI100) During Period A	Week 24	8.16 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 100% Reduction in PASI Relative to Baseline-A (PASI100) During Period A	Week 24	17.31 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 100% Reduction in PASI Relative to Baseline-A (PASI100) During Period A	Week 4	2.09 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 100% Reduction in PASI Relative to Baseline-A (PASI100) During Period A	Week 16	15.82 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 100% Reduction in PASI Relative to Baseline-A (PASI100) During Period A	Week 8	7.46 percentage of participants

Secondary

Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During Period A

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A; NRI

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During Period A	Week 4	28.70 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During Period A	Week 8	55.29 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During Period A	Week 16	65.26 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During Period A	Week 24	59.52 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During Period A	Week 24	73.13 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During Period A	Week 4	54.63 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During Period A	Week 16	79.40 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During Period A	Week 8	75.52 percentage of participants

Secondary

Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During the CP-690,550 Re-Treatment (Period C)

Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

Population: FAS-C; n equals the number of participants with an observation

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During the CP-690,550 Re-Treatment (Period C)	Baseline	96.30 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During the CP-690,550 Re-Treatment (Period C)	Week 4	100.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During the CP-690,550 Re-Treatment (Period C)	Week 8	92.59 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During the CP-690,550 Re-Treatment (Period C)	Week 16	85.19 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During the CP-690,550 Re-Treatment (Period C)	Week 4	69.33 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During the CP-690,550 Re-Treatment (Period C)	Week 8	81.33 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During the CP-690,550 Re-Treatment (Period C)	Week 16	82.67 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During the CP-690,550 Re-Treatment (Period C)	Baseline	42.67 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During the CP-690,550 Re-Treatment (Period C)	Week 8	95.24 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During the CP-690,550 Re-Treatment (Period C)	Baseline	92.86 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During the CP-690,550 Re-Treatment (Period C)	Week 16	85.71 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During the CP-690,550 Re-Treatment (Period C)	Week 4	92.86 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During the CP-690,550 Re-Treatment (Period C)	Week 16	79.17 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During the CP-690,550 Re-Treatment (Period C)	Week 8	89.17 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During the CP-690,550 Re-Treatment (Period C)	Week 4	84.17 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During the CP-690,550 Re-Treatment (Period C)	Baseline	49.17 percentage of participants

Secondary

Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During Period A

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During Period A	Week 24	20.24 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During Period A	Week 4	1.21 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During Period A	Week 8	8.76 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During Period A	Week 16	18.73 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During Period A	Week 16	36.72 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During Period A	Week 24	37.31 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During Period A	Week 8	24.78 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During Period A	Week 4	6.27 percentage of participants

Secondary

Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During the CP-690,550 Re-Treatment (Period C)

Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

Population: FAS-C; n equals the number of participants with an observation

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During the CP-690,550 Re-Treatment (Period C)	Week 8	48.15 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During the CP-690,550 Re-Treatment (Period C)	Week 4	48.15 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During the CP-690,550 Re-Treatment (Period C)	Baseline	48.15 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During the CP-690,550 Re-Treatment (Period C)	Week 16	33.33 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During the CP-690,550 Re-Treatment (Period C)	Week 4	17.33 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During the CP-690,550 Re-Treatment (Period C)	Baseline	12.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During the CP-690,550 Re-Treatment (Period C)	Week 8	21.33 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During the CP-690,550 Re-Treatment (Period C)	Week 16	21.33 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During the CP-690,550 Re-Treatment (Period C)	Week 16	45.24 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During the CP-690,550 Re-Treatment (Period C)	Week 4	47.62 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During the CP-690,550 Re-Treatment (Period C)	Baseline	45.24 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During the CP-690,550 Re-Treatment (Period C)	Week 8	47.62 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During the CP-690,550 Re-Treatment (Period C)	Week 8	42.50 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During the CP-690,550 Re-Treatment (Period C)	Baseline	15.83 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During the CP-690,550 Re-Treatment (Period C)	Week 16	44.17 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During the CP-690,550 Re-Treatment (Period C)	Week 4	35.00 percentage of participants

Secondary

Percentage of Participants Achieving Both a PASI50-75 Response and Dermatology Life Quality Index (DLQI) ≤5 Response During Initial CP-690,550 Treatment (Period A)

PASI50-75 response defined as a reduction of at least 50% but less than 75%. The DLQI is a general dermatology questionnaire that consists of 10 items that assess participant health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving Both a PASI50-75 Response and Dermatology Life Quality Index (DLQI) ≤5 Response During Initial CP-690,550 Treatment (Period A)	Week 4	12.69 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving Both a PASI50-75 Response and Dermatology Life Quality Index (DLQI) ≤5 Response During Initial CP-690,550 Treatment (Period A)	Week 8	18.73 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving Both a PASI50-75 Response and Dermatology Life Quality Index (DLQI) ≤5 Response During Initial CP-690,550 Treatment (Period A)	Week 16	18.13 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving Both a PASI50-75 Response and Dermatology Life Quality Index (DLQI) ≤5 Response During Initial CP-690,550 Treatment (Period A)	Week 24	10.88 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving Both a PASI50-75 Response and Dermatology Life Quality Index (DLQI) ≤5 Response During Initial CP-690,550 Treatment (Period A)	Week 24	10.15 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving Both a PASI50-75 Response and Dermatology Life Quality Index (DLQI) ≤5 Response During Initial CP-690,550 Treatment (Period A)	Week 4	21.19 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving Both a PASI50-75 Response and Dermatology Life Quality Index (DLQI) ≤5 Response During Initial CP-690,550 Treatment (Period A)	Week 16	13.13 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving Both a PASI50-75 Response and Dermatology Life Quality Index (DLQI) ≤5 Response During Initial CP-690,550 Treatment (Period A)	Week 8	19.40 percentage of participants

Secondary

Percentage of Participants Achieving DLQI ≤1 Response During CP-690,550 Re-Treatment (Period C)

Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

Population: FAS-C participants with a Baseline-C DLQI \>1, where Baseline-C is defined as the last observation up to first dosing date in Period C.

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During CP-690,550 Re-Treatment (Period C)	Baseline	0.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During CP-690,550 Re-Treatment (Period C)	Week 4	16.67 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During CP-690,550 Re-Treatment (Period C)	Week 8	16.67 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During CP-690,550 Re-Treatment (Period C)	Week 16	16.67 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During CP-690,550 Re-Treatment (Period C)	Week 4	24.59 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During CP-690,550 Re-Treatment (Period C)	Week 8	26.23 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During CP-690,550 Re-Treatment (Period C)	Week 16	29.51 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During CP-690,550 Re-Treatment (Period C)	Baseline	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During CP-690,550 Re-Treatment (Period C)	Week 8	31.25 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During CP-690,550 Re-Treatment (Period C)	Week 4	37.50 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During CP-690,550 Re-Treatment (Period C)	Week 16	37.50 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During CP-690,550 Re-Treatment (Period C)	Baseline	0.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving DLQI ≤1 Response During CP-690,550 Re-Treatment (Period C)	Week 16	40.86 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving DLQI ≤1 Response During CP-690,550 Re-Treatment (Period C)	Week 4	24.73 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving DLQI ≤1 Response During CP-690,550 Re-Treatment (Period C)	Baseline	0.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving DLQI ≤1 Response During CP-690,550 Re-Treatment (Period C)	Week 8	40.86 percentage of participants

Secondary

Percentage of Participants Achieving DLQI ≤1 Response During Double-Blind Treatment Withdrawal (Period B)

Time frame: Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B participants with Baseline-B DLQI \>1 where Baseline-B defined as last observation up to first dosing date in Period B.

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During Double-Blind Treatment Withdrawal (Period B)	Week 8	7.69 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During Double-Blind Treatment Withdrawal (Period B)	Week 12	7.69 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During Double-Blind Treatment Withdrawal (Period B)	Week 16	7.69 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During Double-Blind Treatment Withdrawal (Period B)	Week 4	7.69 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During Double-Blind Treatment Withdrawal (Period B)	Baseline	0.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During Double-Blind Treatment Withdrawal (Period B)	Week 4	4.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During Double-Blind Treatment Withdrawal (Period B)	Week 8	0.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During Double-Blind Treatment Withdrawal (Period B)	Week 12	0.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During Double-Blind Treatment Withdrawal (Period B)	Baseline	0.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During Double-Blind Treatment Withdrawal (Period B)	Week 16	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During Double-Blind Treatment Withdrawal (Period B)	Week 16	16.67 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During Double-Blind Treatment Withdrawal (Period B)	Baseline	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During Double-Blind Treatment Withdrawal (Period B)	Week 4	41.67 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During Double-Blind Treatment Withdrawal (Period B)	Week 12	8.33 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During Double-Blind Treatment Withdrawal (Period B)	Week 8	33.33 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving DLQI ≤1 Response During Double-Blind Treatment Withdrawal (Period B)	Week 16	9.68 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving DLQI ≤1 Response During Double-Blind Treatment Withdrawal (Period B)	Week 12	9.68 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving DLQI ≤1 Response During Double-Blind Treatment Withdrawal (Period B)	Baseline	0.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving DLQI ≤1 Response During Double-Blind Treatment Withdrawal (Period B)	Week 8	9.68 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving DLQI ≤1 Response During Double-Blind Treatment Withdrawal (Period B)	Week 4	12.90 percentage of participants

Secondary

Percentage of Participants Achieving DLQI ≤1 Response During the Initial CP-690,550 Treatment (Period A)

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A participants with a Baseline-A DLQI ≤1, where Baseline-A is defined as the last observation up to first dosing date in Period A.

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During the Initial CP-690,550 Treatment (Period A)	Week 4	13.44 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During the Initial CP-690,550 Treatment (Period A)	Week 8	25.94 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During the Initial CP-690,550 Treatment (Period A)	Week 16	30.94 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During the Initial CP-690,550 Treatment (Period A)	Week 24	30.63 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During the Initial CP-690,550 Treatment (Period A)	Week 24	50.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During the Initial CP-690,550 Treatment (Period A)	Week 4	26.88 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During the Initial CP-690,550 Treatment (Period A)	Week 16	53.13 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≤1 Response During the Initial CP-690,550 Treatment (Period A)	Week 8	41.88 percentage of participants

Secondary

Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A participants with a Baseline-A DLQI ≥5, where Baseline-A is defined as the last observation up to first dosing date in Period A. n=participants with an observation.

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)	Week 16	70.77 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)	Week 8	70.42 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)	Week 24	59.86 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)	Week 4	59.86 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)	Week 24	72.95 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)	Week 8	80.78 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)	Week 16	79.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)	Week 4	75.44 percentage of participants

Secondary

Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-B Response During Double-Blind Treatment Withdrawal (Period B)

Time frame: Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B participants with Baseline-B DLQI ≥5.

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-B Response During Double-Blind Treatment Withdrawal (Period B)	Week 4	0.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-B Response During Double-Blind Treatment Withdrawal (Period B)	Week 12	11.11 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-B Response During Double-Blind Treatment Withdrawal (Period B)	Week 8	0.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-B Response During Double-Blind Treatment Withdrawal (Period B)	Week 16	0.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-B Response During Double-Blind Treatment Withdrawal (Period B)	Week 8	0.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-B Response During Double-Blind Treatment Withdrawal (Period B)	Week 16	8.33 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-B Response During Double-Blind Treatment Withdrawal (Period B)	Week 12	0.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-B Response During Double-Blind Treatment Withdrawal (Period B)	Week 4	16.67 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-B Response During Double-Blind Treatment Withdrawal (Period B)	Week 8	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-B Response During Double-Blind Treatment Withdrawal (Period B)	Week 4	33.33 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-B Response During Double-Blind Treatment Withdrawal (Period B)	Week 12	66.67 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-B Response During Double-Blind Treatment Withdrawal (Period B)	Week 16	33.33 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-B Response During Double-Blind Treatment Withdrawal (Period B)	Week 16	11.11 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-B Response During Double-Blind Treatment Withdrawal (Period B)	Week 12	11.11 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-B Response During Double-Blind Treatment Withdrawal (Period B)	Week 8	11.11 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-B Response During Double-Blind Treatment Withdrawal (Period B)	Week 4	0.00 percentage of participants

Secondary

Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-C Response During CP-690,550 Re-Treatment (Period C)

Time frame: Weeks 4, 8, and 16 (Period C)

Population: FAS-C participants with Baseline-C DLQI ≥5

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-C Response During CP-690,550 Re-Treatment (Period C)	Week 16	12.50 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-C Response During CP-690,550 Re-Treatment (Period C)	Week 4	0.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-C Response During CP-690,550 Re-Treatment (Period C)	Week 8	12.50 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-C Response During CP-690,550 Re-Treatment (Period C)	Week 4	47.50 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-C Response During CP-690,550 Re-Treatment (Period C)	Week 16	47.50 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-C Response During CP-690,550 Re-Treatment (Period C)	Week 8	55.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-C Response During CP-690,550 Re-Treatment (Period C)	Week 8	25.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-C Response During CP-690,550 Re-Treatment (Period C)	Week 4	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-C Response During CP-690,550 Re-Treatment (Period C)	Week 16	12.50 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-C Response During CP-690,550 Re-Treatment (Period C)	Week 4	65.79 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-C Response During CP-690,550 Re-Treatment (Period C)	Week 16	64.47 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-C Response During CP-690,550 Re-Treatment (Period C)	Week 8	77.63 percentage of participants

Secondary

Percentage of Participants Achieving ISI ≥2-Point Reduction During the CP-690,550 Re-Treatment (Period C)

Time frame: Weeks 4, 8, and 16 (Period C)

Population: FAS-C participants with a Baseline-C ISI ≥2, where Baseline-C is defined as the last observation up to first dosing date in Period C.

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving ISI ≥2-Point Reduction During the CP-690,550 Re-Treatment (Period C)	Week 16	21.43 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving ISI ≥2-Point Reduction During the CP-690,550 Re-Treatment (Period C)	Week 4	28.57 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving ISI ≥2-Point Reduction During the CP-690,550 Re-Treatment (Period C)	Week 8	28.57 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving ISI ≥2-Point Reduction During the CP-690,550 Re-Treatment (Period C)	Week 4	61.29 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving ISI ≥2-Point Reduction During the CP-690,550 Re-Treatment (Period C)	Week 16	62.90 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving ISI ≥2-Point Reduction During the CP-690,550 Re-Treatment (Period C)	Week 8	64.52 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving ISI ≥2-Point Reduction During the CP-690,550 Re-Treatment (Period C)	Week 8	28.57 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving ISI ≥2-Point Reduction During the CP-690,550 Re-Treatment (Period C)	Week 4	14.29 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Achieving ISI ≥2-Point Reduction During the CP-690,550 Re-Treatment (Period C)	Week 16	28.57 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving ISI ≥2-Point Reduction During the CP-690,550 Re-Treatment (Period C)	Week 16	69.47 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving ISI ≥2-Point Reduction During the CP-690,550 Re-Treatment (Period C)	Week 8	78.95 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Achieving ISI ≥2-Point Reduction During the CP-690,550 Re-Treatment (Period C)	Week 4	80.00 percentage of participants

Secondary

Percentage of Participants Achieving ISI ≥2-Point Reduction During the Initial CP-690,550 Treatment (Period A)

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A participants with a Baseline-A ISI ≥2, where Baseline-A is defined as the last observation up to first dosing date in Period A.

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving ISI ≥2-Point Reduction During the Initial CP-690,550 Treatment (Period A)	Week 4	81.59 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving ISI ≥2-Point Reduction During the Initial CP-690,550 Treatment (Period A)	Week 8	80.32 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving ISI ≥2-Point Reduction During the Initial CP-690,550 Treatment (Period A)	Week 16	73.97 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving ISI ≥2-Point Reduction During the Initial CP-690,550 Treatment (Period A)	Week 24	65.71 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving ISI ≥2-Point Reduction During the Initial CP-690,550 Treatment (Period A)	Week 24	74.92 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving ISI ≥2-Point Reduction During the Initial CP-690,550 Treatment (Period A)	Week 4	88.89 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving ISI ≥2-Point Reduction During the Initial CP-690,550 Treatment (Period A)	Week 16	84.76 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving ISI ≥2-Point Reduction During the Initial CP-690,550 Treatment (Period A)	Week 8	87.94 percentage of participants

Secondary

Percentage of Participants Achieving ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A)

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A participants with a Baseline-A ISI \>1, where Baseline-A is defined as the last observation up to first dosing date in Period A.

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A)	Week 24	31.11 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A)	Week 8	34.29 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A)	Week 4	27.62 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Achieving ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A)	Week 16	34.92 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A)	Week 24	55.24 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A)	Week 16	60.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A)	Week 4	46.03 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Achieving ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A)	Week 8	60.00 percentage of participants

Secondary

Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). Severity is measured using the following categories of scores: 0-1=no effect on patients' lives; 2-5=small effect; 6-10=moderate effect; 11-20=very large effect; 21-30=extremely large effect.

Time frame: Baseline and Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A

Arm	Measure	Group	Value (NUMBER)	Dispersion
CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 24, Moderate effect (6-10;n=273,277)	19.0 percentage of participants	19
CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 8, No effect (0-1) (n=321,319)	28.0 percentage of participants	28
CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Baseline, Very large effect (11-20;n=330,333)	39.1 percentage of participants	39.1
CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 8, Small effect (2-5;n=321,319)	34.0 percentage of participants	34
CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Baseline, No effect (0-1) (n=330,333)	3.0 percentage of participants	3
CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 8, Moderate effect (6-10;n=321,319)	23.7 percentage of participants	23.7
CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 8, Very large effect (11-20;n=321,319)	11.8 percentage of participants	11.8
CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Baseline, Extremely large effect (21-30;n=330,333)	15.8 percentage of participants	15.8
CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 8, Extremely large effect (21-30;n=321,319)	2.5 percentage of participants	2.5
CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 16, Moderate effect (6-10;n=310,303)	18.4 percentage of participants	18.4
CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 16, No effect (0-1) (n=310,303)	34.2 percentage of participants	34.2
CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 4, No effect (0-1) (n=326,330)	15.6 percentage of participants	15.6
CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 16, Small effect (2-5;n=310,303)	34.5 percentage of participants	34.5
CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Baseline, Small effect (2-5;n=330,333)	15.2 percentage of participants	15.2
CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 4, Small effect (2-5;n=326,330)	35.9 percentage of participants	35.9
CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 16, Very large effect (11-20;n=310,303)	11.0 percentage of participants	11
CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 24, Very large effect (11-20;n=273,277)	12.8 percentage of participants	12.8
CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 16, Extremely large effect (21-30;n=310,303)	1.9 percentage of participants	1.9
CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 4, Moderate effect (6-10;n=326,330)	25.8 percentage of participants	25.8
CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 24, No effect (0-1) (n=273,277)	38.1 percentage of participants	38.1
CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 4, Very large effect (11-20;n=326,330)	18.7 percentage of participants	18.7
CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 24, Small effect (2-5;n=273,277)	27.1 percentage of participants	27.1
CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Baseline, Moderate effect (6-10;n=330,333)	27.0 percentage of participants	27
CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 24, Extremely large effect (21-30;n=273,277)	2.9 percentage of participants	2.9
CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 4, Extremely large effect (21-30;n=326,330)	4.0 percentage of participants	4
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 24, Extremely large effect (21-30;n=273,277)	1.8 percentage of participants	1.8
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 8, Moderate effect (6-10;n=321,319)	12.5 percentage of participants	12.5
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 24, Moderate effect (6-10;n=273,277)	9.0 percentage of participants	9
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 24, Very large effect (11-20;n=273,277)	3.2 percentage of participants	0.32
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Baseline, No effect (0-1) (n=330,333)	3.9 percentage of participants	3.9
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Baseline, Small effect (2-5;n=330,333)	17.1 percentage of participants	17.1
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Baseline, Moderate effect (6-10;n=330,333)	21.3 percentage of participants	21.3
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Baseline, Very large effect (11-20;n=330,333)	41.7 percentage of participants	41.7
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Baseline, Extremely large effect (21-30;n=330,333)	15.9 percentage of participants	15.9
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 4, No effect (0-1) (n=326,330)	29.4 percentage of participants	29.4
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 4, Small effect (2-5;n=326,330)	37.3 percentage of participants	37.3
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 4, Very large effect (11-20;n=326,330)	9.7 percentage of participants	9.7
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 4, Extremely large effect (21-30;n=326,330)	1.5 percentage of participants	1.5
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 8, No effect (0-1) (n=321,319)	45.5 percentage of participants	45.5
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 8, Small effect (2-5;n=321,319)	34.8 percentage of participants	34.8
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 8, Very large effect (11-20;n=321,319)	5.0 percentage of participants	5
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 8, Extremely large effect (21-30;n=321,319)	2.2 percentage of participants	2.2
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 16, No effect (0-1) (n=310,303)	59.4 percentage of participants	59.4
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 16, Small effect (2-5;n=310,303)	22.1 percentage of participants	22.1
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 16, Moderate effect (6-10;n=310,303)	10.6 percentage of participants	10.6
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 16, Very large effect (11-20;n=310,303)	6.3 percentage of participants	6.3
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 16, Extremely large effect (21-30;n=310,303)	1.7 percentage of participants	1.7
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 24, No effect (0-1) (n=273,277)	61.0 percentage of participants	61
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 24, Small effect (2-5;n=273,277)	24.9 percentage of participants	24.9
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)	Week 4, Moderate effect (6-10;n=326,330)	22.1 percentage of participants	22.1

Secondary

Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)

The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe

Time frame: Baseline and Weeks 4, 8, 16 and 24 (Period A)

Population: FAS-A

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Baseline, Mild (n=330,335)	3.6 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 8, Moderate (n=320,321)	30.0 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 4, Mild (n=325,331)	24.9 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 8, Severe (n=320,321)	15.0 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Baseline Severe (n=330,335)	66.1 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 16, Clear (n=310,303)	5.5 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 4, Moderate (n=325,331)	40.6 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 16, Almost Clear (n=310,303)	27.1 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Baseline, Almost clear (n=330,335)	0.0 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 16, Mild (n=310,303)	30.6 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 4, Severe (n=325,331)	22.5 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 16, Moderate (n=310,303)	27.7 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 4, Clear (n=325,331)	0.3 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 16, Severe (n=310,303)	9.0 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 8, Clear (n=320,321)	1.9 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 24, Clear (n=273,277)	8.1 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Baseline, Moderate (n=330,335)	30.3 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 24, Almost Clear (n=273,277)	27.8 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 8, Almost Clear (n=320,321)	21.3 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 24, Mild (n=273,277)	23.8 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 4, Almost Clear (n=325,331)	11.7 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 24, Moderate (n=273,277)	30.0 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 8, Mild (n=320,321)	31.9 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 24, Severe (n=273,277)	10.3 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Baseline, Clear (n=330,335)	0.0 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 24, Severe (n=273,277)	4.0 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Baseline, Clear (n=330,335)	0.0 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Baseline, Almost clear (n=330,335)	0.3 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Baseline, Mild (n=330,335)	1.2 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Baseline, Moderate (n=330,335)	34.6 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Baseline Severe (n=330,335)	63.9 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 4, Clear (n=325,331)	1.2 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 4, Almost Clear (n=325,331)	20.2 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 4, Mild (n=325,331)	30.5 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 4, Moderate (n=325,331)	37.8 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 4, Severe (n=325,331)	10.3 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 8, Clear (n=320,321)	5.9 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 8, Almost Clear (n=320,321)	41.4 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 8, Mild (n=320,321)	25.2 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 8, Moderate (n=320,321)	22.4 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 8, Severe (n=320,321)	5.0 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 16, Clear (n=310,303)	16.8 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 16, Almost Clear (n=310,303)	43.6 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 16, Mild (n=310,303)	20.8 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 16, Moderate (n=310,303)	11.9 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 16, Severe (n=310,303)	6.9 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 24, Clear (n=273,277)	20.9 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 24, Almost Clear (n=273,277)	41.5 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 24, Mild (n=273,277)	20.2 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)	Week 24, Moderate (n=273,277)	13.4 percentage of participants

Secondary

Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)

Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

Population: FAS-C

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 8, Clear (n=26,71,41,118)	19.2 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 4, Severe (n=27,74,42,118)	0.0 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 4, Clear (n=27,74,42,118)	18.5 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Baseline, Almost Clear (n=27,75,42,120)	33.3 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 4, Moderate (n=27,74,42,118)	11.1 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 4, Mild (n=27,74,42,118)	33.3 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 4, Almost Clear (n=27,74,42,118)	37.0 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Baseline, Clear (n=27,75,42,120)	22.2 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 16, Almost Clear (n=22,65,38,101)	31.8 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 16, Clear (n=22,65,38,101)	13.6 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Baseline, Mild (n=27,75,42,120)	18.5 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 16, Severe (n=22,65,38,101)	4.5 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 8, Severe (n=26,71,41,118)	3.8 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 8, Moderate (n=26,71,41,118)	19.2 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Baseline, Moderate (n=27,75,42,120)	25.9 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 16, Moderate (n=22,65,38,101)	13.6 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 8, Mild (n=26,71,41,118)	30.8 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 8, Almost Clear (n=26,71,41,118)	26.9 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Baseline, Severe (n=27,75,42,120)	0.0 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 16, Mild (n=22,65,38,101)	36.4 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 16, Mild (n=22,65,38,101)	27.7 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Baseline, Clear (n=27,75,42,120)	2.7 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Baseline, Almost Clear (n=27,75,42,120)	18.7 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Baseline, Mild (n=27,75,42,120)	18.7 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Baseline, Moderate (n=27,75,42,120)	37.3 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Baseline, Severe (n=27,75,42,120)	22.7 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 4, Clear (n=27,74,42,118)	5.4 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 4, Almost Clear (n=27,74,42,118)	23.0 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 4, Mild (n=27,74,42,118)	41.9 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 4, Moderate (n=27,74,42,118)	25.7 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 4, Severe (n=27,74,42,118)	4.1 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 8, Clear (n=26,71,41,118)	7.0 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 8, Almost Clear (n=26,71,41,118)	36.6 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 8, Mild (n=26,71,41,118)	38.0 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 8, Moderate (n=26,71,41,118)	16.9 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 8, Severe (n=26,71,41,118)	1.4 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 16, Clear (n=22,65,38,101)	10.8 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 16, Almost Clear (n=22,65,38,101)	43.1 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 16, Moderate (n=22,65,38,101)	13.8 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 16, Severe (n=22,65,38,101)	4.6 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 4, Severe (n=27,74,42,118)	4.8 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Baseline, Severe (n=27,75,42,120)	0.0 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 16, Mild (n=22,65,38,101)	10.5 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 8, Clear (n=26,71,41,118)	19.5 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 8, Almost Clear (n=26,71,41,118)	51.2 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Baseline, Moderate (n=27,75,42,120)	14.3 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Baseline, Clear (n=27,75,42,120)	19.0 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 8, Mild (n=26,71,41,118)	19.5 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 16, Severe (n=22,65,38,101)	7.9 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 8, Moderate (n=26,71,41,118)	7.3 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Baseline, Mild (n=27,75,42,120)	16.7 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 16, Moderate (n=22,65,38,101)	5.3 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 8, Severe (n=26,71,41,118)	2.4 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 16, Clear (n=22,65,38,101)	18.4 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Baseline, Almost Clear (n=27,75,42,120)	50.0 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 4, Almost Clear (n=27,74,42,118)	50.0 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 16, Almost Clear (n=22,65,38,101)	57.9 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 4, Mild (n=27,74,42,118)	11.9 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 4, Clear (n=27,74,42,118)	19.0 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 4, Moderate (n=27,74,42,118)	14.3 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 4, Moderate (n=27,74,42,118)	20.3 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 4, Severe (n=27,74,42,118)	4.2 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 8, Severe (n=26,71,41,118)	4.2 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Baseline, Almost Clear (n=27,75,42,120)	18.3 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 16, Moderate (n=22,65,38,101)	10.9 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 8, Clear (n=26,71,41,118)	15.3 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Baseline, Moderate (n=27,75,42,120)	33.3 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 16, Mild (n=22,65,38,101)	18.8 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 4, Mild (n=27,74,42,118)	23.7 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 8, Almost Clear (n=26,71,41,118)	46.6 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 16, Clear (n=22,65,38,101)	20.8 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Baseline, Severe (n=27,75,42,120)	25.8 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 16, Severe (n=22,65,38,101)	2.0 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 8, Mild (n=26,71,41,118)	24.6 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Baseline, Mild (n=27,75,42,120)	17.5 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 16, Almost Clear (n=22,65,38,101)	47.5 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 4, Almost Clear (n=27,74,42,118)	41.5 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 8, Moderate (n=26,71,41,118)	9.3 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Week 4, Clear (n=27,74,42,118)	10.2 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)	Baseline, Clear (n=27,75,42,120)	5.0 percentage of participants

Secondary

Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)

Time frame: Baseline and Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B; n equals the number of participants with observations

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Baseline, Clear (n=31,82,45,133)	16.1 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 16, Severe (n=27,45,38,68)	0.0 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 12, Mild (n=28,52,41,83)	32.1 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 4, Mild (n=30,82,43,126)	23.3 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 12, Almost Clear (n=28,52,41,83)	35.7 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Baseline, Mild (n=31,82,45,133)	25.8 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 16, Almost Clear (n=27,45,38,68)	33.3 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 4, Moderate (n=30,82,43,126)	6.7 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 8, Severe (n=30,68,43,104)	0.0 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Baseline, Severe (n=31,82,45,133)	0.0 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 8, Moderate (n=30,68,43,104)	10.0 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 4, Severe (n=30,82,43,126)	3.3 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 16, Moderate (n=27,45,38,68)	25.9 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Baseline, Almost Clear (n=31,82,45,133)	45.2 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 16, Clear (n=27,45,38,68)	22.2 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 8, Clear (n=30,68,43,104)	23.3 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 4, Clear (n=30,82,43,126)	23.3 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 12, Clear (n=28,52,41,83)	17.9 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 12, Moderate (n=28,52,41,83)	10.7 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 8, Almost Clear (n=30,68,43,104)	30.0 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 16, Mild (n=27,45,38,68)	18.5 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Baseline, Moderate (n=31,82,45,133)	12.9 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 12, Severe (n=28,52,41,83)	3.6 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 8, Mild (n=30,68,43,104)	36.7 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 4, Almost Clear (n=30,82,43,126)	43.3 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 8, Mild (n=30,68,43,104)	23.5 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 12, Moderate (n=28,52,41,83)	28.8 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 8, Moderate (n=30,68,43,104)	26.5 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 8, Severe (n=30,68,43,104)	14.7 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 12, Mild (n=28,52,41,83)	36.5 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 12, Clear (n=28,52,41,83)	1.9 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 12, Almost Clear (n=28,52,41,83)	19.2 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Baseline, Severe (n=31,82,45,133)	0.0 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Baseline, Almost Clear (n=31,82,45,133)	61.0 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 16, Mild (n=27,45,38,68)	22.2 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 4, Clear (n=30,82,43,126)	8.5 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Baseline, Clear (n=31,82,45,133)	19.5 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 4, Almost Clear (n=30,82,43,126)	34.1 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 16, Almost Clear (n=27,45,38,68)	28.9 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 4, Mild (n=30,82,43,126)	30.5 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 4, Moderate (n=30,82,43,126)	15.9 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Baseline, Mild (n=31,82,45,133)	12.2 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 16, Clear (n=27,45,38,68)	4.4 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 4, Severe (n=30,82,43,126)	11.0 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 16, Severe (n=27,45,38,68)	11.1 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 8, Clear (n=30,68,43,104)	7.4 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 16, Moderate (n=27,45,38,68)	33.3 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 12, Severe (n=28,52,41,83)	13.5 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 8, Almost Clear (n=30,68,43,104)	27.9 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Baseline, Moderate (n=31,82,45,133)	7.3 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 12, Clear (n=28,52,41,83)	14.6 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Baseline, Clear (n=31,82,45,133)	24.4 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Baseline, Almost Clear (n=31,82,45,133)	62.2 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Baseline, Mild (n=31,82,45,133)	11.1 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Baseline, Moderate (n=31,82,45,133)	2.2 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Baseline, Severe (n=31,82,45,133)	0.0 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 4, Clear (n=30,82,43,126)	23.3 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 4, Almost Clear (n=30,82,43,126)	58.1 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 4, Mild (n=30,82,43,126)	11.6 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 4, Moderate (n=30,82,43,126)	7.0 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 4, Severe (n=30,82,43,126)	0.0 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 8, Clear (n=30,68,43,104)	20.9 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 8, Almost Clear (n=30,68,43,104)	48.8 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 8, Mild (n=30,68,43,104)	23.3 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 8, Moderate (n=30,68,43,104)	7.0 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 8, Severe (n=30,68,43,104)	0.0 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 12, Almost Clear (n=28,52,41,83)	58.5 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 12, Mild (n=28,52,41,83)	22.0 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 12, Moderate (n=28,52,41,83)	4.9 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 12, Severe (n=28,52,41,83)	0.0 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 16, Clear (n=27,45,38,68)	18.4 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 16, Almost Clear (n=27,45,38,68)	52.6 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 16, Mild (n=27,45,38,68)	21.1 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 16, Moderate (n=27,45,38,68)	7.9 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 16, Severe (n=27,45,38,68)	0.0 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 12, Moderate (n=28,52,41,83)	24.1 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 8, Almost Clear (n=30,68,43,104)	29.8 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 8, Clear (n=30,68,43,104)	5.8 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 16, Severe (n=27,45,38,68)	11.8 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 12, Severe (n=28,52,41,83)	14.5 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 4, Severe (n=30,82,43,126)	11.1 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 4, Moderate (n=30,82,43,126)	27.0 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 16, Moderate (n=27,45,38,68)	30.9 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 16, Clear (n=27,45,38,68)	7.4 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 4, Mild (n=30,82,43,126)	17.5 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 4, Almost Clear (n=30,82,43,126)	33.3 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Baseline, Almost Clear (n=31,82,45,133)	46.6 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 16, Almost Clear (n=27,45,38,68)	25.0 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 4, Clear (n=30,82,43,126)	11.1 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Baseline, Severe (n=31,82,45,133)	0.0 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Baseline, Clear (n=31,82,45,133)	35.3 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 16, Mild (n=27,45,38,68)	25.0 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 12, Almost Clear (n=28,52,41,83)	32.5 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 12, Clear (n=28,52,41,83)	4.8 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 8, Severe (n=30,68,43,104)	15.4 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Baseline, Moderate (n=31,82,45,133)	3.0 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 12, Mild (n=28,52,41,83)	24.1 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 8, Moderate (n=30,68,43,104)	23.1 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Week 8, Mild (n=30,68,43,104)	26.0 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)	Baseline, Mild (n=31,82,45,133)	15.0 percentage of participants

Secondary

Percentage of Participants Maintaining Adequate PASI Response and Maintaining PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)

Adequate PASI response defined as less than or equal to 50% reduction of the Visit A4/Week 24 PASI Response.

Time frame: Week 24 (Period A) and Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining Adequate PASI Response and Maintaining PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)	Week 4	100.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining Adequate PASI Response and Maintaining PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)	Week 8	96.7 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining Adequate PASI Response and Maintaining PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)	Week 12	96.7 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining Adequate PASI Response and Maintaining PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)	Week 16	92.3 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining Adequate PASI Response and Maintaining PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)	Week 8	72.0 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining Adequate PASI Response and Maintaining PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)	Week 12	58.8 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining Adequate PASI Response and Maintaining PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)	Week 16	32.8 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining Adequate PASI Response and Maintaining PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)	Week 4	90.0 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Maintaining Adequate PASI Response and Maintaining PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)	Week 12	93.0 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Maintaining Adequate PASI Response and Maintaining PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)	Week 8	97.7 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Maintaining Adequate PASI Response and Maintaining PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)	Week 16	93.0 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Maintaining Adequate PASI Response and Maintaining PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)	Week 4	100.0 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Maintaining Adequate PASI Response and Maintaining PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)	Week 16	43.5 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Maintaining Adequate PASI Response and Maintaining PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)	Week 8	68.4 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Maintaining Adequate PASI Response and Maintaining PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)	Week 4	85.9 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Maintaining Adequate PASI Response and Maintaining PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)	Week 12	58.4 percentage of participants

Secondary

Percentage of Participants Maintaining PtGA Response of Clear or Almost Clear During the Double-Blind Treatment Withdrawal (Period B) Among Participants Who Had a Response of Clear or Almost Clear at Beginning of Period B

Time frame: Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining PtGA Response of Clear or Almost Clear During the Double-Blind Treatment Withdrawal (Period B) Among Participants Who Had a Response of Clear or Almost Clear at Beginning of Period B	Week 4	94.7 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining PtGA Response of Clear or Almost Clear During the Double-Blind Treatment Withdrawal (Period B) Among Participants Who Had a Response of Clear or Almost Clear at Beginning of Period B	Week 8	89.2 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining PtGA Response of Clear or Almost Clear During the Double-Blind Treatment Withdrawal (Period B) Among Participants Who Had a Response of Clear or Almost Clear at Beginning of Period B	Week 12	77.3 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining PtGA Response of Clear or Almost Clear During the Double-Blind Treatment Withdrawal (Period B) Among Participants Who Had a Response of Clear or Almost Clear at Beginning of Period B	Week 16	77.3 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining PtGA Response of Clear or Almost Clear During the Double-Blind Treatment Withdrawal (Period B) Among Participants Who Had a Response of Clear or Almost Clear at Beginning of Period B	Week 8	32.8 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining PtGA Response of Clear or Almost Clear During the Double-Blind Treatment Withdrawal (Period B) Among Participants Who Had a Response of Clear or Almost Clear at Beginning of Period B	Week 12	21.3 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining PtGA Response of Clear or Almost Clear During the Double-Blind Treatment Withdrawal (Period B) Among Participants Who Had a Response of Clear or Almost Clear at Beginning of Period B	Week 16	16.0 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Maintaining PtGA Response of Clear or Almost Clear During the Double-Blind Treatment Withdrawal (Period B) Among Participants Who Had a Response of Clear or Almost Clear at Beginning of Period B	Week 4	50.7 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Maintaining PtGA Response of Clear or Almost Clear During the Double-Blind Treatment Withdrawal (Period B) Among Participants Who Had a Response of Clear or Almost Clear at Beginning of Period B	Week 12	68.8 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Maintaining PtGA Response of Clear or Almost Clear During the Double-Blind Treatment Withdrawal (Period B) Among Participants Who Had a Response of Clear or Almost Clear at Beginning of Period B	Week 8	71.4 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Maintaining PtGA Response of Clear or Almost Clear During the Double-Blind Treatment Withdrawal (Period B) Among Participants Who Had a Response of Clear or Almost Clear at Beginning of Period B	Week 16	0.0 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Maintaining PtGA Response of Clear or Almost Clear During the Double-Blind Treatment Withdrawal (Period B) Among Participants Who Had a Response of Clear or Almost Clear at Beginning of Period B	Week 4	82.0 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Maintaining PtGA Response of Clear or Almost Clear During the Double-Blind Treatment Withdrawal (Period B) Among Participants Who Had a Response of Clear or Almost Clear at Beginning of Period B	Week 16	0.0 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Maintaining PtGA Response of Clear or Almost Clear During the Double-Blind Treatment Withdrawal (Period B) Among Participants Who Had a Response of Clear or Almost Clear at Beginning of Period B	Week 8	33.3 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Maintaining PtGA Response of Clear or Almost Clear During the Double-Blind Treatment Withdrawal (Period B) Among Participants Who Had a Response of Clear or Almost Clear at Beginning of Period B	Week 4	55.5 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Maintaining PtGA Response of Clear or Almost Clear During the Double-Blind Treatment Withdrawal (Period B) Among Participants Who Had a Response of Clear or Almost Clear at Beginning of Period B	Week 12	24.2 percentage of participants

Secondary

Percentage of Participants Regaining PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C

PASI75 response defined as at least a 75% reduction in PASI relative to baseline.

Time frame: Weeks 4, 8, and 16 (Period C)

Population: FAS-C

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants Regaining PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C	Week 4	14.3 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Regaining PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C	Week 16	64.3 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Regaining PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C	Week 8	28.6 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Regaining PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C	Week 4	7.7 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Regaining PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C	Week 16	100.0 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Regaining PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C	Week 8	32.3 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Regaining PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C	Week 8	42.9 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Regaining PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C	Week 4	14.3 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Regaining PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C	Week 16	42.9 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Regaining PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C	Week 4	37.0 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Regaining PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C	Week 16	57.2 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Regaining PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C	Week 8	48.5 percentage of participants

Secondary

Percentage of Participants Regaining PASI75 and PGA Response (PGA of Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Who Had Lost Both PASI75 Response and PGA Response at the Beginning of Period C

PASI75 response defined as at least a 75% reduction in PASI relative to baseline. PASI responses at each period are relative to Baseline-A, where Baseline-A is defined as the last observation up to first dosing date in Period A. 95% confidence interval constructed using the normal approximation to the binomial distribution of one-sample proportion.

Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

Population: FAS-C

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants Regaining PASI75 and PGA Response (PGA of Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Who Had Lost Both PASI75 Response and PGA Response at the Beginning of Period C	Baseline	0.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Regaining PASI75 and PGA Response (PGA of Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Who Had Lost Both PASI75 Response and PGA Response at the Beginning of Period C	Week 4	14.29 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Regaining PASI75 and PGA Response (PGA of Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Who Had Lost Both PASI75 Response and PGA Response at the Beginning of Period C	Week 8	28.57 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants Regaining PASI75 and PGA Response (PGA of Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Who Had Lost Both PASI75 Response and PGA Response at the Beginning of Period C	Week 16	28.57 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Regaining PASI75 and PGA Response (PGA of Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Who Had Lost Both PASI75 Response and PGA Response at the Beginning of Period C	Week 4	7.69 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Regaining PASI75 and PGA Response (PGA of Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Who Had Lost Both PASI75 Response and PGA Response at the Beginning of Period C	Week 8	28.85 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Regaining PASI75 and PGA Response (PGA of Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Who Had Lost Both PASI75 Response and PGA Response at the Beginning of Period C	Week 16	21.15 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants Regaining PASI75 and PGA Response (PGA of Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Who Had Lost Both PASI75 Response and PGA Response at the Beginning of Period C	Baseline	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Regaining PASI75 and PGA Response (PGA of Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Who Had Lost Both PASI75 Response and PGA Response at the Beginning of Period C	Week 8	42.86 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Regaining PASI75 and PGA Response (PGA of Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Who Had Lost Both PASI75 Response and PGA Response at the Beginning of Period C	Week 4	14.29 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Regaining PASI75 and PGA Response (PGA of Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Who Had Lost Both PASI75 Response and PGA Response at the Beginning of Period C	Week 16	42.86 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants Regaining PASI75 and PGA Response (PGA of Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Who Had Lost Both PASI75 Response and PGA Response at the Beginning of Period C	Baseline	0.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Regaining PASI75 and PGA Response (PGA of Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Who Had Lost Both PASI75 Response and PGA Response at the Beginning of Period C	Week 16	41.98 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Regaining PASI75 and PGA Response (PGA of Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Who Had Lost Both PASI75 Response and PGA Response at the Beginning of Period C	Week 4	37.04 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Regaining PASI75 and PGA Response (PGA of Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Who Had Lost Both PASI75 Response and PGA Response at the Beginning of Period C	Baseline	0.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants Regaining PASI75 and PGA Response (PGA of Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Who Had Lost Both PASI75 Response and PGA Response at the Beginning of Period C	Week 8	41.98 percentage of participants

Secondary

Percentage of Participants With a PASI75 Response During Double-Blind Withdrawal Treatment (Period B)

PASI75 response defined as at least a 75% reduction in PASI relative to baseline. PASI responses in each period are relative to Baseline-A, where Baseline-A is defined as the last observation until first dosing date in Period A. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.

Time frame: Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI75 Response During Double-Blind Withdrawal Treatment (Period B)	Week 4	87.10 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI75 Response During Double-Blind Withdrawal Treatment (Period B)	Week 8	70.97 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI75 Response During Double-Blind Withdrawal Treatment (Period B)	Week 12	67.74 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI75 Response During Double-Blind Withdrawal Treatment (Period B)	Week 16	64.52 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI75 Response During Double-Blind Withdrawal Treatment (Period B)	Week 8	34.15 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI75 Response During Double-Blind Withdrawal Treatment (Period B)	Week 12	30.49 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI75 Response During Double-Blind Withdrawal Treatment (Period B)	Week 16	24.39 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI75 Response During Double-Blind Withdrawal Treatment (Period B)	Week 4	63.41 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With a PASI75 Response During Double-Blind Withdrawal Treatment (Period B)	Week 12	77.78 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With a PASI75 Response During Double-Blind Withdrawal Treatment (Period B)	Week 8	86.67 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With a PASI75 Response During Double-Blind Withdrawal Treatment (Period B)	Week 16	62.22 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With a PASI75 Response During Double-Blind Withdrawal Treatment (Period B)	Week 4	86.67 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With a PASI75 Response During Double-Blind Withdrawal Treatment (Period B)	Week 16	27.82 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With a PASI75 Response During Double-Blind Withdrawal Treatment (Period B)	Week 8	38.35 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With a PASI75 Response During Double-Blind Withdrawal Treatment (Period B)	Week 4	59.40 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With a PASI75 Response During Double-Blind Withdrawal Treatment (Period B)	Week 12	33.83 percentage of participants

Secondary

Percentage of Participants With a PASI75 Response During the CP-690,550 Re-Treatment (Period C)

Time frame: Weeks 4, 8, and 16 (Period C)

Population: FAS-C

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI75 Response During the CP-690,550 Re-Treatment (Period C)	Week 4	70.37 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI75 Response During the CP-690,550 Re-Treatment (Period C)	Week 16	55.56 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI75 Response During the CP-690,550 Re-Treatment (Period C)	Week 8	62.96 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI75 Response During the CP-690,550 Re-Treatment (Period C)	Week 4	34.67 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI75 Response During the CP-690,550 Re-Treatment (Period C)	Week 16	45.33 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI75 Response During the CP-690,550 Re-Treatment (Period C)	Week 8	48.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With a PASI75 Response During the CP-690,550 Re-Treatment (Period C)	Week 8	66.67 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With a PASI75 Response During the CP-690,550 Re-Treatment (Period C)	Week 4	73.81 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With a PASI75 Response During the CP-690,550 Re-Treatment (Period C)	Week 16	69.05 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With a PASI75 Response During the CP-690,550 Re-Treatment (Period C)	Week 4	60.83 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With a PASI75 Response During the CP-690,550 Re-Treatment (Period C)	Week 16	61.67 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With a PASI75 Response During the CP-690,550 Re-Treatment (Period C)	Week 8	68.33 percentage of participants

Secondary

Percentage of Participants With a PASI75 Response During the Initial CP-690,550 Treatment (Period A)

PASI75 response defined as at least a 75% reduction in PASI relative to baseline. Baseline defined as the last observation up to the first dosing date in Period A. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI75 Response During the Initial CP-690,550 Treatment (Period A)	Week 4	7.85 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI75 Response During the Initial CP-690,550 Treatment (Period A)	Week 8	23.87 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI75 Response During the Initial CP-690,550 Treatment (Period A)	Week 16	38.07 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI75 Response During the Initial CP-690,550 Treatment (Period A)	Week 24	38.97 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI75 Response During the Initial CP-690,550 Treatment (Period A)	Week 24	59.40 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI75 Response During the Initial CP-690,550 Treatment (Period A)	Week 4	22.39 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI75 Response During the Initial CP-690,550 Treatment (Period A)	Week 16	60.60 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI75 Response During the Initial CP-690,550 Treatment (Period A)	Week 8	50.45 percentage of participants

Secondary

Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B)

Time frame: Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B; n equals the number of participants with observations

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	0.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B)	Overall (n=31,82,45,132)	0.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,70,43,104)	0.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,128)	0.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,53,42,84)	0.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	0.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,53,42,84)	0.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,128)	0.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B)	Overall (n=31,82,45,132)	0.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,70,43,104)	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,70,43,104)	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B)	Overall (n=31,82,45,132)	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,128)	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,53,42,84)	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	0.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B)	Overall (n=31,82,45,132)	0.76 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,70)	0.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,128)	0.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=28,53,42,84)	1.19 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=30,70,43,104)	0.00 percentage of participants

Secondary

Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Initial CP-690,550 Treatment (Period A)

PASI quantifies the severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk, and lower limbs), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis.

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Initial CP-690,550 Treatment (Period A)	Week 8 (n=322,323)	0.62 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Initial CP-690,550 Treatment (Period A)	Week 24 (n=277,279)	1.08 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Initial CP-690,550 Treatment (Period A)	Week 16 (n=311,307)	0.96 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Initial CP-690,550 Treatment (Period A)	Overall (n=329,333)	2.13 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Initial CP-690,550 Treatment (Period A)	Week 4 (n=326,331)	0.92 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Initial CP-690,550 Treatment (Period A)	Overall (n=329,333)	2.10 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Initial CP-690,550 Treatment (Period A)	Week 4 (n=326,331)	0.60 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Initial CP-690,550 Treatment (Period A)	Week 8 (n=322,323)	0.62 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Initial CP-690,550 Treatment (Period A)	Week 16 (n=311,307)	0.98 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Initial CP-690,550 Treatment (Period A)	Week 24 (n=277,279)	0.36 percentage of participants

Secondary

Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During the CP-690,550 Re-Treatment (Period C)

Time frame: Weeks 4, 8, and 16 (Period C)

Population: FAS-C; n equals the number of participants with an observation

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During the CP-690,550 Re-Treatment (Period C)	Overall (n=27,75,42,120)	0.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	0.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	0.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,101)	0.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	0.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,101)	0.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	0.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During the CP-690,550 Re-Treatment (Period C)	Overall (n=27,75,42,120)	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During the CP-690,550 Re-Treatment (Period C)	Overall (n=27,75,42,120)	2.38 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,101)	2.56 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	0.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During the CP-690,550 Re-Treatment (Period C)	Overall (n=27,75,42,120)	0.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 16 (n=23,67,39,101)	0.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 4 (n=27,74,42,119)	0.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During the CP-690,550 Re-Treatment (Period C)	Week 8 (n=26,72,41,118)	0.00 percentage of participants

Secondary

Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)

Time frame: Weeks 4, 8, and 16 (Period C)

Population: FAS-C participants with Baseline-C DLQI ≥5, where Baseline-C defined as the last observation up to first dosing date in Period C.

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)	Week 8	12.5 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)	Week 16	12.5 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)	Week 4	0.0 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)	Week 4	47.5 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)	Week 8	72.5 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)	Week 16	81.3 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)	Week 16	25.0 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)	Week 8	25.0 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)	Week 4	0.0 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)	Week 8	80.9 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)	Week 16	88.4 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)	Week 4	65.8 percentage of participants

Secondary

Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A participants with Baseline-A DLQI ≥5, where Baseline-A was defined as the last observation before the first dosing date in Period A.

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)	Week 4	60.1 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)	Week 8	77.4 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)	Week 16	85.7 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)	Week 24	91.9 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)	Week 24	96.1 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)	Week 4	76.6 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)	Week 16	94.9 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)	Week 8	88.7 percentage of participants

Secondary

Percentage of Participants With ISI Score of 0 During CP-690,550 Re-Treatment (Period C)

Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

Population: FAS-C participants with a Baseline-C ISI greater than (\>) 0, where Baseline-C is defined as the last observation up to first dosing date in Period C.

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants With ISI Score of 0 During CP-690,550 Re-Treatment (Period C)	Baseline	0.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With ISI Score of 0 During CP-690,550 Re-Treatment (Period C)	Week 4	0.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With ISI Score of 0 During CP-690,550 Re-Treatment (Period C)	Week 8	5.56 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With ISI Score of 0 During CP-690,550 Re-Treatment (Period C)	Week 16	11.11 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With ISI Score of 0 During CP-690,550 Re-Treatment (Period C)	Week 4	11.27 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With ISI Score of 0 During CP-690,550 Re-Treatment (Period C)	Week 8	18.31 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With ISI Score of 0 During CP-690,550 Re-Treatment (Period C)	Week 16	15.49 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With ISI Score of 0 During CP-690,550 Re-Treatment (Period C)	Baseline	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With ISI Score of 0 During CP-690,550 Re-Treatment (Period C)	Week 8	18.52 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With ISI Score of 0 During CP-690,550 Re-Treatment (Period C)	Week 4	7.41 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With ISI Score of 0 During CP-690,550 Re-Treatment (Period C)	Week 16	25.93 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With ISI Score of 0 During CP-690,550 Re-Treatment (Period C)	Baseline	0.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With ISI Score of 0 During CP-690,550 Re-Treatment (Period C)	Week 16	28.85 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With ISI Score of 0 During CP-690,550 Re-Treatment (Period C)	Week 4	23.08 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With ISI Score of 0 During CP-690,550 Re-Treatment (Period C)	Baseline	0.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With ISI Score of 0 During CP-690,550 Re-Treatment (Period C)	Week 8	38.46 percentage of participants

Secondary

Percentage of Participants With ISI Score of 0 During the Initial CP-690,550 Treatment (Period A)

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A participants with a Baseline-A ISI greater than (\>) 0, where Baseline-A is defined as the last observation up to first dosing date in Period A.

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants With ISI Score of 0 During the Initial CP-690,550 Treatment (Period A)	Week 4	12.92 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With ISI Score of 0 During the Initial CP-690,550 Treatment (Period A)	Week 8	16.92 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With ISI Score of 0 During the Initial CP-690,550 Treatment (Period A)	Week 16	20.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With ISI Score of 0 During the Initial CP-690,550 Treatment (Period A)	Week 24	19.38 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With ISI Score of 0 During the Initial CP-690,550 Treatment (Period A)	Week 24	37.31 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With ISI Score of 0 During the Initial CP-690,550 Treatment (Period A)	Week 4	25.69 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With ISI Score of 0 During the Initial CP-690,550 Treatment (Period A)	Week 16	37.92 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With ISI Score of 0 During the Initial CP-690,550 Treatment (Period A)	Week 8	41.28 percentage of participants

Secondary

Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B)

The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI responses at each period are relative to Baseline-A where Baseline-A was defined as the last observation up to first dosing date in Period A. 95% confidence interval is constructed using the normal approximation to the binomial distribution of two-sample proportion.

Time frame: Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B; Overall number (n) indicates the total number of participants with PASI Score ≥125% of baseline at least once during Weeks 4 to 16 of Period B.

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,72)	0.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=31,70,43,106)	0.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B)	Overall (n=31,82,45,132)	0.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=30,53,43,87)	0.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,128)	0.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=30,53,43,87)	0.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,72)	0.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B)	Overall (n=31,82,45,132)	0.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=31,70,43,106)	0.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,128)	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=30,53,43,87)	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,128)	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=31,70,43,106)	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,72)	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B)	Overall (n=31,82,45,132)	0.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B)	Week 16 (n=28,45,38,72)	0.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B)	Week 8 (n=31,70,43,106)	0.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B)	Week 4 (n=30,82,43,128)	0.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B)	Week 12 (n=30,53,43,87)	1.15 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B)	Overall (n=31,82,45,132)	0.76 percentage of participants

Secondary

Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Period Between Week 24 and Week 32 (Period B)

The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI responses at each period are relative to Baseline-A where Baseline-A was defined as the last observation up to first dosing date in Period A. Weeks 4 and 8 are relative to the Period B baseline and are the same as Weeks 28 and 32, which are relative to Period A baseline. 95% confidence interval is constructed using the normal approximation to the binomial distribution of two-sample proportion.

Time frame: Weeks 4 and 8 (Period B)

Population: FAS-B; Overall number (n) indicates the total number of participants with PASI Score ≥125% of baseline at least once during Weeks 4 to 8 of Period B.

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Period Between Week 24 and Week 32 (Period B)	Week 4 (n=30,82,43,128)	0.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Period Between Week 24 and Week 32 (Period B)	Overall (n=31,82,44,132)	0.00 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Period Between Week 24 and Week 32 (Period B)	Week 8 (n=31,70,43,106)	0.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Period Between Week 24 and Week 32 (Period B)	Week 4 (n=30,82,43,128)	0.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Period Between Week 24 and Week 32 (Period B)	Overall (n=31,82,44,132)	0.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Period Between Week 24 and Week 32 (Period B)	Week 8 (n=31,70,43,106)	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Period Between Week 24 and Week 32 (Period B)	Week 8 (n=31,70,43,106)	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Period Between Week 24 and Week 32 (Period B)	Week 4 (n=30,82,43,128)	0.00 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Period Between Week 24 and Week 32 (Period B)	Overall (n=31,82,44,132)	0.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Period Between Week 24 and Week 32 (Period B)	Week 4 (n=30,82,43,128)	0.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Period Between Week 24 and Week 32 (Period B)	Overall (n=31,82,44,132)	0.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Period Between Week 24 and Week 32 (Period B)	Week 8 (n=31,70,43,106)	0.00 percentage of participants

Secondary

Percentage of Participants With PGA Response of Clear or Almost Clear During Double-Blind Withdrawal Treatment (Period B)

PGA response was defined as 0 (clear) or 1 (almost clear) on a 5-point scale where 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. 95% confidence interval is constructed using the normal approximation to the binomial distribution of two-sample proportion.

Time frame: Weeks 4, 8, 12, and 16 (Period B)

Population: FAS-B

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During Double-Blind Withdrawal Treatment (Period B)	Week 4	77.42 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During Double-Blind Withdrawal Treatment (Period B)	Week 8	74.19 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During Double-Blind Withdrawal Treatment (Period B)	Week 12	70.97 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During Double-Blind Withdrawal Treatment (Period B)	Week 16	58.06 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During Double-Blind Withdrawal Treatment (Period B)	Week 8	32.93 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During Double-Blind Withdrawal Treatment (Period B)	Week 16	28.05 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During Double-Blind Withdrawal Treatment (Period B)	Week 4	57.32 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During Double-Blind Withdrawal Treatment (Period B)	Week 12	28.05 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During Double-Blind Withdrawal Treatment (Period B)	Week 4	77.78 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During Double-Blind Withdrawal Treatment (Period B)	Week 16	62.22 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During Double-Blind Withdrawal Treatment (Period B)	Week 12	66.67 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During Double-Blind Withdrawal Treatment (Period B)	Week 8	82.22 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With PGA Response of Clear or Almost Clear During Double-Blind Withdrawal Treatment (Period B)	Week 16	21.05 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With PGA Response of Clear or Almost Clear During Double-Blind Withdrawal Treatment (Period B)	Week 4	48.12 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With PGA Response of Clear or Almost Clear During Double-Blind Withdrawal Treatment (Period B)	Week 8	33.08 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With PGA Response of Clear or Almost Clear During Double-Blind Withdrawal Treatment (Period B)	Week 12	26.32 percentage of participants

Secondary

Percentage of Participants With PGA Response of Clear or Almost Clear During the CP-690,550 Re-Treatment (Period C)

Time frame: Weeks 4, 8, and 16 (Period C)

Population: FAS-C

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During the CP-690,550 Re-Treatment (Period C)	Week 4	62.96 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During the CP-690,550 Re-Treatment (Period C)	Week 16	55.56 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During the CP-690,550 Re-Treatment (Period C)	Week 8	62.96 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During the CP-690,550 Re-Treatment (Period C)	Week 4	40.00 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During the CP-690,550 Re-Treatment (Period C)	Week 16	49.33 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During the CP-690,550 Re-Treatment (Period C)	Week 8	49.33 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During the CP-690,550 Re-Treatment (Period C)	Week 8	54.76 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During the CP-690,550 Re-Treatment (Period C)	Week 4	61.90 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During the CP-690,550 Re-Treatment (Period C)	Week 16	59.52 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With PGA Response of Clear or Almost Clear During the CP-690,550 Re-Treatment (Period C)	Week 4	59.17 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With PGA Response of Clear or Almost Clear During the CP-690,550 Re-Treatment (Period C)	Week 16	55.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With PGA Response of Clear or Almost Clear During the CP-690,550 Re-Treatment (Period C)	Week 8	63.33 percentage of participants

Secondary

Percentage of Participants With PGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)	Week 16	37.16 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)	Week 4	14.20 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)	Week 8	30.51 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)	Week 24	37.16 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)	Week 24	55.22 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)	Week 16	58.81 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)	Week 8	54.03 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)	Week 4	37.91 percentage of participants

Secondary

Percentage of Participants With PtGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PtGA of Mild, Moderate or Severe During CP-690,550 Treatment Withdrawal (Period B)

Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

Population: FAS-C

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants With PtGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PtGA of Mild, Moderate or Severe During CP-690,550 Treatment Withdrawal (Period B)	Baseline (n=14,63,17,100)	14.29 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With PtGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PtGA of Mild, Moderate or Severe During CP-690,550 Treatment Withdrawal (Period B)	Week 4 (n=14,63,17,100)	21.43 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With PtGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PtGA of Mild, Moderate or Severe During CP-690,550 Treatment Withdrawal (Period B)	Week 8 (n=14,63,17,100)	21.43 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With PtGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PtGA of Mild, Moderate or Severe During CP-690,550 Treatment Withdrawal (Period B)	Week 16 (n=14,63,17,100)	21.43 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PtGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PtGA of Mild, Moderate or Severe During CP-690,550 Treatment Withdrawal (Period B)	Week 4 (n=14,63,17,100)	19.05 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PtGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PtGA of Mild, Moderate or Severe During CP-690,550 Treatment Withdrawal (Period B)	Week 16 (n=14,63,17,100)	41.27 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PtGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PtGA of Mild, Moderate or Severe During CP-690,550 Treatment Withdrawal (Period B)	Baseline (n=14,63,17,100)	6.35 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PtGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PtGA of Mild, Moderate or Severe During CP-690,550 Treatment Withdrawal (Period B)	Week 8 (n=14,63,17,100)	34.92 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With PtGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PtGA of Mild, Moderate or Severe During CP-690,550 Treatment Withdrawal (Period B)	Baseline (n=14,63,17,100)	23.53 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With PtGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PtGA of Mild, Moderate or Severe During CP-690,550 Treatment Withdrawal (Period B)	Week 16 (n=14,63,17,100)	58.82 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With PtGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PtGA of Mild, Moderate or Severe During CP-690,550 Treatment Withdrawal (Period B)	Week 8 (n=14,63,17,100)	41.18 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With PtGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PtGA of Mild, Moderate or Severe During CP-690,550 Treatment Withdrawal (Period B)	Week 4 (n=14,63,17,100)	35.29 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With PtGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PtGA of Mild, Moderate or Severe During CP-690,550 Treatment Withdrawal (Period B)	Week 16 (n=14,63,17,100)	53.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With PtGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PtGA of Mild, Moderate or Severe During CP-690,550 Treatment Withdrawal (Period B)	Baseline (n=14,63,17,100)	8.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With PtGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PtGA of Mild, Moderate or Severe During CP-690,550 Treatment Withdrawal (Period B)	Week 4 (n=14,63,17,100)	42.00 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With PtGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PtGA of Mild, Moderate or Severe During CP-690,550 Treatment Withdrawal (Period B)	Week 8 (n=14,63,17,100)	54.00 percentage of participants

Secondary

Percentage of Participants With PtGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: FAS-A

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants With PtGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)	Week 4	11.78 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With PtGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)	Week 8	22.36 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With PtGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)	Week 16	30.51 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With PtGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)	Week 24	29.61 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PtGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)	Week 24	51.64 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PtGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)	Week 4	21.19 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PtGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)	Week 16	54.63 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With PtGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)	Week 8	45.37 percentage of participants

Secondary

Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During CP-690,550 Re-Treatment (Period C)

Time frame: Weeks 4, 8, and 16 (Period C)

Population: Safety-C

Arm	Measure	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During CP-690,550 Re-Treatment (Period C)	0.0 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During CP-690,550 Re-Treatment (Period C)	0.0 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During CP-690,550 Re-Treatment (Period C)	0.0 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During CP-690,550 Re-Treatment (Period C)	0.0 percentage of participants

Secondary

Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During Double-Blind Treatment Withdrawal (Period B)

Time frame: Weeks 4, 8, 12, and 16 (Period B)

Population: Safety-B

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During Double-Blind Treatment Withdrawal (Period B)	Erythrodermic psoriasis	0.0 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During Double-Blind Treatment Withdrawal (Period B)	Pustular psoriasis	0.0 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During Double-Blind Treatment Withdrawal (Period B)	Guttate psoriasis	0.0 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During Double-Blind Treatment Withdrawal (Period B)	Erythrodermic psoriasis	0.0 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During Double-Blind Treatment Withdrawal (Period B)	Pustular psoriasis	0.0 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During Double-Blind Treatment Withdrawal (Period B)	Guttate psoriasis	0.0 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During Double-Blind Treatment Withdrawal (Period B)	Guttate psoriasis	0.0 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During Double-Blind Treatment Withdrawal (Period B)	Erythrodermic psoriasis	0.0 percentage of participants
CP-690,550 10 mg (Period B)	Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During Double-Blind Treatment Withdrawal (Period B)	Pustular psoriasis	0.0 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During Double-Blind Treatment Withdrawal (Period B)	Erythrodermic psoriasis	0.0 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During Double-Blind Treatment Withdrawal (Period B)	Pustular psoriasis	0.0 percentage of participants
Placebo for 10 mg CP-690,550	Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During Double-Blind Treatment Withdrawal (Period B)	Guttate psoriasis	0.8 percentage of participants

Secondary

Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During the Initial CP-690,550 Treatment (Period A)

Time frame: Weeks 4, 8, 16, and 24 (Period A)

Population: Safety-A

Arm	Measure	Group	Value (NUMBER)
CP-690,550 5 mg (Period B)	Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During the Initial CP-690,550 Treatment (Period A)	Erythrodermic psoriasis	0.0 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During the Initial CP-690,550 Treatment (Period A)	Guttate psoriasis	0.0 percentage of participants
CP-690,550 5 mg (Period B)	Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During the Initial CP-690,550 Treatment (Period A)	Pustular psoriasis	0.0 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During the Initial CP-690,550 Treatment (Period A)	Erythrodermic psoriasis	0.6 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During the Initial CP-690,550 Treatment (Period A)	Guttate psoriasis	0.0 percentage of participants
Placebo for CP-690,550 5 mg (Period B)	Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During the Initial CP-690,550 Treatment (Period A)	Pustular psoriasis	0.3 percentage of participants

Source: ClinicalTrials.gov · Data processed: Mar 17, 2026

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Percentage of Participants Achieving a PASI75 Response During CP-690,550 Re-Treatment (Period C) Among Those Who Had a Greater Than (>)50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)

Percentage of Participants Achieving a PGA Response of Clear or Almost Clear During CP-690,550 Re-treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe During Double-Blind Treatment Withdrawal (Period B)

Percentage of Participants Maintaining a Physician's Global Assessment (PGA) Response During the Double-Blind Treatment Withdrawal (Period B)

Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B)

ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C) - Percentage of Participant With a Response

ISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response

ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C) - Percentage of Participants With a Response

ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response

Mean Change From Baseline-A in DLQI Score During the Initial CP-690,550 Treatment (Period A)

Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)

Mean Change From Baseline-A in EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)

Mean Change From Baseline-A in EQ-5D Utility Score and VAS Scores During the Initial CP-690,550 Treatment Period (Period A)

Mean Change From Baseline-A in ISI Score During the Initial CP-690,550 Treatment (Period A)

Mean Change From Baseline-A in PASI Score During Initial CP-690,550 Treatment (Period A)

Mean Change From Baseline-A in SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)

Mean Change From Baseline-A in SF-36 PCS and MCS Scores During the Initial CP-690,550 Treatment (Period A)

Mean Change From Baseline-B in DLQI Score During the Double-Blind Treatment Withdrawal (Period B)

Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)

Mean Change From Baseline-B in ISI Score During the Double-Blind Treatment Withdrawal (Period B)

Mean Change From Baseline-B in PASI Score During Double-Blind Treatment Withdrawal (Period B)

Mean Change From Baseline-C in DLQI Score During the CP-690,550 Re-Treatment (Period C)

Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)

Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)

Mean Change From Baseline-C in EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)

Mean Change From Baseline-C in ISI Score During the CP-690,550 Re-Treatment (Period C)

Mean Change From Baseline-C in PASI Score During the CP-690,550 Re-Treatment (Period C)

Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)

Mean Change From Baseline-C in SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)

Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)

Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)

Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)

Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)

Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)

Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)

Mean Change From Baseline in Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)

Mean Change From Baseline in Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)

Mean Change From Baseline in Total Percent of Psoriatic BSA During Initial CP-690,550 Treatment (Period A)

Mean Dermatology Life Quality Index (DLQI) Score During the Initial CP-690,550 Treatment (Period A)

Mean DLQI Score During the CP-690,550 Re-Treatment (Period C)

Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)

Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)

Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)

Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)

Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)

Mean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)

Mean EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)

Mean EuroQol 5 Dimensions (EQ-5D) Health State Profile Utility Score and VAS Scores During the Initial CP-690,550 Treatment Period (Period A)

Mean ISI Score During the CP-690,550 Re-Treatment (Period C)

Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B)

Mean Itch Severity Item (ISI) Score During the Initial CP-690,550 Treatment (Period A)

Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)

Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)

Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)

Mean PASI Score During Double-Blind Treatment Withdrawal (Period B)

Mean PASI Score During Initial CP-690,550 Treatment (Period A)

Mean PASI Score During the CP-690,550 Re-Treatment (Period C)

Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)

Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)

Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)